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ABSTRACT 
MECHANISTIC INSIGHTS INTO COPPER-INDUCED REGRESSION 
OF HEART HYPERTROPHY 
Katherine Bourcy 
July 26, 2011 
Previous studies have shown that copper (Cu) supplementation at physiologically 
relevant levels reverses cardiac myocyte hypertrophy induced by phenylephrine (PE), and 
that this effect was VEGF-dependent. Yet, the amount of VEGF in the media was 
unchanged. However, we observed that Cu caused an increase in the ratio of VEGFR-
1:VEGFR-2 as well as an increase in PKG-1 activity. PKG-1 activity is associated with 
the regression of cardiac myocyte hypertrophy. The present study was undertaken to test 
the hypothesis that VEGFR-1 is associated with PKG-1 and their association is involved 
in Cu induced regression of cardiomyocyte hypertrophy. Human cardiac myocytes 
(HCM) in cultures were exposed to phenylephrine (PE) at a final concentration of 100 
flM for 48 hours to induce cell hypertrophy. Copper sulfate at a final concentration of 5 
flM was added to the hypertrophic HCM cultures for 24 hours with the concomitant 
presence of PE to reverse the hypertrophy. Both hypertrophic and hypertrophic-reversed 
HCM cells underwent immunoprecipitation using anti-VEGFR-1 antibody or anti-PKG-1 
antibody. The immune complex underwent gel-electrophoresis separation and Western 
blotting and LC-MSIMS analysis. Proteomic analysis identified Vimentin in the immune 
v 
complexes that immunoprecipitated with VEGFR-l and PKG-l. This study thus 
demonstrates that the association between VEGFR-l with PKG-l is mediated by 
Vimentin, and that Vimentin plays a critical role in copper regression of cardiac myocyte 
hypertrophy. 
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I. INTRODUCTION 
Heart disease is the leading cause of death in the United States, killing more than 
927,000 people every year. While it does not receive as much attention as cancer, 
cardiovascular disease claims more lives than all cancers combined, fewer than 560,000 
deaths 1. With these statistics come with a tremendous cost to society in the form of 
health care costs, as health care spending is projected to reach $4.7 trillion dollars by the 
year 20202• Additionally, this also comes with personal costs as well, as this disease is so 
prevalent it is highly unlikely anyone will go through life and somehow not be affected 
by heart disease. 
The heart is the first organ to develop during embryogenesis3. Throughout the 
lifetime of the organism, there will be many changes in stress and demand on the heart, 
and in some circumstances the heart will undergo growth, or hypertrophy. There are two 
kinds of hypertrophy: physiological and pathological4• Physiological hypertrophy is both 
normal and reversible5. In response to an increased workload and stress, the heart muscle 
(myocardium) will become thicker to preserve normal heart function. This can occur in 
athletes, for example, who train intensively. However, once the stimulus is removed, the 
heart will eventually go back to its normal size. In contrast, pathological hypertrophy is 
neither normal nor it is considered reversible. In the case of pathological hypertrophy, 
the stimulus is often some type of injury to the heart, such as a myocardial infarction. 
The heart undergoes an adaptive response and becomes enlarged in an attempt to 
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preserve function. However, pathological hypertrophy is an important milestone in the 
progression to heart failure, and once developed cannot be reversed6. Moreover, the 
prognosis for those with heart failure is often worse than those with cancer? While there 
are current therapies for heart failure, such as beta-blockers, angiotensin converting 
enzyme (ACE) inhibitors, diuretics and digoxin, these can, in some cases, buy the patient 
some time but will not stop or reverse the progression to heart failure. Other options such 
as heart transplantation are often prohibitive in nature for no other reason than the cost. 
The past two decades have brought better understanding and improved approaches to 
treating cardiac hypertrophy and heart failure. As it turns out, while it was previously 
thought that pathological hypertrophy was irreversible, there are data suggesting that it 
may, in fact, be reversible. 
Copper is a critical micronutrient and is essential for life8. Roughly twenty 
enzymes within the human body contain copper, and of those, ten require copper to 
function. Additionally, because these enzymes are found within most tissues, the effects 
of copper deficiency are systemic and widespread9• Copper is essential for the 
development of healthy bones 10, skin 11, and blood vessels 12. The cardiovascular system 
is especially sensitive to copper levels 13. The strongest evidence for this can be found by 
the extreme consequences of copper deficiency mainly manifesting as damage to the 
heart and blood vessels l4. It is interesting to note that while the recent health benefits of 
red wine are often touted as being due to resveratrol, red wine is made with the skins of 
the grape intact; copper-based fungicides are often used on wine grapes thereby making 
red wine a good source of copper. For centuries, copper has been used to treat a wider 
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variety of maladies. As it turns out, it may also be useful in healing an injured, and 
maybe even a failing heart. 
Previous studies have shown that copper (Cu) supplementation at physiologically 
relevant levels can reverse cardiac myocyte hypertrophy induced by phenylephrine (PE), 
and that this phenomenon was VEGF-dependent. This observation recaptures the in vivo 
observation that Cu supplementation can reverse cardiac hypertrophy induced by pressure 
overload in a mouse model, and this effect is also VEGF-dependent15 • However, there 
are fundamental differences between in vivo observations and those observed in cardiac 
myocytes grown in cultures. Coronary angiogenesis clearly plays a critical role in the 
regression of cardiac hypertrophy, however there are no blood vessels in cell cultures, 
which indicates VEGF has a direct effect on cardiac myocytes in the regression of cell 
hypertrophy. 
Because the amount of VEGF in the media was unchanged, we looked to VEGF 
receptors. We observed that Cu caused an increase in the ratio ofVEGFR-l:VEGFR-2 
as well as an increase in PKG-l activity, which is associated with the regression of 
cardiac myocyte hypertrophy. The present study was undertaken to test the hypothesis 
that VEGFR -1 is associated with PKG-l and their association is involved in Cu induced 
regression of cardiomyocyte hypertrophy. 
When the phenomenon of the regression of cardiac hypertrophy was first 
observed, it was observed in vivo in a mouse model, then in rat cardiac myocytes. We 
used human cardiac myocytes. Because there are differences between human and rat 
cells, we first established a phenotype. Indeed, Cu supplementation also reversed cardiac 
myocyte hypertrophy induced by PE in human cardiac myocytes. 
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Human cardiac myocytes (HCM) in cultures were exposed to phenylephrine (PE) 
at a final concentration of 100 /lM for 48 hours to induce cell hypertrophy. Copper 
sulfate at a final concentration of 5 /lM was added to the hypertrophic HCM cultures for 
24 hours with the concomitant presence of PE to reverse the hypertrophy. Both 
hypertrophic and hypertrophic-reversed HCM cells underwent immunoprecipitation 
using anti-VEGFR-l antibody or anti-PKG-l antibody. The immune complex underwent 
gel-electrophoresis separation and Western blotting and LC-MSIMS analysis. 
Initially, we had hypothesized that VEGFR-l and PKG-l were directly linked, 
and this is, in part, how cardiac myocyte hypertrophy is reversed. But we found that the 
link was not direct, but indirect. Functional proteomic analysis identified Vimentin in the 
immune complex likely involves VEGFR-l and PKG-l. This study thus demonstrates 
that the association between VEGFR-l with PKG-l is mediated by Vimentin, and that 
Vimentin plays a critical role in copper regression of cardiac myocyte hypertrophy. 
While initially thought to be nothing more than a 'decoy' receptor, these data 
suggest that VEGFR-l plays a critical role in the regulation of cardiac myocyte size. And 
once thought to be nothing more than an intermediate filament that helped provide 
scaffolding for the cell, this study suggests Vimentin, a known Cu-binding protein, may 
playa critical role in signaling pathways in cardiac myocytes, perhaps acting as a 
molecular switch, shutting down hypertrophic pathways, while allowing regression 
signaling to prevail and thus reversing the size of hypertrophic cardiac myocytes. 
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1-1. THE HEART & HEART FAILURE 
The heart is a pump that rivals any man-made machine. Before the day is done, 
the heart will beat over 100,000 times, propelling blood throughout the pulmonary 
and systemic circulation, supplying the body with life-supporting oxygen and 
nutrients. During the average lifetime, the human heart will beat roughly 2.5 billion 
times, without cessation. It is the first organ to develop during embryogenesis, and 
all subsequent events throughout the life of the organism are dependent upon its 
function. 
In its most simplistic view, the heart can be organized into three layers: the 
endocardium, the innermost layer of tissue that lines the chambers of the heart; the 
myocardium, the middle, muscular layer of the heart; and the epicardium, which is 
composed of the connective tissue surrounding the heart. Most of the heart is 
composed of non-muscle cells that constitute more than 2/3 of the total populations of 
the cardiac cells. However, the contractile muscle cells, which are known as 
myocytes or cardiac myocytes, are less than 1/3 of the total populations of the cardiac 
cells, but account for nearly 75% of cardiac volume. The rest of the heart is 
composed of pacemaker and conducting tissue, which are involved in the initiation 
and conduction of electrical impulses to the ventricles; blood vessels and extracellular 
space. 
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Cardiac myocytes consist of mainly contractile proteins. Z lines are found at the 
ends of the myocyte. From the Z line, thin actin filaments stretch inward and form 
cross-links with the much larger and thicker myosin filaments. Myosin filaments, 
which typically resemble golf clubs lying on their side, extend from the center of the 
myofibril toward the Z line but do not touch them. Titan elastic molecules indirectly 
link myosin fibers to the Z line. The release of calcium ions initiates muscle 
contraction. The heads of the myosin fibers flex and move actin fibers such that the Z 
lines move towards one another. 
The concentration of intracellular calcium ions is regulated in a series of 
interconnecting events. The sarcolemma, or external cell membrane contains calcium 
channels. With the arrival of each action potential and wave of electrical excitation, 
these channels open, allowing a small amount of calcium to enter the cell. Electrical 
impulses make their way into the cardiac myocyte by way of invaginations called T 
tubules, which are in close proximity to the sarcoplasmic reticulum, which stores 
calcium ions. A conformational change in the ryanodine receptor triggers the release 
of more calcium from the sarcoplasmic reticulum, a process called calcium-induced 
calcium release. Contractions are triggered by an increase in internal cytosolic 
calcium. 
Just as the release of calcium initiates contraction, relaxation of contractile 
proteins occurs when calcium is uptaken into the longitudinal component of the 
sarcoplasmic reticulum. While the increase in calcium concentrations acts upon the 
sarcoplasmic reticulum, it also triggers the phosphorylation of the regulatory protein 
phospholamban, which in turn activates ATP-dependent calcium uptake pumps of the 
6 
sarcoplasmic reticulum. Phorphorylated phospholamban blocks the inhibition of the 
calcium pump of the sarcoplasmic reticulum. Calcium is removed and relaxation 
occurs. 
The heart is a dynamic organ; its component muscle is capable of growing and 
adapting to changing workloads. The contraction of the myocardium plays a critical 
role in regulating the circulatory system by ejecting blood from the left ventricle; the 
tone of the peripheral arterioles provides most of the resistance that the heart must 
work against. In order to adapt to changes in workload, or arterial tone, the heart will 
undergo remodeling. The main players in this remodeling are cardiac myocytes. 
Enlargement of the heart is attributed to enlargement of individual cardiac myocytes 
In certain circumstances, such as pregnancy or increased aerobic activity, the 
heart will undergo physiological hypertrophy. This type of hypertrophy is normal, 
reversible, and associated with normal or enhanced cardiac functionality. 
Conversely, in response to disease-induced stimuli, such as pressure overload or 
myocardial infarction, congenital malformations, myocarditis, or diabetic 
cardiomyopathy, pathological hypertrophy may result. These stimuli damage the 
heart. In an attempt to compensate for the damage, the heart increases the pump 
function along with an irreversible enlargement of the size, or undergoes pathological 
hypertrophy. Pathological hypertrophy ultimately leads to cardiac dilation and loss of 
contractility. It is associated with an upregulation of fetal genes, cardiac dysfunction, 
decreased contractile function and increased mortality. It is an early milestone in the 
clinical progression to heart failure and in many cases, sudden cardiac death l6. Once 
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a patient develops pathological hypertrophy, it cannot be reversed and the progression 
to heart failure becomes inevitable17. 
At the most basic understanding, heart failure is when the heart can no longer· 
deliver the necessary nutrients and oxygen to peripheral tissues in the body. In the 
Western world, adult cardiac disease, most frequently in the form of heart failure, 
kills more people than all cancers combined18. Patients with heart failure fall under 
two major categories: systolic heart failure or diastolic heart failure, and the 
distinction is whether the dominant functional problems result from decreased 
contractility (systolic failure) or decreased relaxation (diastolic failure). Nearly a 
third of patients with evidential heart failure have preserved ejection fractions, and 
their symptoms are either largely or entirely stem from diastolic dysfunction19. This 
negative lusitropic state is attributed to structural changes in the heart such as fibrosis, 
hypertrophy and infiltrative processes. Additionally, subcellular aberrations in 
repolarization-relaxation coupling are often present in many cases20,21. 
Heart failure ca~ involve the right, left or both ventricles of the heart, most often 
both ventricles. The right ventricle of the heart pumps blood to the lungs where blood 
is reoxygenated. The left ventricle of the heart pumps oxygen-rich blood and 
nutrients to the rest of the body. Right ventricle heart failure often follows long-term 
high blood pressure in the pulmonary arteries, or pulmonary hypertension, causing a 
strain on the right side of the heart. In the event of right ventricle heart failure, the 
heart cannot pump enough blood to the lungs. Left ventricle heart failure can be 
caused by coronary artery disease as well as many other factors, and similarly with 
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left ventricle heart failure, the heart cannot pump enough blood to the peripheral 
tissue. 
Heart failure is the most expensive cardiovascular disorder in the United States 
with annual expenditures estimated to be in excess of $29.6 billion22.23. It is a leading 
cause of death in the u.S.24 and is quickly becoming more prevalent globally25. By 
the year 2020, it is projected that deaths from cardiovascular disease will exceed 
those from infectious and parasitic diseases for the first time throughout the world 
with the exception of sub-Saharan Africa26.27. While there are current treatments 
available for heart failure ranging from pharmacological intervention to heart 
transplantation, they all carry inherent risks and hefty price tags. Medications used to 
treat heart failure may exacerbate the condition. Additionally, medications used to 
treat heart maladies other than heart failure, such as antiarrhythmics and calcium 
channel blockers, may induce heart failure28. Currently, no treatment is available that 
can reverse hypertrophy, thereby halting the progression to heart failure. 
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1-2. ELKMENT #29: CUPRUM 
Cup rum or what is more commonly known as copper is a transition metal. It is 
used as an electrical conductor, as well as in the construction of metal alloys such as 
bronze and brass. While Hippocrates was known for prescribing copper compounds 
to treat disease29 as well as to prevent pregnancy30 the use of copper compounds such 
as copper carbonate, copper oxide, copper sulfate and copper chloride predates the 
ancient Egyptians. In fact, the use of copper as a medicinal agent can be traced as far 
back as Aztec civilization where it was used to treat sore throats. Throughout history, 
copper compounds have been used to treat a wide variety of diseases; Ancient 
Egyptians used copper for the sterilization of drinking water as well as the treatment 
of wounds; the Romans recorded numerous medicinal uses for copper; in Persia and 
India it was used to treat maladies from boils to venereal ulcers31 . 
After iron and zinc, copper is the third most common trace element in the human 
body. Copper is an important micronutrient for man and it is essential for life. The 
most compelling evidence for this can be found by the severe consequences of copper 
deficiency mainly manifesting as damage to the heart and blood vessels. At least 
twenty enzymes within the human body contain copper, and of those ten are 
dependent upon copper to function. Additionally, because these enzymes are found 
within most tissue, the effects of copper deficiency are systemic and widespread. 
Low copper levels can result in numerous pathological states including, but not 
limited to: poor neuronal myelination, reduced aortic elasticity, impaired immune 
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responses, decreased motor function, blood vessel abnormalities and cardiac 
hypertroph y32,33,34. 
The cardiovascular system is especially vulnerable to alterations in copper status. 
The essentiality of copper in the cardiovascular system has been demonstrated in 
numerous clinical and experimental studies35,36,37,38,39,40,41,42,43,44. Because copper 
facilitates the absorption and utilization of iron, it follows that copper deficiency is 
also associated with anemia, decreasing the amount of oxygen that is delivered to 
tissue45,46. Furthermore, copper deficiency decreases clotting capabilities after injury, 
increasing the amount of blood lost47. And once clots are formed, their ability to 
dissolve is also impaired. Copper deficient blood vessels are inherently leaky, and 
exacerbate swelling. 
Yet the strongest evidence for the importance of copper to the cardiovascular 
system has been observed in laboratory mouse model with pre-established 
hypertrophic cardiomyopathy induced by ascending aortic constriction. Copper 
supplementation alone reversed cardiac hypertrophy and this recovery occurred 
despite sustained pressure overload48. This suggests that copper supplementation 
prevents heart failure by reversing cardiac hypertrophy. Upon further investigation, it 
was discovered that cytochrome c oxidase recovery is essential to this copper-
supplementation-induced recovery, and is also validated by other studies which 
demonstrated that copper deficiency reduced the hearts ability to utilize energy and 
contribute to reduced coronary function49, 50, 51, 52 . 
As a transition metal, it also plays an important role as a cofactor in a wide variety 
of biological reduction and oxidation (redox) reactions. However, some suggest that 
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this also contributes to its potential for toxicity. In cases of copper overload, copper 
may cause oxidative damage to cells in a Fenton-type redox reaction. However, it is 
interesting to note that there is no free copper within the ce1l53, and it is tightly 
controlled. 
Copper metabolism was of little interest to researchers until the 1920s after the 
discovery that copper was required for the formation of hemoglobin in rats54. 
Subsequent studies in the 1930s and 40s were done in humans amounted to studies in 
the ADME (Absorption, Distribution, Metabolism and Excretion) of copper55,56,57,58. 
Much of the debate regarding the metabolic fate of copper in the 1930s and 40s are 
not much different than the debates that occur today, and the same can be said for 
minimum dietary copper requirements; amounts vary from 0.63 mg/d to 2.65 mg/d. 
The current RDI for copper is 0.9 mg per day59. Though, it goes without saying that 
the study of whole body copper metabolism in humans is inherently difficult. Tissues 
available for analysis are few, and this alone greatly limits what can be learned. The 
few tissues which can be sampled, for example skin and the liver, are only available 
through invasive means and even then, concentrations of copper in tissue can only 
give limited information. Also, it is impossible to determine which copper was 
already in the body, and which copper came from a meal without the use of isotopic 
tracers. 
Copper is obtained by the body from the diet60 and drinking water from copper 
piping. It is absorbed through the duodenum and intestinal mucosa and transported to 
the liver through the portal vein. The liver is the most important organ for copper 
homeostasis and is primarily responsible for removal of excess copper from the body. 
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In the liver, it was thought that copper is incorporated into ceruloplasmin and released 
into the bloodstream as Cu-ceruloplasmin, and is taken up by various tissues within 
the body. However studies have demonstrated that ceruloplasmin is not essential for· 
copper transport to extrahepatic tissue as aceruloplasminemia did not exhibit signs of 
organ system copper deficiency61. Copper is also released into the blood from the 
intestine in the form of Cu-albumin, Cu-histidine, Cu-transcuprein, as well as other 
unidentified complexes. Most dietary copper is excreted into the gastrointestinal tract 
and lost in the bile. After combining with the small amount of copper that is excreted 
from intestinal and pancreatic fluids and intestinal cells, it is eliminated from the 
body. Copper concentrations are highest in the liver, followed by the brain, kidney 
and heart. As the amount of copper intake increases, so does absorption, however a 
higher percentage is absorbed when intake is low. Studies suggest the primary factor 
to influence copper absorption is the amount of available copper. 
Whole-body copper metabolism can vary depending on conditions, such as 
pregnancy, and disease states. Metabolic defects, such as Wilson disease or Menkes 
syndrome are two frequently encountered copper malmetabolism disease conditions. 
Wilson disease is a rare, autosomal recessive disorder affecting normal copper 
metabolism. Typically, excess copper is excreted in the bile, but with this disease, 
mutations in the putative copper transporting P-type ATPase, ATP7B cause copper to 
build up in the liver. Over time, the liver is damaged and copper is released directly 
into the bloodstream causing damage to the kidneys, brain and eyes. Symptoms can 
appear as early as 4 years old, but onset can also be as late as 40 years of age. A 
rusty, brown ring around the cornea of the eye is the most characteristic sign of the 
13 
disease. On the other extreme is Menkes syndrome. This syndrome is caused by a 
defect in the ATP7 A gene, which manifests as a mutation in the MNK protein, a P-
type ATPase. This results in copper defiCiency as copper distribution and transport 
into the cells are inadequate. Consequently, the brain and other parts of the body do 
not get enough copper. Symptoms include structural abnormalities in the hair 
(Menekes syndrome is also known as "kinky hair syndrome" as it results in brittle, 
kinky hair), abnormal bone structure and severe neurological impairment. Most 
Menkes patients die in early childhood. Both of these disorders illustrate how critical 
copper metabolism and balance is within the body, and the need for strict homeostatic 
control of copper. 
The exact mechanism by which copper is taken into cells, and its journey within 
the cell is not completely understood, yet there is still much that is known. Under 
normal conditions, copper is thought to be transported into intestinal cells through the 
high affinity copper transporter, CTRI and bound to cytosolic copper chaperones. 
COX17 and SCOl/I1 are believed to act as chaperones, delivering copper to the 
mitochondria and facilitating the incorporation of copper into cytochrome c oxidase. 
Cu-ATPases ATP7A and ATP7B receive copper from ATOX1, transporting copper 
into the lumen of the secretory pathway of the trans Golgi network, as well as 
removing excess copper from the cell. CCS (copper chaperon for superoxide 
dismutase), as the name implies, delivers copper to cytosolic CU,Zn superoxide 
dismutase 1 (SOD1). 
Due to the regulation of body copper stores, indices of copper (save under 
extreme conditions) are resistant to change62. Even after dietary intake of copper 
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went from 0.8 to 7.5 mg/d, traditional indexes of copper status, such as 
ceruloplasmin, plasma copper, erythrocyte superoxide dismutase and urinary copper 
excretion were not significantly different63 . However, recent studies have 
demonstrated that there is no reliable biomarker for copper. Neither cuproenzymes 
nor plasma copper reflect copper status64,65,66. While traditionally, ceruloplasmin has 
been used as a biomarker for copper status, it is subject to season changes67, and is 
also age-dependent68• The only known exact indicator of copper status is copper 
content in the liver, which is not readily measured69. Alternatively, a recent 
promising candidate as a biomarker for copper status is CCS. In a rat feeding study, 
it was shown to increase in a dose-response manner as copper intake decreased in 
erythrocytes and liver70. Furthermore, there was a concomitant decrease in SOD! 
levels, and the authors of the study have suggested using the CCS:SODI ratio as an 
indices of copper deficiency. Thus far, it seems to be the most promising candidate 
of not only a measure of copper deficiency, but excess as well. 
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1-3. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND ITS 
RECEPTORS 
Vascular Endothelial Growth Factor (VEGF) is a robust mitogen for endothelial 
cells derived from lymphatics, arteries and veins, although it does not elicit a consistent 
and appreciable mitogenic response in any other types of cells71 ,n,73,74,75,76,77. Because of 
its ability to induce vascular leakage in guinea pig skin, VEGF is also known as Vascular 
Permeability Factor (VPF)78,79. Additional effects of VEGF include the stimulation of 
hexose transport in the vascular endothelium8o, promote the expression of VCAM 
(Vascular Cell Adhesion Molecule-I), ICAM (Intracellular Adhesion Molecule-I) and E-
selectin, all of which are adhesion molecules, via NF-KS with PI3K 
(phosphotidylinositol-3 kinase )-mediated suppression, in endothelial cells81 , 82 and may 
regulate or promote monocyte chemotaxis83. In vitro studies have shown VEGF induces 
vasodilation in a dose-dependent manner and can produce hypotension, tachycardia and 
decreased cardiac output when injected intravenously in rats84. However in vitro studies 
have shown VEGF does not affect contractility in isolated rat hearts85 . It is important to 
note, though that these hemodynamic effects are not limited to VEGF whereas other 
angiogenic factors can also induce hypotension and nitric oxide-mediated vasodilation86. 
There are several VEGF isoforms, each arising as a result of alternative splicing, 
VEGFI21, 145, 165, 183, 189 and 206. They are characterized by the presence of eight 
conserved cysteine residues and a cystine knot residue87. Native VEGF is a heparin-
binding, basic, homodimeric glycoprotein88 . VEGFI65, the other major isoform, shares 
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the same properties. VEGF165 appears to be the most abundant and potent isoform in 
man, acting as an angiogenic cytokine regulating vascular permeability,89 followed by 
VEGF121 and 1899°. VEGF is induced by hypoxia and cytokines, such as TNF-a, ILl, 6 
and 8, and oncostatin M91. Despite numerous isoforms, VEGF can be easily categorized 
by the biological property of their ability to bind heparin and heparin-sulfate. VEGF121 
is the most soluble, weakly acidic and does not bind heparin or the extra cellular matrix 
(ECM)92,93, however, VEGF189 and 206 are more basic, bind heparin and are completely 
sequestered to the ECM94. VEGF165 does bind heparin, and roughly 50-70% is bound to 
the cell surface and the ECM. Both VEGF145 and 165 induce angiogenesis in vivo, 
however VEGF145 is mainly expressed in cells derived from reproductive organs, as is 
VEGF206. These findings suggest there are two different mechanisms by which VEGF 
may become available to endothelial cells: by protease activation following cleavage of 
the larger isoforms, or freely diffusible proteins (VEGF121, VEGFI65). When 
comparing VEGF165 to VEGF121 or VEGFIlO, a 50-fold reduction in potency was 
observed in an endothelial cell growth assa/5. These results allude to VEGF exerting 
structural and functional heterogeneity in order to yield a controlled biological response. 
The biological consequences of VEGF are mediated by two receptors, VEGFR-l 
(also known as FIt-I) and VEGFR-2 (also known as Flk-l/KDR), both of which are 
receptor tyrosine kinases (RTK) and are how VEGF induces biological responses96• 
VEGFR-3 is a member of RTK family, but it does not bind VEGF instead binding its 
homologues, VEGFC and VEGFD97. In mice lacking VEGFR-2, the development of 
hematopoietic and endothelial cells is impaired98, It was observed in Flt-l null mice 
overgrowth of endothelial cells and blood vessel disorganization99, While our 
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understanding of these receptors is incomplete, the distinct phenotypes of VEGFR -1 and 
VEGFR-2 knockout mice suggest these receptors have differing biological functions. It 
then follows that the downstream signaling transduction pathways are also different and 
have considerably different signaling properties 100. VEGFR-1 and 2 are similar in 
structure with an extracellular domain that is comprised of seven immunoglobulin-like 
domains, one transmembrane region and a consensus tyrosine kinase sequence that is 
split by a kinase-insert domain lO l,l02. Both receptors bind VEGF with a very high 
affinity. VEGFR-1 has the highest affinity for rhVEGF165, with a Kd of 10-20 pM103• 
VEGFR-2 binds VEGF with a slightly lower affinity, with a Kd of 75-125 pM104• 
For almost thirty years, it has been known that eu stimulates angiogenesis in the 
avascular cornea of rabbits 105. This has been demonstrated in subsequent studies in both 
experimental and clinical settings lO6 . Another study showed that eu stimulates VEGF 
synthesis in human keratinocytes lO7 . The exact mechanism by which eu regulates VEGF 
expression is unknown. It is known, however, that HIF-1a is a required transcription 
factor for VEGFI08,109, ergo oxygen tension plays a critical role in VEGF regulation. 
During normoxia conditions HIF-1a undergoes hydroxylation at a proline residue by 
prolyl hydroxylase (PHD), which requires oxygen, iron and 2-oxoglutarate to 
function" 0,"1,1l2,13. This increases (and is also required for) HIF-la binding to von 
Hippel-Lindau (VHL) tumor suppressor protein, thereby targeting HIF-1a for 
proteasomal degradation"4. However, under hypoxic conditions, PHD cannot function. 
HIF-1a is neither hydroxylated nor targeted for degradation; it accumulates in the cells 
and its activity increases ll5 . Studies in the lab have demonstrated that eu 
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supplementation reverses cardiac hypertrophy in part by Cu chaperone for superoxide 
dismutase-1(CCS)-mediated HIF-1a activation ofVEGF116. 
Our preliminary studies have demonstrated the requirement of VEGF for the 
reversal of cardiac hypertrophy in primary culture of neonatal rat cardiomyocytes. 
Because these cells are treated with VEGF in culture without the presence of blood 
vessels, the effect of VEGF is independent of angiogenesis. Additionally, a recent study 
showed that chronic activation of PKG-1 prevents and reverses cardiac hypertrophy in 
hearts exposed to sustained pressure overload l17. Upon further investigation into the 
mechanism, it was discovered that this effect was also mediated by the upregulation of 
VEGF. 
While investigating the potential mechanisms by which Cu reverses cardiac 
hypertrophy, we observed Cu deficiency suppressed and Cu repletion restored VEGF 
expression in the heart1l8. The heart is designed such that every cell is in contact with a 
blood vessel, supplying the cardiomyocyte with a constant flow of oxygen and nutrients. 
Consequently, coronary angiogenesis is critical. And a delicate balance between cardiac 
growth and angiogenesis must be maintained. During the acute phase of cardiac 
hypertrophy, angiogenesis is increased. However, if angiogenesis is reduced, the heart 
undergoes pathological remodeling. Further, if cardiac growth and angiogenesis are not 
coordinated, the transition to heart failure occurs 119. This disruption suppresses VEGF. 
It is also interesting to note that blocking VEGF promotes and VEGF administration 
delays the transition to heart failure in pressure overloaded mouse models 120,121. In our 
preliminary studies, we observed that Cu supplementation enhanced VEGF expression, 
reversed hypertrophic cardiomyopathy and restored angiogenesis despite pressure 
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overload in mouse models with AAC-induced cardiac hypertrophy and dysfunction. 
Together, this suggests that Cu is involved in the regulation of VEGF expression in the 
heart. 
VEGF is critical in Cu induced reversal of cardiac hypertrophy. It also plays a 
role in and is required for the cell growth that leads to cardiac hypertrophy. This suggests 
that VEGF plays a dual role in controlling the physiological function of cardiomyocytes. 
Under stress conditions, it is required for cell growth, but also decreases the size of 
hypertrophied cardiomyocytes. While the importance of VEGF-induced angiogenesis 
has been demonstrated for the amelioration of ischemic myocardium122,123, VEGF alone 
is not a good strategy for the reversal of cardiac hypertrophyl24. VEGF, which is also 
known as vascular permeability factor, can induce vascular leakage125,126, and in cases of 
mitochondrial dysfunction, the addition of VEGF culminates in the creation of leaky 
vessels 127. However, an independent and direct effect ofVEGF that is independent of 
angiogenesis on cardiomyocytes should playa crucial role in the retrogression of 
hypertrophic cardiomyopathy. 
The main focus of this dissertation is the identification and characterization of 
VEGFR mediated signaling pathways involved in the reduction of hypertrophied 
cardiomyocyte cell size and thus, reversal of cardiac hypertrophy. In order to gain a 
comprehensive understanding of these signaling pathways, VEGFR associated pathways 
of normal cardiomyocytes were compared to that of hypertrophied cardiomyocytes. We 
observed that Cu-induced regression of heart hypertrophy is VEGF-dependent. Yet, the 
amount of VEGF in cultures did not change. VEGF mediates its effects through its 
receptors. It was later determined that Cu causes a change in the ratio of VEGFR-
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l:VEGFR-2 and hypothesized that this leads to a switch in signaling pathways from 
growth to the regression of cell hypertrophy. Additionally, siRNA targeting VEGFR-2, 
which elevated the ratio of VEGFR -1: VEGFR -2 differentiated but also reproduced the 
Cu-induced reversal of cardiac myocyte hypertrophy. Further, Anti-VEGF antibody 
blocked the reversal of cardiac myocyte hypertrophy induced by VEGFR-2 knock down. 
Finally, siRNA targeting VEGFR-1 ablated Cu-induced reversal of hypertrophy, further 




Before the day is done, the heart will beat over 100,000 times, faithfully fulfilling 
its role in delivering oxygen and nutrients to peripheral tissues. With this also comes 
the need to adapt rapidly to ever changing demands and stresses, from the stress 
induced by physiological or pathological stimuli. Within the heart lies regulators that 
can aid in this process, cyclic nucleotides 3' ,5' -monophosphates such as cAMP and 
cGMP and their respective effector enzymes, protein kinase A (PKA) and protein 
kinase G (PKG). The pathway of cAMPIPKA controls excitation-contraction 
coupling associated with the phosphorylation of voltage-gated calcium channels, 
phospholamban, ryanodine receptors and sarcomeric proteins, which increase and 
drives calcium cycling through the sarcoplasmic reticulum and triggers contraction 
and relaxation. Conversely, the pathway of cGMPIPKG acts as a myocardial 
decelerator, countering cAMP-dependent-stimulation and signaling different 
pathways that act to blunt growth, while increasing relaxation128. 
PKG-l is believed to be the primary target of cyclic GMP (cGMP). This 
serine/threonine protein kinase is activated by paracrine and autocrine stimuli, which 
increase nitric oxide (NO) and cGMP. In mammals, there are three molecular forms 
ofPKG: PKG-la, PKG-l~, and PKG-II. PKG-la and PKG-l~ result from 
alternative mRNA splicing and differ only by about 100 amino acids in the N-
terminal dimerization domainI29,13o,l3l; and PKGII arises from a different gene locus. 
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PKG-1 is the major isoform in cardiac myocytes and will therefore be the focus 
of this chapterI32,133. The aforementioned N-terminal homodimerization domains of 
PKG-1a and ~ consequently determine their isoform-specific interactions with cell 
substrates and docking proteins. While PKG-1a and PKG-1~ have indistinguishable 
cGMP binding sites, PKG1a binds cGMP with a lO-fold higher affinity than PKG-
1~134,135. Additionally, PKG-1a dimerization is subject to ROS-regulation, its 
dimerization forming a disulfide bond between reactive Cys42 residues that adjoin in 
the enzyme homodimer. PKG-1 ~ is neither ROS-sensitive nor does it contain 
. C h' .. 136 reactive ys at t IS posItIon . 
In 1986, Murry et al observed the phenomenon that would later become known as 
cardioprotection137. Since then, a growing body of evidence has shown the complex 
signaling pathways involved in the hypertrophic regulation of the heart, and that it is 
dependent upon multiple components. One important and well-studied pathway is 
cyclic GMP and cGMP-dependent protein kinase (PKG). Studies in mice with 
increased cGMP synthesis, which upregulated natriuretic peptide receptor signaling 
showed overactivity of cGMP blunted hypertrophy in vitro, and despite abnormal 
loading conditions in vivo I38,139. Similar observations are made with PKG-1 
activation 140, and conversely, PKG-1 inhibition exacerbates hypertrophyl41. A recent 
study that also demonstrated the important role that PKG plays in the regulation of 
cardiac hypertrophy showed that hyperstimulation of the PKG-1 pathway can prevent 
and reverse cardiac hypertrophy98. However, it did not abolish hypertrophy induced 
by overexpression of Akt in vivo. Additionally, further studies into the mechanism of 
this phenomenon showed that it was VEGF-dependentI42,143. However, it has been 
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suggested that other signaling pathways may playa role in the observed 
antihypertrophic effects, as one study reported that cardiac hypertrophy was not 
exacerbated by the deletion of PKG-l in cardiac myocytes 144. 
It has been reported that PDE5, a cGMP-specific phosphodiesterase type 5 
. 1 d . . h f·l 145 1 h . 146 d enzyme, IS upregu ate In congestIve eart at ure , pu monary ypertenslOn an 
right ventricle hypertrophyl47. The preconditioning-like cardioprotective effects of 
sildenafil against injury sustained by ischemia-reperfusion were observed in the intact 
hearts of animals 148. It was observed in other studies in adult mice that sildenafil had 
a direct effect in the heart by protecting against necrosis and apoptosis through 
activation of the NO-signaling pathway, and this effect was ablated by gene knock 
down of NO synthase l49. While sildenafil has demonstrated powerful 
d · . f1' .. h· f··· 150151 152153 . f . car lOprotectIve elects agaInst ISC emIa-reper USlOn Injury , , , post-m arcHon 
heart failure l54 and cardiomyopathy induced by doxorubicinl55 , these observations are 
not limited to sildenafil as other PDE5 inhibitors, vardenafil156 and tadalafil157 limit or 
reduce infarct sizes. 
As there are activators of cardiac hypertrophy, there are also negative modulators, 
and their inactivation may play an important role in cardiac hypertrophy and failure. 
One important negative modulator is GSK3B, a serine/threonine kinase that regulates 
cardiac development, cell development and cycling, gene transcription, apoptosis and 
metabolisml58. Normally, when GSK3B is active, it inhibits hypertrophy. However, 
when it is phosphorylated by Akt or PKA, its activity is suppressed and the inhibition 
of hypertrophic pathways is removed, paving the way for hypertrophy to develop. 
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Studies have suggested that GSK3~ plays an integral role in regulating VEGF, 
which may be critical for cardioprotection159 and also may be another clue to 
understanding the mechanism by which eu can reverse cardiac hypertrophy. Further, 
it was observed that Akt phosphorylation was insignificantly abrogated by PKG 
inhibitor KT5823 or shRNA-PKG160. VEGFR-l plays a critical role in modulating 
VEGF/Akt signaling161 by preventing excessive activation of Akt. This is in 
agreement with other studies that showed acute activation of Akt exerted protective 
effects against both myocardial infarction and ventricular dysfunction following 
ischemia-reperfusion in vivo and in vitro162.163. Sildenafil resulted in PKG-
independent increases in Akt phosphorylation, suggesting that perhaps PKG-l and 
VEGFR-l act synergistically to switch signaling pathways from hypertrophy to 
regression in cell size. 
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1-5. VIlVIENTIN 
The cytoskeleton is unique to eukaryotic cells. Filling the role of both muscle and 
skeleton, it aids in both movement and stability of the cell. The cytoskeleton is 
composed of three types of filaments: microfilaments, microtubules and intermediate 
filaments 164. Microfilaments, the smallest of the three, are roughly 3-6 nm in 
diameter. The most well-known examples of microfilaments are actin and myosin, 
which carry out the roles of contraction and cytokinesis in the cell. Microtubules are 
cylindrical in appearance, which are 20-25 nm in diameter and are composed of the 
protein tubulin, whose subunits are termed alpha and beta. Microtubules are thought 
to act as a scaffolding to determine cell shape, and act as a "track" on which 
organelles and vesicles within the cell to move. Additionally, during mitosis, 
microtubules form spindle fibers that separate the chromosomes during anaphase. 
Finally, intermediate filaments, named for their diameter because they fall between 
microfilamens and microtubules in size, are roughly 10 nm in diameter, and are 
thought to provide the cell with tensile strengthl65 . 
Intermediate filaments constitute approximately 1 % of the total protein of cells. 
In humans, there are more than 50 intermediate filaments genes which are expressed 
in nearly all cells within the bodyl66. And while microfilaments and microtubules are 
highly conserved and similar within cells of a particular species, intermediate 
filaments exhibit diversity in their numbers, sequence and abundancel67. However, 
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they do share a common structure: a dimer consisting of two a-helical chains in 
parallel and intertwined, making a coiled-coil rod. Though the structure may be 
similar, the properties vary and can be quite unique. For example, keratin 
intermediate filaments found in hair are highly insoluble, but nuclear lamin 
intermediate filaments are dynamic and dissociate and reform in a cell cycle-
dependent manner. 
Vimentin is the most abundant intermediate filament protein. It is widely 
expressed and once thought to be a static element involved mainly in structural 
processes. Initially it was believed to playa main role in providing stability for the 
architecture of the cell, yet some studies report that knockout models in which the 
animals do not express Vimentin exhibit a normal phenotype, develop and reproduce 
normally. Therefore it was concluded that Vimentin is not necessary for the viability 
of eukaryotic cells 168. However, under certain circumstances, Vimentin knockout 
mice do exhibit phenotypic abnormalities under specific conditions, such as 
injuryI69,170. This suggests Vimentin has a specialized biological function that 
contributes to specific dynamic cellular processes 171, With respect to the 
cardiovascular system, Vimentin is an integral part of the vascular endothelium, and 
has been suggested to play an important role in shear stress-induced responses, such 
. 1 d I' 172 as artena remo e mg . 
In endothelial cells, Vimentin is phosphorylated at serine and threonine residues, 
and its secretion is increased by phosphatase inhibitors, and conversely, blocked by 
the inhibitor G06983, which is specific for protein kinase C. This is consistent with 
other findings that phosphorylation of Vimentin affects its intracellular localization; 
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Vimentin is phosphorylated by numerous protein kinases and is a substrate for protein 
kinase C (PKC). Further studies have observed that PKC directly phosphorylates 
Vimentin at Ser/Thr residues, possibly marking it for secretory pathways. Also, other 
studies have demonstrated that IL-lO, an anti-inflammatory cytokine mediates its 
effects by inhibiting the PKC pathway. TNF-a is a well-known cytokine which 
functions in opposition to IL-lO in macrophages. It was observed that even at 
extremely low doses, TNF-a induced the secretion of Vimentin by as much as 120-
fold in human monocytes. Yet current models for TNF-a signaling do not transpire 
through PKC thus suggesting both PKC and TNF-a activate pathways that mediate 
the secretion of Vimentin. 
Hypoxia is a physiological stimulus that can occur in various conditions, 
including but not limited to ischemia, anemia, high altitude and lung disease. While 
these conditions can alter systemic responses, it can also exert direct effects on 
individual cells, in particular, endothelial cells. It is interesting to note that Vimentin 
is also regulated by hypoxia and undergoes redistribution under hypoxic conditions. 
A study investigating the mechanism by which hypoxia precipitated the redistribution 
of Vimentin focused on the phosphorylation of Vimentin and its interaction with heat 
shock protein 27 (HSP27). The investigators observed that HSP27 overexpression 
increased total Vimentin levels in endothelial cells, and both hypoxia and HSP27 
overexpression appeared to increase the amount of Vimentin that 
coimmunoprecipitated with HSP27. It was thus hypothesized that HSP27 may target 
a regulatory subunit of Vimentin. Under hypoxic conditions, cells appear to undergo 
changes in biomechanical properties, which would prepare for an adaptive response 
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to strengthen tissue and thereby protect it against injury. Some have suggested that 
these changes bolster adhesive properties and barrier integrity under hypoxic and 
other possible conditions as well. 
Coincidently, the mediator of hypoxic responses within cells, the activity of 
hypoxia-inducible factor-l activity (HIP-I) is regulated by copper. Previous studies 
have shown that pressure overload results in copper decrease in the heart. This is also 
associated with the inhibition of angiogenesis, as well as the transition from cardiac 
hypertrophy to heart failure in a mouse model159• Copper supplementation at 
physiologically relevant levels reversed heart hypertrophy in the presence of pressure 
overload, and this reversal effect was through CCS-mediated HIF-I activation of 
VEGF expression and angiogenesis. Copper chelation decreases transcriptional 
activity of HIF-l, and siRNA targeting the a subunit of HIF-l blocked copper-
induced stimulation of VEGF. Cu is capable of stabilizing HIF-l a by inhibiting 
prolyl hydroxylases, and thereby preventing its degradation. While the role of 
Vimentin in cardiac myocytes has yet to be elucidated, we observed that after PE 
treatment, Vimentin levels decreased and with Cu treatment, Vimentin levels 
increased. We hypothesize that in cardiac myocytes, Vimentin acts as a molecular 
switch. Upon the addition of PE, the decrease in Vimentin acts as a molecular switch, 
switching signaling pathways to hypertrophic pathways and resulting in an increase in 
cardiac myocyte size. Conversely, the Cu treatment causes an increase in VEGFR-l 
signaling and Vimentin and thereby switches signaling pathways from hypertrophic, 
to regression of hypertrophy. 
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1-6. HYPOTHESIS 
We hypothesize that Cu supplementation generates a change in VEGF receptor 
distribution and the subsequent signaling pathways, leading to the reversal of cardiac 
hypertrophy. More specifically, we hypothesize that VEGFR-I is associated with 
PKG-I and their association is involved in Cu induced regression of cardiomyocyte 
hypertrophy. 
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II. MATERIALS, INSTRUMENTS & METHODS 
A. MATERIALS AND VENDORS: 
The first 1-13 were used for the isolation of neonatal rat cardiac myocytes. 
1. Hanks' balanced salt solution (HBSS): Sterile, calcium and magnesium-free HBSS 
was purchased from Worthington Biochemical Corporation, Catalog # LKL003210, 
pH 7.4, and was stored at 4°C. This solution was used to dissolve trypsin and trypsin 
inhibitor as indicated, in addition to incubation of minced neonatal rat hearts on the 
first day. For washing purposes, HBSS was purchased from GIBCO, Catalog # 
14185. This solution was also calcium, magnesium and magnesium sulphate-free. 
The lOX solution was diluted to IX and the pH was adjusted to 7.4. 
2. L-15 media powder: This powder was purchased from Worthington Biochemical 
Corporation. Catalog # LK003250 and stored at 4°C. To prepare the solution, one 
pouch of the L-15 powder was placed into aIL glass beaker. 900 mL of double 
distilled water (ddH20) was used to reconstitute the powder, and the pouch was also 
rinsed out to remove all traces of the powder. The solution was mixed with a 
magnetic stir bar, and the pH adjusted to 7.2. The volume was brought to 1000 mL 
with ddH20. After filter sterilization, the solution was stored at 4°C until needed. 
3. Trypsin: This was purchased from Worthington Biochemical Corporation. Catalog # 
LK003235. The powder was stored at 4°C. 2 mL of sterile HBSS was used to 
dissolve the powder. The solution was prepared freshly for each experiment. 
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4. Trypsin inhibitor: This was purchased from Worthington Biochemical Corportation. 
Catalog # LK003225. The powder was stored at 4°C. 1 mL of sterile HBSS solution 
was used to dissolve the powder. This solution was prepared fresh for each 
experiment. 
5. Collagenase: This was purchased from Worthington Biochemical Corporation. 
Catalog # LK003245. The powder was stored at 4°C. 5 mL of sterile L-15 media 
was used to reconstitute the powder. The solution was prepared fresh for each 
experiment. 
6. DMEMlF12: Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (Ham) 
(1:1) powder was purchased from GIBCO, Catalog # 12500-062 and was stored at 
4°C. One pouch ofDMEMlF12 powder was placed into a 1 L glass beaker. 800 mL 
of ddH20 was used to dissolve the powder, as well as rinse out the pouch of any 
remaining powder. 2.38 grams of HE PES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, Sigma, Catalog # H0891) was added to the solution. 
The solution was mixed with a magnetic stir bar, and the pH adjusted to 7.4. The 
final volume was brought to 1000 mL with ddH20. After filter sterilization, the 
solution was stored at 4°C until needed. 
7. DMEM: Dulbecco's Modified Eagle Medium. This powder was purchased from 
Sigma-Aldrich, Catalog # D7777 and stored at 4°C. To reconstitute, one pouch of the 
DMEM powder was placed into a 1 L glass beaker. The powder and the remaining 
contents in the pouch were dissolved with 800 mL of ddH20. 3.7 grams of sodium 
bicarbonate (NaHC03) was added to the solution. The solution was mixed with a 
magnetic stir bar and the pH was adjusted to 7.2. The final volume was brought to 
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1000 mL using ddH20. After filter sterilization, the solution was stored at 4°C until 
needed. 
8. Cell strainers: These were purchased from Worthington Biochemical Corporation. 
Catalog # LK003265 and was used to remove tissue debris during the cell isolation 
process. They were stored at room temperature. 
9. Antibiotic-antimycotic solution: This solution was purchased from Celigro, Catalog 
#30-004-CI. The content includes 10,000 U penicillin, 10,000 /lglmL streptomycin 
and 25 /lglmL amphotericin B. 1 % of this solution was used in working media (1 mL 
of solution per 100 mL of media). This solution was stored at -20°C, and thawed 
prior to use. 
10. Phosphate Buffered Saline (PBS): IX PBS (1 L) was composed of 8 grams NaCl, 
0.2 grams KCI, 1.44 grams Na2HP04, 0.24 grams KH2P04. The pH of the solution 
was adjusted to 7.4, filter sterilized and stored at 4°C until needed. 
11. Gelatin: Gelatin from porcine skin (type A) was purchased from Sigma-Aldrich, 
Catalog # G-2500. Gelatin (2.5%) was prepared by adding 2.5 grams gelatin powder 
to 100 mL of PBS. The solution was autoclaved to dissolve and sterilize the solution. 
Sterilized gelatin was stored at 4°C until needed. Prior to use, the solution as warmed 
up in a 37°C water bath for 15 minutes. 1 % of the gelatin solution was used in 
working media (1 mL of 2.5% gelatin solution per 24 mL PBS). 
12. Fetal Bovine Serum (FBS)-premium select: This was purchased from Atlanta 
Biologicals, Catalog # S11550. FBS was ali quoted and stored in -20°e. 10% of FBS 
was used in working media (10 mL serum was added per 100 mL media). 
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13. Penicillin-Streptomycin: This solution was a 100X dual antibiotic solution. It was 
purchased from MP Biomedicals, Catalog # 1670046. It contained 5,000 IU/mL 
penicillin and 5 mglmL streptomycin. 1 % of this solution was used in working media 
(1 mL antibiotic solution per 100 mL media). It was stored at -20°C and thawed in a 
37°C water bath prior to use. 
14. 5-Bromo-2'-deoxyuridine (BrdU): This powder was purchased from Sigma Aldrich, 
Catalog # B5002. BrdU (10 mM) was prepared as a stock solution by adding 307 mg 
BrdU powder to 100 mL of ddH20. The solution was filter sterilized, and ali quoted 
to 10 mL and stored at -20°C prior to use. The reason for the usage of BrdU is that it 
is a thymadine analog, and selectively incorporates into cellular DNA during S-phase. 
It was used to inhibit the growth of fibroblasts and other proliferative cells in the 
primary cultures of neonatal rat cardiac myocytes. 
15. Disposable sterile bottle-top filters: Filters were purchased from Corning, Catalog # 
43026. It has a funnel volume of 150 mL and the pore size of the cellulose acetate 
membrane is 0.22 11m. They screw onto the mouths of the cell culture bottles and 
were used to sterilize all solutions used in cell culture. They were stored at room 
temperature. 
16. Copper sulfate (CuS04): Copper sulfate was purchased from Sigma-Aldrich, 
Catalog # C1297. CuS04 (10 mM) was prepared as a stock solution. 8 mg CuS04 
powder was added to 5 mL of ddH20. The solution was filter sterilized, then 
ali quoted to 100 ilL and stored at -20°C prior to use. 
17. Phenylephrine (PE): Phenylephrine was purchased from Acros Organics, Catalog # 
61-76-7. PE (10 mM) was prepared as a stock solution. 10 mg PE powder was added 
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to 5 mL ddH20. The solution was filter sterilized, then aliquoted to 100 ilL and 
stored at -20°C prior to use. 
18.0.25% Trypsin-EDTA·4Na solution (IX): This was purchased from GIBCO, 
Catalog # 25200-056. The content containes 2.5 gIL of trypsin and 0.38 gIL 
EDTA·4Na in HBSS solution without CaCI2, MgC12·6H20 and MgS04·7H20. It 
also contained phenol red as a pH indicator. This solution was used to detach cells in 
cultures. 
19. Lysis buffer: Two different kinds of lysis buffer were used. In the cultures of 
neonatal rat cardiac myocytes, the content of the lysis buffer included 20 mM Tris-
HCI (pH 7.4), 150 mM NaCl, 1 % Triton-X, 10% glycerol. Phenylmethylsulfonyl 
fluoride (PMSF) at a final concentration of 1 mM and 1 % protease inhibitor cocktail 
(Sigma-Aldrich, Catalog # P8340) were freshly added prior to use. In the cultures of 
human cardiac myocytes, the lysis buffer included 30 mM MOPS, pH 7, 0.15 M 
NaCl, 1 mM NaV04, 5 mM NaF, 1 mM EDTA, 1 % NP-40 and 1 mM PMSF and 1 % 
protease inhibitor cocktail were freshly added prior to use. 
20. Human Cardiac Myocytes (HCM), embryonic: Cardiac myocytes were purchased 
from ScienCell, Catalog # 6200. These cells were grown in several flasks, collected 
and then stored in liquid nitrogen for use in experiments. 
21. Cardiac Myocyte Medium (CMM): Medium was purchased from ScienCell, 
Catalog # 6201. CMM arrived filter sterilized and incomplete, but with reagents 
needed for completion kept separate. Prior to usage, FBS and antibiotic solution 
shipped with CMM was added to the medium. Medium was stored at 4°C and 
warmed up in a 37°C bath for 30 minutes prior to usage. 
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22. Poly-L-Lysine (PLL): PLL (1 mglmL) was purchased from ScienCell, Catalog # 
0403. PLL was used to pre-treat cell culture flasks to promote cell adhesion in 
cultures. The company recommended 15 J.lL of PLL per 1 J.lL of ddH20, however 
some optimization was required depending on the flasks used for cell culture. Flasks 
must be treated for at least 1 hour prior to seeding cells, or were treated overnight. 
After treatment with PLL, flasks were rinsed with PBS twice, and not allowed to dry 
out prior to cell seeding. PLL was stored at -20°C prior to usage, and was warmed in 
a 37°C bath briefly when needed. 
23. Protein assay kit: This was purchased from BioRad, Catalog # 500-0006 and was 
used according to the manufacturer's instructions. 
24. Protein G Sepbarose beads: These beads were purchased from Sigma-Aldrich, 
Catalog # P3296-5ML. These beads were washed 3X with lysis buffer, centrifuging 
between each wash to collect the beads in the bottom of a microcentrifuge tube. After 
the last wash, a 50/50 solution of beads/lysis buffer was made. 20-40 J.lL of this 
slurry solution was added to sample tubes during co-immunoprecipitation 
experiments. 
25. Agarose-conjugated cGMP beads: These beads were purchased from Santa Cruz 
Biotechnology, Catalog # sc10335ac. 2 J.lg of antibody was added tocelUysates and 
incubated overnight for immunoprecipitation. The reason for using agarose-
conjugates is to minimize signal disturbance during subsequent LCIMS-MS analysis. 
26. Agarose-conjugated Flt-! beads: These beads were purchased from Santa Cruz 
Biotechnology, Catalog # sc316ac. 2 J.lg of antibody was added to celllysates and 
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incubated overnight for irnmunoprecipitation. The reason for using agarose-
conjugates is to minimize signal disturbance during subsequent LCIMS-MS analysis. 
27. Vimentin antibody for Western blot: This antibody was purchased from Cell 
Signaling, Catalog # 3932S. Vimentin antibody used for Western blot was incubated 
with the membrane overnight with diluted antibody (1 :500-1: 1000) in 5% w/v BSA, 
IX TBS, 0.1 % Tween-20 at 4°C with gentle shaking. 
28. Vimentin antibody for Immunoprecipitation: This antibody was purchased from 
Cell Signaling, Catalog # 3390. Vimentin antibody was added to lysate slurry 1:50 
and incubated overnight at 4°C under rotation. 
29. Fit-! antibody for Western blot: This antibody was purchased from Santa Cruz 
Biotechnology, Catalog # sc316. It is critical for this experiment that the membrane 
not be blocked with non-fat milk, instead BSA must be used or no band will appear. 
Antibody dilution ranged from 1 :500-1: 1000. 
30. Detergent removal spin columns: These columns were purchased from Thermo 
Scientific, Catalog # 87777 and were used according to the manufacturer's 
instructions. 
B. Methods 
1. Primary culture 
Primary cultures of neonatal rat cardiac myocytes were established according to a 
previously published procedure but with some modifications (Hoffmann, et aI., 1995). 
The hearts of 1-3 day old Sprague-Dawley rats were isolated, minced on ice and 
incubated overnight at 4°C with 50 /lglmL trypsin (Worthington Biochemical 
Corporation, Lakewood, NJ) in 20 mL calcium and magnesium-free Hanks Balanced 
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Salt Solution (HBSS, Life Technologies Ltd, Carlsbad, CA). After 16 hours incubation, 
soybean trypsin inhibitor was added at a final concentration of 100 mglmL for 30 
minutes. During this time, the flask was placed in an incubator, 37°C and the tissue was 
digested with collagenase (Worthington Biochemical Corporation) in 5 mL L-15 media 
(Worthington Biochemical Corporation) at 3TC for 70 minutes. After pipetting the cells 
gently, and filtering through a cell strainer, the solution was centrifuged at 1000 rpm for 5 
minutes; this was to remove cells such as endothelial cells and fibroblasts. The 
supernatant was removed, and the pellet of cells was resuspended in DMEMIHam's 
nutrient mixture F12 (1:1 vol/vol, Life Technologies Ltd) supplemented with antibiotics 
(100 U/mL penicillin and 100 JlglmL streptomycin, MP Biomedicals, LLC, Solon, OH), 
10% fetal bovine serum (FBS, Life Technologies Ltd) and 0.1 mM 5-bromo-2'-
deoxyuridine (BrdU, Sigma-Aldrich, St. Louis, MO). Fibroblasts were removed by pre-
incubation for 2 hours at 3TC in the cultures. Cardiac myocytes in suspension were 
collected by centrifugation, further purifying the cardiac myocytes. The cardiac 
myocytes were seeded in 1 % gelatin-coated plates containing DMEMlF12 media 
supplemented with FBS, BrdU and antibiotics for 24 hours before subsequent 
experiments. Myocytes were seeded at a density of 1.5x106/1O cm culture dish; 6x105/60 
mm culture dish, 2x 105/35 mm culture dish. After 4 hours the media was changed to 
serum-free Dulbecco's modified Eagle's media (DMEM, Gibco, Gaithersburg, MD) 
supplemented with BrdU and antibiotics. Beating cardiac myocytes were observed under 
routine microscopy. Unless 90% of the cells were beating, the preparation was not used. 
The purity of the cultured cardiac myocytes was examined by staining with anti-a-
sarcomeric actin antibody (Sigma-Aldrich) as described below. 
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At the end of each experiment (48 hours PE treatment and 24 hours with Cu), the 
purity of the cardiac myocytes was determined using flow cytometry. The purity was 
more than 90%. Briefly, cells were trypsinized, washed with PBS and fixed in 75% 
ethanol at 4°C for at least 18 hours. Primary anti-a-sarcomeric actin antibody (Sigma-
Aldrich) was diluted in PBS and incubated at room temperature for 1 hour. Secondary 
fluorescein-conjugated goat anti-mouse IgM antibody (FITC, Southern Biotech, 
Temecula, CA) was used for immunofluorescence and incubated for 30 minutes at room 
temperature. The fluorescence distribution from 30,000 cells was captured and recorded 
using a Cell Quest Acquisition program (Becton & Dickinson, Franklin Lakes, NJ). Data 
were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR) and the perentage of 
the a-sarcomeric actin labeled cardiac myocytes in the population was calculated. 
2. Experimental procedure 
Cell hypertrophy was induced by phenylephrine (Sigma-Aldrich) at a final concentration 
of 100 11M for 48 hours in serum-free media, following a previously published 
procedure 173. At the end of the 48 hour incubation, Cu in the form of copper sulfate 
(CuS04) was added directly to the cultures at a final concentration of 5 11M for an 
additional 24 hours. At the end of the treatment, or 72 hours, the media were collected 
for VEGF secretion analysis. The cells were collected by trypsinization, suspended in 
PBS buffer and counted using a hemocytometer. Protein content was measured using a 
Bradford method (Bio-Rad, Hercules, CA) and normalized by the cell number. For flow 
cytometry analysis of VEGF receptors, the harvested cells were subjected to fixation and 
incubation with different markers before analysis as described below. 
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To assess the role of PKG-l in the Cu-induced regression of cell hypertrophy, we 
used the PKG-la antagonist, (Rp-8-CPT-cGMPS) (Sigma), at a final concentration of 0.5 
/lM in cultures. The antagonist was added to the cultures 1 hour prior to the addition of 
Cu in cultures. In VEGFR-2 siRNA-induced regression of cell hypertrophy, the same 
concentration of VEGF antibody and PKG antagonist was applied. 
3. Protein assay 
Protein concentrations were measured by the Bradford method using a commercially 
available assay kit according to the manufacturer's instructions (Bio-Rad, Hercules, CA). 
The absorbance at 595 nm was measured using a Beckman CU 650 spectrophotometer 
(Pegasus Scientific, Frederick, MD). Protein content per cell was determined by dividing 
the total amount of protein by the cell number and the final concentration was expressed 
as micrograms per 106 cells. 
4. Cell size determination 
Cell volume was determined using a Lovins microslide field finder (Fisher Scientific, 
Pittsburgh, PA) following the procedure described previously174. Briefly, cardiac 
myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide 
field finder. The diameters of approximately 150 cells from each group were assessed 
and recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)nr3 
where V = cell volume, 1t = 3.14 and r = radius. 
In addition, cell size was also determined by flow cytometry. Briefly, cells were 
trypsinized, suspended in PBS and directly passed through the flow cytometer. For each 
sample, 30,000 cells were recorded and analyzed through the forward scatter light (FSC), 
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which is proportional to cell size. The data were quantitatively analyzed sing the FlowJo 
software. 
5 .. Immunocytochemistry 
The examine morphological changes of cardiac myocytes in cultures after treatment 
with PE and Cu, cells were cultured in an 8-well chamber slide and treated as described 
in experimental procedure. After Cu treatment for 24 hours, cells were fixed in 4% 
paraformaldehyde in PBS. After fixation, the culture chamber was incubated with 
monoclonal anti-a-sarcoeric-actin antibody (Sigma-Aldrich) followed by incubation with 
FITC-conjugated goat anti-mouse IgM. Fluorescence was visualized by a phase contrast 
microscope (Nikon Instruments, Melville, NY). Images were acquired by a Nikon digital 
camera DXM 1200 (Nikon Instruments) using a Nikon ACT-1 software. 
6. Double immunochemistry staining 
To examine the alterations of the distribution of VEGF receptors of the membrane of 
cardiac myocytes after treatment with PE and/or Cu, cells were cultured in 8-well 
chamber slides and treated as described in the experimental procedure. After Cu 
treatment for 24 hours, cells were fixed in 100% methanol. After fixation, the culture 
chamber was incubated with polyclonal anti-VEGFR-1 antibody (Santa Cruz) followed 
by incubation with Alexa Fluor 488 conjugated goat anti-rabbit IgG. After washing the 
culture chamber was incubated with monoclonal antiVEGFR-2 antibody (Santa Cruz) 
followed by incubation with Alexa Fluor 594 conjugated goat anti-mouse IgG. 
Fluorescence was visualized by a phase contrast microscope (Nikon Instruments, 
Melville, NY). Images were acquired by a Nikon camera DXM 1200 (Nikon 
Instruments) using a Nikon ACT-1 software. 
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7. Flow cytometric analysis of VEGF receptors 
Quantitative analysis of VEGF receptors in cardiac myocytes under different 
treatments was done by flow cytometric assay. Briefly, cells were trypsinized, washed 
with PBS and fixed in 75% ethanol at 4°C for at least 18 hours. Immunofluorescence 
staining with an Alexa Fluor 488 conjugated antibody to VEGF-l (1 :50, Santa Cruz) and 
Alexa Fluor 594 conjugated antibody to VEGFR-2 (1:50, Santa Cruz) were performed on 
fixed cardiac myocytes. Receptor expression was determined by the intensity of the 
fluorescence using the software FlowJo based on the data collected from 30,000 cells per 
sample. The data were plotted in two-dimensional fluorescence intensity versus cell 
number. 
8. siRNA 
siRNA targeting rat VEGFR-2 and negative mismatched control siRNA were 
purchased from Ambion, Inc. (Applied Biosystems, Cambridge, MA siRNA ID#: 
S130202). The siRNA sequences for VEGFR-2 were (from 5' to 3'): 
GGGUAUCACUCAGACGAGAtt (sense); UGUCGUCUGAGUGAUACCCag 
(antisense). The siRNA sequences for VEGFR-l were (from 5' to 3'): 
GAAGCGGUCUUCUUCCGAAtt (sense); UUCGGAAGAAGACCGCUUCag 
(antisense). The optimal transfection efficiency was determined from our preliminary 
study testing the range from 5-20 nM, and at the selected level of siRNA with maximum 
silencing effect with minimal toxicity. After PE treatment, cardiac myocytes were 
transfected for 4 hours with 10 nM annealed siRNA targeting rat VEGFR -1 or VEGFR -2 
or neative mismatched siRNA in antibiotic-free media as antibiotics can cause cell death 
under these conditions. Lipofectamine 2000 (Invitrogen) was used as the transfection 
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reagent according to the manufacturer's instructions. After 4 hours of incubation, cardiac 
myocytes were changed to the original serum-free media with antibiotics and PE was 
added again for hypertrophic groups. At 48 hours post-transfection, cells were 
trypisinzed and collected. The silencing effect of siRNA was examined by flow 
cytometry 24 hours after siRNA transfection. From preliminary results, VEGFR-2Ievel 
was increased after PE treatment in cardiac myocytes compared with control, and Cu 
addition lowered the protein expression. To investigate the effect of siRNA, PE treated 
cells were used as a positive control. siRNA-treated cardiac myocytes decreased the 
protein expression of VEGFR-2 in PE-treated cells, which is very similar to the effect of 
Cu. 
9. cGMP-dependent protein kinase activity 
cGMP-dependent protein kinase G (PKG)-l activity was assayed by coloimetric 
analysis with a non-radioisotopic kit (MBL, Woburn, MA). The assay was performed 30 
minutes after treatment with Cu in the experiment of VEGFR-l siRNA-blocked 
regression of hypertrophic cardiac myocytes. Each sample was measured in duplicate 
carefully following the manufacturer's instructions. 
10. Human Cardiac Myocytes Cell Culture Experimental procedure 
T-75 flasks were pre-treated with PLL for either 1 hour or overnight, then washed 2 
times with PBS prior to cell plating. HCM were obtained, grown and maintained in 
CMM. When the cell density is low «50% confluent) media may be changed every 
other day, however for higher density cell popUlations, media must be changed daily. 
Cardiac myocyte hypertrophy was induced by PE at a final concentration of 100 /lM 
for 48 hours. Copper (Cu) in the form of copper sulfate (CUS04) was added directly to 
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the cultures at a final concentration of 5 IlM for an additional 24 hours in the concomitant 
presence of PE. At the conclusion of Cu treatment, cells were washed with phosphate 
buffered saline (PBS), and collected by trypsinization and centrifuged at 2000 RPM for 5 
minutes at 4°C. Cells were washed with PBS to remove trypsin and centrifuged again 
under the aforementioned conditions and the PBS was removed. If cells were not used 
immediately, they were stored in -80°C until needed. 
11. Western Blot Procedure 
Cells were collected as previously described using trypsinization and centrifugation. 
The pellet was washed 2X with ice-cold PBS, after the final wash, remove as much PBS 
as possible without disturbing the pellet. Lysis buffer: 30mM MOPS, pH 7.0,0.15 M 
NaCI, 1 mM Na3V04, 5 mM NaF, 1 mM EDTA, 1 % NP-40 and protease inhibitors were 
added to the pellet. The tubes were always kept on ice and handling kept to a minimum 
to keep the contents and tube as cool as possible. 
Cell lysis was achieved by using a cell sonicator. The sonicator was set to 3-5. The 
cells were sonicated for 1 second, and then rest on ice for 10 seconds. This was repeated 
2 more times. After, the tubes were placed under constant agitation or in head-over-tail 
rotor in 4°C for 30-60 minutes. In order to pellet non-soluble material, the tubes 
underwent centrifugation at 12,000 x g for 15 minutes at 4°C. The supernatant was 
carefully removed and transfered to a fresh tube on ice. 
Protein concentration was determined as previously described using the Bradford 
method. Proteins were reduced and denatured by the addition of ~-mercaptoethanol to the 
loading buffer, and samples were boiled at 95°C for 10 minutes. 
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Samples were carefully loaded into pre-cast gels and the gel was placed on ice or in 
4°C. 60 volts was applied to the gel for 30 minutes, then 120 V until the bands are 
roughly 1 centimeter from the bottom of the gel. 
Following SDS-PAGE, the gel was prepared to undergo electroblotting using a 
nitrocellulose membrane (GE Healthcare) at 100 volts for 150 minutes. The membrane 
was then washed with 1 X TBST and blocked with 5% w/v BSA, IX TBS, 0.1 % Tween-
20 for 1 hour at room temperature. The membrane was incubated with diluted antibody. 
Vimentin was detected by incubation overnight at 4°C with 1:500-1:1000 of anti-
Vimentin antibody (Cell Signaling Technology, Inc). PKG-1 was detected by incubation 
overnight at 4°C with 1:500-1:1000 of anti-PKG-1 antibody (Santa Cruz Biotechnology). 
VEGFR-1 was detected by incubation overnight at 4°C with 1:500-1:1000 of anti-
VEGFR-1 antibody (Santa Cruz Biotechnology). 
The following morning, membranes were washed 3X for 5 minutes each with IX 
TBST, then incubated with the secondary antibody, horseradish peroxidase (HRP) 
conjugated goat anti-rabbit immunoglobulin G antibody, diluted 1:1,000 in TBS 
containing 0.5% Tween-20 at room temperature for 1 hour. Proteins were visualized 
using enhanced chemiluminescence (ECL) (Amersham, Buckinghamshire, UK), 
according to the manufacturer's instructions, to visualize HRP-conjugates. 
12. Immunoprecipitation 
400-500 Ilg of protein from celllysates were incubated overnight with anti-VEGFR-1 
(Santa Cruz Biotechnology), anti-Vimentin (Cell Signaling Technology) or anti-PKG-1 
agarose-conjugated beads (Santa Cruz Biotechnology) antibody at a concentration of 2 
ug/mL for 16 hours at 4° C under rotation. The following morning, 20-40 ilL of a Protein 
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G sepharaose beads slurry to the mixture and incubate under rotation at 4°C for 4 hours. 
The samples underwent centrifugation at 1000 X g, and the supernatant was carefully 
removed, and the bead pellet 3 times with ice-cold PBS. After the final wash, as much of 
the supernatant was removed as possible. 
For co-immunoprecipitation, in which IP is followed by Western blot: lysis buffer 
was added to the beads and the tube was boiled at 95°C for 10 minutes. Samples were 
centrifuged again, and the supernatant underwent SDS-PAGE for Western blot analysis. 
For subsequent analysis via LC/MS-MS, after washing the pellet 3X, to elute the immune 
complex, capture beads were resuspended in 50 III of 0.1 M gl yeine, pH 2.5 and 
incubated with agitation for 10 minutes at 4°C. The supernatant was collected after 
centrifugation, run through detergent removal spin columns (Thenno Scientific) 
according to the manufacturer's instructions, and analyzed using LC/MS-MS. 
13. LC/MS-MS 
After immunopreeipitation, samples were sent off to Dr. Jian Cai for MALDI-TOF 
analysis. Mass spectrometers contain 3 components: an ionization source, a mass 
analyzer, in this case, time-of-flight, and a detector. Typically the ionization source 
comes from a UV light. The mass analyzer functions to separate or resolve ions 
formed in the ionization source according to the mass/charge (m/z) ratio. Finally, the 
detector monitors the ion currents, in the form of mass spectra. 
MALDI-TOF, or Matrix Assisted Laser Desorption/Ionization Time of Flight 
mass spectrometry is a powerful analytical tool for the identification of unknown 
biomolecules which utilizes a UV -light absorbing matrix. This matrix, which 
contains the proteins in the sample, is irradiated by a nanosecond laser pulse. The 
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majority of the energy is absorbed by the matrix, thereby preventing unwanted 
fragmentation of the molecules. At the same time, the molecules become ionized, 
leaving it with a positive charge. The purpose of this is because magnetic force only 
affects charged particles. The ions then travel through an electric field where they are 
accelerated, and enter a flight tube. In this tube, they are separated according to 
their mass/charge ratio, ions with a smaller mass traveling faster than those with a 
larger mass. Each biomolecule reach the detector at a different time, yielding a 
distinct signal. This method is highly sensitive, with an accuracy of 0.1-0.01 %. 
Many things should be taken into consideration for successful experiments when 
using this procedure. One big source of problems during LC-MSIMS analysis is 
detergents, which can cause large, unknown peaks. Another source is keratin. In 
order to minimize potential problems, do as much work as feasible in a laminar flow 
hood or biological safety cabinet (BSC). 
Assume nothing is free of keratin (it probably isn't). That means assuming your 
pipette tips, Eppindorf tubes, reagent containers, skin-everything is a potential 
source of keratin. Be mindful of the clothing worn while experimental procedures are 
being carried out. Wool sweaters are a terrific source of keratin and probably not the 
best choice of clothing to wear while conducting experiments upstream of mass 
spectrometry analysis. Even cotton lab coats shed significant amounts of dust, which 
may contain keratin. If possible, wear a disposable clean-room type lab coat. 
Latex gloves contain a significant amount of keratin as well as proteinaceous 
materials. Nitrile or vinyl gloves are the best choice. Rinse gloves under a stream of 
water before handling samples. Additionally, working surfaces should be cleaned 
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with water and absolute ethanol, and wiped down with clean-room wipes, not dusty, 
keratin-rich paper towels. Anything that is placed into the BSC should be wiped 
down thoroughly. 
All supplies, whether it be pipette tip boxes or bags of microcentrifuge tubes, 
should be opened only in the BSC while it is in full operation. Further, detergents are 
the enemy. Detergents, while important for solubilizing, stabilizing and 
dis aggregating protein complexes will also do nasty things to your sample. It can 
form adducts with peptides and proteins, and in MS analysis, this will shift mlz 
values, which is bad news. Another big no-no for MS is plasticizers. 
Lastly, anything that will come into contact with samples (vials, pipette tips, etc.) 
should be rinsed with HPLC grade Acetonitrile or high grade methanol if none is 
available, then with HPLC grade water. 
14. Statistical analysis 
Data were obtained from three separate experiments and are expressed as means ± 
S.E.M. A 2X2 factorial design was applied to all experiments and the data were 
analyzed according to the experimental design. After a significant interaction was 
detected by the analysis of variance (ANOV A) based on the factorial design, the 
significance of the main effects was further determined by the F-test. The level of 
significance was considered when P <0.05. 
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III. RESULTS 
A. Previous studies have shown that adding physiologically relevant amounts of Cu 
to cardiac myocytes in cell cultures can reverse hypertrophy induced by 
phenylephrine. This effect is blocked by adding a VEGF antibody. This re-
captures the in vivo observation that Cu-induced regression of hypertrophy is 
VEGF-dependent. Additionally, the induction of hypertrophy by phenylephrine 
can be blocked by using a VEGF antibody. This led us to the question: does 
VEGF have a duel function, acting to stimulate cell growth leading to 
hypertrophy as well as reversing hypertrophy? 
Cardiac myocyte hypertrophy was induced by PE at a final concentration of 100 11M 
in cultures for 48 hours in serum-free media. Cells were then treated with CUS04 by 
direct addition into the cultures at a final concentration of 5 11M. As seen below in 
Figure 1, and much to our surprise, PE induced VEGF production, but not Cu. Cu did 
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Figure 1. Quantitative analysis of VEGF secretion. Hypertrophy was induced by PE at a final 
concentration of 100 IlM for 48 hours in serum-free media. CUS04 was added directly to the 
cultures at a final concentration of 51lM for 24 hours. VEGF levels in collected media were 
determined by a Quantikine VEGF Immunoassay kit. The absorbance of standards and samples 
was measured spectrophotometrically at 450 run with a wavelength of 540 nm using a microplate 
reader. VEGF concentrations were calculated (in pg/mL) on the basis of the standard curve. 
Values are means ±SEM. * denotes statistically significant from Control group. n=3 . 
B. The effect of Cll treatment on VEGFRs 
The effect of VEGF is mediated through its receptors. VEGF receptors (VEGFRs) 
belong to a family of receptors called tyrosine kinases. Upon the binding of VEGF to its 
receptor, the receptors undergo dimerization and signal transduction. Since the amount 
of VEGF in the media of cell cultures was unchanged by Cu, the next thing we 
investigated was the effect that Cu had upon VEGFRs. There are 2 VEGF receptors in 
the cardiovascular system, FIt-I, also known as VEGF Receptor 1 (VEGFR-I) and KDR, 
also known as VEGF Receptor 2 (VEGFR-2). Activation of VEGFR-2 is associated with 
a mitogenic response, and is also involved in angiogenesis and survival signaling. A 
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decoy VEGFR-2.receptor blocked Akt-1 signalling pathway, which is associated with 
growth and is a critical component in the process of myocardial hypertrophy. VEGFR-1 
function was previously enigmatic. Our data suggests it may be associated with the 
reversal of hypertrophy. A schematic representationl75 can be seen in Figure 2. 
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Figure 2. A schematic representation of VEGF receptor signaling in cardiac myocytes. 
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The increase in the ratio of VEGFR-l to VEGFR-2 by Co treatment in hypertrophic 
cardiac myocytes 
1. We investigated the effect of Cu on the density of VEGFRs. As shown below in 
Figure 3, PE increased the density of both VEGFR-l (green) and VEGFR-2 (red). 
VEGFR-l was not changed by Cu addition, but markedly reduced that of 
VEGFR-2 in hypertrophic cardiac myocytes. The merged images of the two 
fluorescent labeling showed more green color (VEGFR-l) than the orange 
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Figure 3. Representative fluorescent microscopic images of cellular density of VEGFR-I 
(green) and VEGFR-2 (red) or the combination. Hypertrophy was induced by PE at a 
final concentration of 100 flM for 48 hours in serum-free media. CUS04 was added 
directly to the cultures at a [mal concentration of 5flM for 24 hours . After fixation, cells 
were incubated with polyclonal anti-VEGFR-I antibody, followed by Alexa Fluor 488 
conjugated goat anti-rabbit IgG. After washing the slide, the culture chamber was 
incubated with monoclonal antiVEGFR-2 antibody and incubated with Alexa Fluor 594 
conjugated goat anti-mouse IgG. Fluorescence was visualized by a fluorescent 










2. As shown in Figure 4 and 5, we also did quantitative analysis by flow cytometer 
to confirm the effect of Cu on the density of VEGFRs. The ratio of VEGFR-l to 
VEGFR-2 was significantly increased. Together, with the aforementioned data, 
this suggests a role for VEGF outside of angiogenesis due to the lack of blood 
vessels in cell cultures. Because Cu did not affect the amount of VEGF in 
cultures, this indicates that it has a direct effect that is mediated through VEGF 















Figure 4. Flow cytometric analysis of VEGFR-l and VEGFR-2. Hypertrophy was induced by PE 
at a final concentration of 100 ).lM for 48 hours in serum-free media. CUS04 was added directly to 
the cultures at a final concentration of 5).lM for 24 hours. Representative histograms show changes 
in the density of VEGFR-l and VEGFR-2 under different treatment conditions. The values 
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Figure 5. Flow cytometric analysis of VEGFR- l and VEGFR-2 in cultured neonatal rat cardiac 
myocytes. Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in 
serum-free media. CUS04 was added directly to the cultures at a final concentration of 5~M for 24 
hours. At the end of Cu treatment, cells were collected, fixed and incubated with Alexa Fluor488 
conjugated antibody of VEGFR-l and Alexa Fluor 594 conjugated antibody to VEGFR-2. Cells 
were subjected to flow cytometry analysis and 30,000 cells in each sample were counted. 
Receptor density was determined by the intensity of fluorescence using the software FlowJo based 
on the data collection from 30,000 cells per sample. Data were plotted in two-dimensional 
fluorescence intensity vs. cell number. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
values presented in the figures are means ±SEM. *Significantly different from Control group (P < 
0.05). MFI = Median Fluorescence Intensity. n = 3. 
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c. Reversal of PE-induced cardiac myocyte hypertrophy by gene silencing of 
VEGFR-2 
1. Thus far we have observed that the elevation of VEGFR-1:VEGFR-2 has been 
linked to the Cu-induced regression. This led us to the next question: How does 
VEGF induce the regression phenomenon? Could it be through VEGFR-l? We 
hypothesized that in Cu-treated hypetrophic cardiac myocytes, the distribution of 
VEGFRs would be altered, leading to a swich from cell growth stimulation to 
regression. To differentiate whether the increase in the ratio of VEGFR-
IIVEGFR-2 was related to the Cu-induced reversal of cardiomyocyte 
hypertrophy, we used siRNA targeting VEGFR-2 to increase the ratio of VEGFR-
IIVEGFR-2. It should be noted that the amount of siRNA used determines the 
efficacy of the knock down; in this case, the goal was not to completely silence 
VEGFR-2, but rather mimic the effect of Cu. In figures 6, 7 and 8, we show 
preliminary data of experiments targeting siRNA and flow cytometric analysis of 
VEGFR-l and 2 density, then the data plotted as a ratio of VEGFR-l:VEGFR-2. 
Gene silencing of VEGFR-2 increases the ratio of VEGFR-l to VEGFR-2 the 
same as that induced by Cu treatment, which is also associated with a reversal in 
cardiac myocyte hypertrophy. The effect is comparable to that induced by Cu 
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Figure 6. Quantitative analysis of the density of VEGFR-l based upon flow cytometric analysis . 
Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in serum-free 
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA 
targeting VEGFR-2. Lipofectamine 2000 was used as the transfecton reagent according to the 
manufacturer' s instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed 
and incubated with Alexa Fluor488 conjugated antibody ofVEGFR-1 and Alexa Fluor 594 
conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000 
cells in each sample were counted. Receptor density wa$ determined by the intensity of 
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample. 
Data were plotted in two-dimensional fluorescence intensity vs . cell number. Each group of data 
presented were obtained from three independent experiments and each experiment contains a 
triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
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Figure 7. Quantitative analysis of the density of VEGFR-2 based upon flow cytometric analysis. 
Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in serum-free 
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA 
targeting VEGFR-2. Lipofectamine 2000 was used as the transfecton reagent according to the 
manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed 
and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa Fluor 594 
conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000 
cells in each sample were counted. Receptor density was determined by the intensity of 
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample. 
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data 
presented were obtained from three independent experiments and each experiment contains a 
triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
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Figure 8. Ratio ofVEGFR-l:VEGFR-2 after using siRNA targeting VEGFR-2. Hypertrophy 
was induced by PE at a final concentration of 100 f!M for 48 hours in serum-free media. After PE 
treatment, cardiac myocytes were transfected with 10 nM annealed siRNA targeting VEGFR-2. 
Lipofectamine 2000 was used as the transfection reagent according to the manufacturer's 
instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed and incubated 
with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa Fluor 594 conjugated antibody 
to VEGFR-2. Cells were subjected to flow cytometry analysis and 30,000 cells in each sample 
were counted. Receptor density was determined by the intensity of fluorescence using the 
software FlowJo based on the data collection from 30,000 cells per sample. Data were plotted in 
two-dimensional fluorescence intensity vs. cell number. Each group of data presented were 
obtained from three independent experiments and each experiment contains a triplicate sample for 
each treatment. The values presented in the figures are means ±SEM. *Significantly different 
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Figure 9. Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2. Quantitative 
analysis of cell size based upon flow cytometric analysis . Hypertrophy was induced by PE at a final 
concentration of 100 flM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were 
transfected with 10 nM annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the 
transfection reagent according to the manufacturer's instructions. After 48 hours of transfection, cells 
were trypsinized, collected, fixed and subjected to flow cytometry analysis using forward scatter light, 
which is proportional to the cell size. 30,000 cells in each sample were counted. Each group of data 
presented were obtained from three independent experiments and each experiment contains a triplicate 
sample for each treatment. The values presented in the figures are means ±SEM. *Significantly 
different from Control group (P < 0.05). n = 3. 
60 
2000 
* - 1500 M E 
~ 
<D 
E 1000 :::l 
0 
> 
Q) 500 U 
0 
Control PE siRNA PE+siRNA 
Figure 10. Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2. 
Hypertrophy was induced by PE at a fmal concentration of 100 11M for 48 hours in serum-free 
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA 
targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent according to the 
manufacturer' s instructions. After 48 hours of transfection, cells were trypsinized, collected. Cell 
volume was determined using a Lovins microslide field finder. Briefly, cardiac myocytes in 
cultures were trypsinized, suspended in PBS and loaded onto a microslide field finder. The 
diameters of approximately 150 cells from each group were assessed and recorded. The cell 
volume was calculated using the volume of a sphere: V= (4/3)nr3 where V = cell volume, n = 3.14 
and r = radius. Each group of data presented were obtained from three independent experiments 
and each experiment contains a triplicate sample for each treatment. The values presented in the 
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Figure 11. Regression of PE-induced cell hypertrophy by siRNA targeting VEGFR-2. The protein 
content in the cells measured by a Bradford method and normalized by cell number. Each group of 
data presented were obtained from three independent experiments and each experiment contains a 
triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
*Significantly different from Control group (P < 0.05). 
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D. Regression of PE-induced hypertrophy by siRNA targeting VEGFR-2 and the 
requirement of VEGF in the regression of cardiac myocyte hypertrophy. 
1. The regression of cardiac myocyte hypertrophy induced by Cu is blocked if a anti-
VEGF antibody is added, further demonstrating that VEGF is required for 
angiogenesis and growth, but also plays a role in the regression effect that we 
observe. Further, VEGFR-2 gene silencing-induced regression of cardiac 
myocyte hypertrophy is VEGF-dependent as we1l159• We have observed both in 
vivo and in vitro that the Cu-effect is VEGF-dependent. When silencing 
VEGFR-2, we observed the same phenomenon with Cu. The next question we 
asked is: Is this effect also VEGF-dependent? 
There are three indices of hypertrophy that we used to measure the effect of Cu on the 
reversal of hypertrophy: cell size, cell volume and protein content. Cell size was 
determined by flow cytometry, using forward scatter light, which is proportional to 
cell size. Cell volume was determined using a microslide field finder, and the diamter 
of 150 cells was measured. The equation for the volume of a sphere was used to 
determine the volume, V = (4/3)nr3. Protein content was measured using the 
Bradford method, and was normalized by the cell number. 
And as clearly shown in Figures 12, 13 and 14, the regression of PE-induced hypertrophy 
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Figure 12. Regression ofPE-induced hypertrophy by siRNA targeting VEGFR-2 and the 
requirement of VEGF in the regression of cardiac myocyte hypertrophy induced by siRNA 
targeting VEGFR-2. Quantitative analysis of cell size based upon flow cytometric analysis. 
Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in serum-free 
media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed siRNA 
targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent according to the 
manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed 
and subjected to flow cytometry analysis using forward scatter light, which is proportional to the 
cell size. 30,000 cells in each sample were counted. Each group of data presented were obtained 
from three independent experiments and each experiment contains a triplicate sample for each 
treatment. The values presented in the figures are means ±SEM. *Significantly different from 
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Figure 13. Effect of siRNA targeting VEGFR-2 on the regression of PE-induced hypertrophy, and 
the requirement of VEGF. Hypertrophy was induced by PE at a final concentration of 100 11M for 
48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM 
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent 
according to the manufacturer's instructions. After 48 hours of transfection, cells were 
trypsinized, collected. Cell volume was determined using a Lovins microslide field finder. 
Briefly, cardiac myocytes in cultures were trypsinized, suspended in PBS and loaded onto a 
microslide field finder. The diameters of approximately 150 cells from each group were assessed 
and recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)m3 where V 
= cell volume, 7t = 3.14 and r = radius. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
values presented in the figures are means ±SEM. *Significantly different from Control group (P < 
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Figure 14, Regression ofPE-induced cell hypertrophy by siRNA targeting VEGFR-2in primary 
cultures of neonatal rat cardiomyocytes, and the requirement of VEGF in the regression of 
cardiomyocyte hypertrophy induced by siRNA targeting VEGFR-2. The protein content in the cells 
measured by a Bradford method and normalized by cell number. Each group of data presented were 
obtained from three independent experiments and each experiment contains a triplicate sample for each 
treatment. The values presented in the figures are means ±SEM. *Significantly different from Control 
group (P < 0.05). 
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E. Suppression of eu-induced reversal of cardiomyocyte hypertrophy by gene 
silencing of VEGFR-l. 
1. Up until this point, all the data points to VEGFR-1. The increase in the ratio of 
VEGFR-1NEGFR-2 accompanied with the reversal ofPE-induced cardiac 
myocyte hypertrophy indicated the determinant role of VEGFR-1 in Cu 
regression of cardiac myocyte hypertrophy. The next question that we asked was: 
If you knock out VEGFR-1, what happens? We used siRNA targeting VEGFR-1 
to examine the effect of suppressing VEGFR-1 on Cu reversal of cardiac myocyte 
hypertrophy. Figures 15, 16 and 17 show quantitative analysis of the effect of 
siRNA targeting VEGFR-1 on VEGFR-1, VEGFR-2 and the ratio ofVEGFR-
1:VEGFR-2 respectively. As shown in Figures 18, 19 and 20, gene silencing of 
VEGFR-1 inhibited the response of the cells to PE-induced VEGFR-1 elevation, 
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Figure 15. Effect of siRNA targeting VEGFR-l on the distribution ofVEGFR-l and VEGFR-2 
and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell 
hypertrophy. Quantitative analysis of the density ofVEGFR-l based on the flow cytometric 
analysis. Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in 
serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed 
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according 
to the manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, 
collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa 
Fluor 594 conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 
30,000 cells in each sample were counted. Receptor density was determined by the intensity of 
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample. 
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data 
presented were obtained from three independent experiments and each experiment contains a 
triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
*Significantly different from Control group. tsignificantly different from PE-treated group (P < 
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Figure 16. Effect of siRNA targeting VEGFR-l on the distribution of VEGFR-l and VEGFR-2 
and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell 
hypertrophy. Quantitative analysis of the density ofVEGFR-l based on the flow cytometric 
analysis. Hypertrophy was induced by PE at a final concentration of 100 ~M for 48 hours in 
serum-free media. After PE treatment, cardiac myocytes were trans fee ted with 10 nM annealed 
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according 
to the manufacturer's instructions. After 48 hours of transfection, cells were trypsinized, 
collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l and Alexa 
Fluor 594 conjugated antibody to VEGFR-2. Cells were subjected to flow cytometry analysis and 
30,000 cells in each sample were counted. R.eceptor density was determined by the intensity of 
fluorescence using the software FlowJo based on the data collection from 30,000 cells per sample. 
Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each group of data 
presented were obtained from three independent experiments and each experiment contains a 
triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
*Significantly different from Control group (P < 0.05). MFI = Median Fluorescence Intensity. n 
=3. 
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Figure 17. Quantitative analysis of the density of VEGFR-l based on the flow cytometric analysis. 
Ratio of VEGFR-l :VEGFR-2. Effect of siRNA targeting VEGFR-l on the distribution of 
VEGFR-l and VEGFR-2 and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced 
regression of cell hypertrophy. Effect of siRNA targeting VEGFR-l on the distribution of 
VEGFR-l and VEGFR-2 and the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced 
regression of cell hypertrophy. Hypertrophy was induced by PE at a final concentration of 100 
/lM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with 
10 nM annealed siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection 
reagent according to the manufacturer's instructions. After 48 hours of transfection, cells were 
trypsinized, collected, fixed and incubated with Alexa Fluor488 conjugated antibody of VEGFR-l 
and Alexa Fluor 594 conjugated aritibody to VEGFR-2. Cells were subjected to flow cytometry 
analysis and 30,000 cells in each sample were counted. Receptor density was determined by the 
intensity of fluorescence using the software FlowJo based on the data collection from 30,000 cells 
per sample. Data were plotted in two-dimensional fluorescence intensity vs. cell number. Each 
group of data presented were obtained from three independent experiments and each experiment 
contains a triplicate sample for each treatment. The values presented in the figures are means 
±SEM. *Significantly different from Control group. tsignificantly different from PE-treated 
group (P < 0.05). MFI = Median Fluorescence Intensity. n = 3. 
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Again, we measured the three indices of hypertrophy: cell size, cell volume and 
protein content. Cell size was determined by flow cytometry, using forward scatter 
light, which is proportional to cell size. Cell volume was determined using a 
microslide field finder, and the diamter of 150 cells was measured. The equation for 
the volume of a sphere was used to determine the volume, V = (4/3)nr3. Protein 
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Figure 18. Quantitative analysis of cell size based upon flow cytometric analysis. Hypertrophy 
was induced by PE at a final concentration of 100 11M for 48 hours in serum-free media. After PE 
treatment, cardiac myocytes were transfected with 10 nM annealed siRNA targeting VEGFR-l. 
Lipofectamine 2000 was used as the transfection reagent according to the manufacturer's 
instructions. After 48 hours of transfection, cells were trypsinized, collected, fixed and subjected 
to flow cytometry analysis using forward scatter light, which is proportional to the cell size. 
30,000 cells in each sample were counted. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
values presented in the figures are means ±SEM. *Significantly different from Control group. 
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Figure 19. Hypertrophy was induced by PE at a final concentration Of 100 11M for 48 hours in 
serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM annealed 
siRNA targeting VEGFR-l. Lipofectamine 2000 was used as the transfection reagent according 
to the manufacturer's instructions. After 48 hours of trans feet ion, cells were trypsinized and 
collected. Cell volume was determined using a Lovins microslide field finder. Briefly, cardiac 
myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide field 
finder. The diameters of approximately ISO cells from each group were assessed and recorded. 
The cell volume was calculatred using the volume of a sphere: V= (4/3)1tr3 where V = cell volume, 
1t = 3.14 and r = radius. Each group of data presented were obtained from three independent 
experiments and each experiment contains a triplicate sample for each treatment. The values 
presented in the figures are means ±SEM. *Significantly different from Control group and 
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Figure 20. Effect of siRNA targeting VEGFR-l on the distribution ofVEGFR-l and VEGFR-2 and 
the antagonistic effect of siRNA targeting VEGFR-l on Cu-induced regression of cell hypertrophy. At 
the end of siRNA treatment, cells were collected. The protein content in the cells measured by a 
Bradford method and normalized by cell number. Each group of data presented were obtained from 
three independent experiments and each experiment contains a triplicate sample for each treatment. 
The values presented in the figures are means ±SEM. *Significantly different from Control group and 
tsignificantly different from PE-treated group (P < 0.05). 
In summary, the data suggests that the regression of hypertrophy is associated 
with an increase in the VEGFR-l:VEGFR-2. We also observed that siRNA targeting 
VEGFR-2 mimics the Cu-effect. Additionally, we also observed that siRNA targeting 
VEGFR-l blocks Cu-induced reversal of cardiac myocyte hypertrophy induced by PE. 
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F. Association ofPKG-l with VEGFR-l-mediated reversal of cardiomyocyte 
hypertrophy by eu treatment 
1. The data thus far suggests that VEGFR-l is a mediator in the reversal effect. The 
next question that we asked was: What is the signaling molecule associated with 
VEGFR-l? cGMP-dependent protein kinase-l (PKG-l) has been defined to be 
involved in the inhibition of myocardial growth. The PKG-l signaling pathway is 
a well-studied and important pathway that has also been shown to be involved in 
the regression of cardiac hypertrophy176. Additionally, this effect has also been 
shown to be VEGF-dependent. The link between VEGFR-l and PKG-l was 
examined by the effect of VEGFR-l gene silencing on PKG-l activity. 
We hypothesized that the VEGFR-l increase related regression is mediated by 
PKG-l and set out to determine the role of PKG-l and VEGFR -1 mediated 
regression of cardiac myocyte hypertrophy. The first thing that we examined was 
the effect of VEGFR-l gene silencing on PKG-l activity, as seen in Figure 21. 
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Figure 21. Inhibitory effect of siRNA targeting VEGFR-} on PKG-l activity on PE-elevated 
PKG-l activity. PKG-l activity was assayed by a colormetric analysis procedure. The assay was 
performed 30 minutes after treatment with Cu. Each group of data presented were obtained from 
three independent experiments and each experiment contains a triplicate sample for each 
treatment. The values presented in the figures are means ±SEM. *Significantly different from 
Control group and tsignificantly different from PE-treated group (P < 0.05). 
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2. We also examined the effect ofPKG-l antagonist on Cu- or VEGFR-2 gene 
silencing-induced regression of cardiac myocyte hypertrophy. The results suggest 
that PE treatment significantly elevated PKG-l activity and Cu addition did not 
change PKG-l activity, but VEGFR-l gene silencing significantly attenuated PE-
induced PKG-l activation. Additionally, a PKG-l antagonist, Rp-8-pCPT-
cGMPS, blocked both VEGFR-2 gene silencing- and Cu-induced reversal of 
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Figure 22. Antagonistic effect PKG-I inhibitor, Rp-8-pCPT -cGl\1PS, on regression of cell 
hypertrophy by siRNA targeting VEGFR-2. PKG-l inhibitor was added 1 hour prior to siRNA at 
a concentration of 0.5 11M. Hypertrophy was induced by PE at a final concentration of 100 11M for 
48 hours in serum-free media. After PE treatment, cardiac myocytes were trans fee ted with 10 nM 
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent 
according to the manufacturer's instructions. After 48 hours of trans feet ion, cells were trypsinized 
and collected. Quantitative analysis of cell size based upon flow cytometric analysis. Each group 
of data presented were obtained from three independent experiments and each experiment contains 
a triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
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Figure 23. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT -cGMPS, on regression of cell 
hypertrophy by siRNA targeting VEGFR-2. PKG-l inhibitor was added 1 hour prior to siRNA at 
a concentration of 0.5 11M. Hypertrophy was induced by PE at a final concentration of 100 11M for 
48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected with 10 nM 
annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the transfection reagent 
according to the manufacturer's instructions. After 48 hours oftransfection, cells were trypsinized 
and collected. Cell volume was determined using a Lovins microslide field finder. Briefly, 
cardiac myocytes in cultures were trypsinized, suspended in PBS and loaded onto a microslide 
field finder. The diameters of approximately 150 cells from each group were assessed and 
recorded. The cell volume was calculated using the volume of a sphere: V= (4/3)rrr3 where V = 
cell volume, 1t = 3.14 and r = radius. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
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Figure 24. Antagonistic effect of PKG-I inhibitor, Rp-8-pCPT -cGMPS, on regression of cell 
hypertrophy induced by siRNA targeting VEGFR-2. PKG-I inhibitor was added I hour prior to 
siRNA at a concentration of 0.5 IlM. Hypertrophy was induced by PE at a final concentration of 
100 IlM for 48 hours in serum-free media. After PE treatment, cardiac myocytes were transfected 
with 10 nM annealed siRNA targeting VEGFR-2. Lipofectamine 2000 was used as the 
transfection reagent according to the manufacturer's instructions. After 48 hours of transfection, 
cells were trypsinized and collected. The protein content in the cells measured by a Bradford 
method and normalized by cell number. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
values presented in the figures are means ±SEM. *Significantly different from Control group and 
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Figure 25. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT -cGMPS, on regression of cell 
hypertrophy by Cu supplementation. PKG-l inhibitor was added 1 hour prior to Cu at a 
concentration of 0.5 /!M, Hypertrophy was induced by PE at a final concentration of 100 I!M for 
48 hours in serum-free media. After PE treatment, cardiac myocytes were treated with 5 /!M Cu 
by direct addition to the cultures. Quantitative analysis of cell size based upon flow cytometric 
analysis. Each group of data presented were obtained from three independent experiments and 
each experiment contains a triplicate sample for each treatment. The values presented in the 
figures are means ±SEM. *Significantly different from Control group and tsignificantly different 
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Figure 26. Antagonistic effect PKG-l inhibitor, Rp-8-pCPT-cGMPS, on regression of cell hypertrophy 
by Cu supplementation. PKG-l inhibitor was added 1 hour prior to Cu at a concentration of 0.5 11M. 
Hypertrophy was induced by PE at a final concentration of 100 11M for 48 hours in serum-free media. 
After PE treatment, cardiac myocytes were treated with 5 11M Cu by direct addition to the cultures. 
Cell volume was determined using a Lovins microslide field finder. Briefly, cardiac myocytes in 
cultures were trypsinized, suspended in PBS and loaded onto a microslide field finder. The diameters 
of approximately 150 cells from each group were assessed and recorded. The cell volume was 
calculatred using the volume of a sphere: V= (4/3)m3 where V = cell volume, 1t = 3.14 and r = radius. 
Each group of data presented were obtained from three independent experiments and each experiment 
contains a triplicate sample for each treatment. The values presented in the figures are means ±SEM. 
*Significantly different from Control group and tsignificantly different from PE-treated group (P < 
0.05). 
80 
!!! 0.25 o - PKG antagonist Q) 





a.. - 0.1 C) 
E -c 
'Q) 0.05 -0 
"-a.. 
0 
Control PE Cu PE+Cu 
Figure 27. Antagonistic effect PKG-I inhibitor, Rp-8-pCPT -cGMPS, on regression of cell 
hypertrophy by Cu supplementation. PKG-I inhibitor was added I hour prior to Cu at a 
concentration of 0.5 ~M. Hypertrophy was induced by PE at a final concentration of I 00 ~M for 
48 hours in serum-free media. After PE treatment, cardiac myocytes were treated with 5 ~M Cu 
by direct addition to the cultures. The protein content in the cells measured by a Bradford method 
and normalized by cell number. Each group of data presented were obtained from three 
independent experiments and each experiment contains a triplicate sample for each treatment. The 
values presented in the figures are means ±SEM. *Significantly different from Control group and 
tsignificantly different from PE-treated group (P < 0.05). 
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In summary, these data suggest that PKG-l antagonist blocks the regression of 
cardiac myocyte hypertrophy induced by siRNA targeting VEGFR-2, as well as 
eu-induced regression of cardiac myocyte hypertrophy. 
As a whole, this body of data suggests that the VEGFR-l pathway is somehow 
linked to the PKG-l signaling pathway. It appears that both are involved in the 
regression of cardiac hypertrophy and are somehow linked. 
Regression of cardiac hypertrophy 
Induction of cardiac hypertrophy 
Figure 28. A complete schematic representation of VEGF receptor signaling in cardiac 
myocytes. 
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G. The involvement of Vimentin in the regression of cardiac myocyte 
hypertrophy 
1. The next question we asked was if there was a correlation between VEGFR -1 and 
PKG-l? Was it direct, or indirect? How? We then hypothesized that VEGFR-l and 
PKG-l are members of the same signaling cluster. 
Copper-induced regression of cardiac myocyte hypertrophy is associated with 
enhanced VEGFR-l signaling, as well as an increase in PKG-l activity. In order to 
investigate the mechanisms by which this phenomena occurs, we used functional 
proteomics to identify proteins associated with PKG-l(Tables 1,2 and 3) and 
VEGFR-l (Table 4). There is one caviat: neither VEGFR-l nor.PKG-l are copper-
binding proteins, yet the phenomenon we have observed is related to Cu 
supplementation. 
We used immunoprecipitation to pull down the immune complexes associated with 
VEGFR-l as well as PKG-l. These immune complexes were sent off for LC-MS/MS 
analysis. Hundreds of proteins were identified in both complexes, however we were 
most interested in a copper-binding protein. For this reason, we chose Vimentin. Our 
preliminary Western blot analysis, in Figure 29 showed that PE treatment caused a 
decrease in the amount of Vimentin. 
To further validate this interaction, we used co-immunoprecipitation, pulling down 
Vimentin and then subjecting the immunopreciptate to Western blot analysis. These 
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experiments further validated the protein-protein interaction between Vimentin and 
PKG-1 (Figure 30), and Vimentin and VEGFR-1(Figures 31 and 32). We 
hypothesize that PE causes a decrease in Vimentin, and this tips the scale, favoring 
hypertrophic signaling and growth in cardiac myocytes. 
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Table 1: PKG-1 pull-down 
Control Cu PE PE+Cu 
60 kDa heat shock protein, 60 kDa heat shock protein, 60 kDa heat shock protein, 60 kDa heat shock protein, 
mitochondrial mitochondrial mitochondrial mitochondrial 
ATP synthase subunit alpha, A TP synthase subunit alpha, ATP synthase subunit alpha, 
mitochondrial mitochondrial mitochondrial 
ATP synthase subunit beta, A TP synthase subunit beta, ATP synthase subunit beta, 
mitochondrial mitochondrial mitochondrial 
ATP synthase subunit 0, 
mitochondrial 
Malate dehydrogenase, Malate dehydrogenase, Malate dehydrogenase, Malate dehydrogenase, 
mitocho ndrial mitochondrial mitochondrial mitochondrial 
Serine hydroxymethyltransferase, 
mitochondrial 
14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 
00 14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 
U\ 
14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 
14-3-3 protein eta 14-3-3 protein eta 14-3-3 protein eta 
14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 
14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 
26S proteasome non-ATPase 
regulatory subunit 
40S ribosomal protein SA 40S ribosomal protein SA 40S ribosomal protein SA 
40S ribosomal protein S2 40S ribosomal protein S2 40S ribosomal protein S2 
40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 
40S ribosomal protein S5 40S ribosomal protein S5 
40S ribosomal protein S6 40S ribosomal protein S6 
40S ribosomal protein S12 40S ribosomal protein S12 40S ribosomal protein S12 40S ribosomal protein S12 . 
40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S 18 
40S ribosomal protein S 19 
40S ribosomal protein S20 40S ribosomal protein S20 
40S ribosomal protein S24 
40S ribosomal protein S26 
40S ribosomal protein S28 40S ribosomal protein S28 40S ribosomal protein S28 40S ribosomal protein S28 
60S ribosomal protein L4 60S ribosomal protein L4 60S ribosomal protein L4 
60S ribosomal protein L6 
60S ribosomal protein L 7 60S ribosomal protein L 7 
60S ribosomal protein LII 
60S ribosomal protein LI2 
60S ribosomal protein LI7 
60S ribosomal protein L23 
60S ribosomal protein L23a 60S ribosomal protein L23a 
60S ribosomal protein L24 60S ribosomal protein L24 
60S ribosomal protein L27a 60S ribosomal protein L27a 
60S acidic ribosomal protein PO- 60S acidic ribosomal protein 
like PO-like 
00 60S acidic ribosomal protein PO 60S acidic ribosomal protein PO 60S acidic ribosomal protein PO 
0\ 60S acidic ribosomal protein PI 
60S acidic ribosomal protein P2 60S acidic ribosomal protein P2 60S acidic ribosomal protein P2 
78 kDa glucose-regulated 78 kDa glucose-regulated 






Protein SIOO-AII Protein SIOO-AII Protein S IOO-All Protein SIOO-AII 
SH3 domain-binding glutamic SH3 domain-binding glutamic acid-
acid-rich-like protein rich-like protein 
UPF0568 protein C 14orfl66 UPF0568 protein C14orfl66 UPF0568 protein C14orfl66 UPF0568 protein C14orfl66 
UPF0027 protein C22orf28 UPF0027 protein C22orf28 
Alpha-actinin-l Alpha-actinin-l Alpha-actinin-l Alpha-actinin-l 
Alpha-actinin-2 
Alpha-actinin-4 Alpha-actinin-4 Alpha-actinin-4 Alpha-actinin-4 
Adenylyl cyclase-associated Adenylyl cyclase-associated Adenylyl cyclase-associated Adenylyl cyclase-associated protein 
protein I protein I protein I 1 
Annexin Al AnnexinAI AnnexinAI AnnexinAl 
AnnexinA2 AnnexinA2 AnnexinA2 AnnexinA2 
Putative annexin A2-like 
Putative annexin A2-like protein Putative annexin A2-like protein protein Putative annex in A2-like protein 
AnnexinA5 AnnexinA5 AnnexinA5 AnnexinA5 
AnnexinA6 AnnexinA6 Annexin A6 
Actin, cytoplasmic I Actin, cytoplasmic I Actin, cytoplasmic I Actin, cytoplasmic 1 
Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 
Actin-related protein 3 Actin-related protein 3 Actin-related protein 3 
Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle 
Actin, alpha cardiac muscle I Actin, alpha cardiac muscle I Actin, alpha cardiac muscle I Actin, alpha cardiac muscle 1 
Actin, gamma-enteric smooth Actin, gamma-enteric smooth Actin, gamma-enteric smooth 
muscle muscle muscle Actin, gamma-enteric smooth muscle 
00 
Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle -....l 
ADP-ribosylation factor I ADP-ribosylation factor I ADP-ribosylation factor I ADP-ribosylation factor 1 
ADP-ribosylation factor 3 ADP-ribosylation factor 3 ADP-ribosylation factor 3 ADP-ribosylation factor 3 
ADP-ribosylation factor 4 ADP-ribosylation factor 4 ADP-ribosylation factor 4 ADP-ribosylation factor 4 
ADP-ribosylation factor 5 ADP-ribosylation factor 5 ADP-ribosylation factor 5 ADP-ribosylation factor 5 
ADPI ATP translocase I 
ADP/ATP translocase 2 ADP/ATP translocase 2 
ADPI ATP translocase 3 ADP/ATP translocase 3 ADPI A TP translocase 3 
Apolipoprotein D 
ATP-dependent RNA helicase 
DDX3X 
Beta-actin-like protein 2 Beta-actin-like protein 2 Beta-actin-like protein 2 Beta-actin-like protein 2 
Beta-actin-like protein 3 Beta-actin-like protein 3 Beta-actin-like protein 3 Beta-actin-like protein 3 
Brain acid soluble protein 1 Brain acid soluble protein I Brain acid soluble protein 1 Brain acid soluble protein 1 
Calmodulin Calmodulin Calmodulin Calmodulin 
Cal pain small subunit 1 Calpain small subunit 1 Calpain small subunit 1 
Calponin-2 Calponin-2 Calponin-2 Calponin-2 
Calponin-3 Calponin-3 Calponin-3 
Calreticulin 
Calumenin Calumenin 
Cathepsin B CathepsinB 
CathepsinD CathepsinD 
Chloride intracellular channel Chloride intracellular channel Chloride intracellular channel Chloride intracellular channel protein 
protein I protein I protein I I 
Chloride intracellular channel Chloride intracellular channel protein 
protein 4 4 
Clathrin heavy chain I Clathrin heavy chain I Clathrin heavy chain I 
Coatomer subunit beta 





Complement C4-B 00 
Cullin-associated NEDDS- Cullin-associated NEDDS- Cullin-associated NEDDS-
dissociated protein I dissociated protein I dissociated protein I 
Cytochrome c 
Elongation factor I-alpha 1 Elongation factor I-alpha I Elongation factor I-alpha I Elongation factor I-alpha I 
Putative elongation factor 1- Putative elongation factor 1- Putative elongation factor 1- Putative elongation factor l-alpha-
alpha-like 3 alpha-like 3 alpha-like 3 like 3 
Elongation factor I-beta Elongation factor I-beta Elongation factor I-beta 
Elongation factor 2 Elongation factor 2 Elongation factor 2 Elongation factor 2 
Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 
Elongation factor I-delta Elongation factor I-delta Elongation factor I-delta Elongation factor I-delta 
Elongation factor I-gamma Elongation factor I-gamma Elongation factor I-gamma 
Endoplasmin Endoplasmin Endoplasmin Endoplasmin 
Alpha-enolase Alpha-enolase Alpha-enolase Alpha-enolase 
Beta-enolase Beta-enolase Beta-enolase Beta-enolase 
Gamma-enolase Gamma-enolase Gamma-enolase Gamma-enolase 
Eukaryotic initiation factor 4A-I Eukaryotic initiation factor 4A-I Eukaryotic initiation factor 4A-I Eukaryotic initiation factor 4A-I 
Eukaryotic initiation factor 4A- Eukaryotic initiation factor 4A-
Eukaryotic initiation factor 4A-II II II Eukaryotic initiation factor 4A-I1 
Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation 
factor 5A-I factor 5A-I factor 5A-I factor 5A-I 
Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation 
factor 5A-l-Iike factor 5A-l-Iike factor 5A-I-like factor 5A-I-like 
Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation Eukaryotic translation initiation 
factor 5A-2 factor 5A-2 factor 5A-2 factor 5A-2 
Exportin-2 Exportin-2 
Ezrin 





Fructose-bisphosphate aldolase Fructose-bisphosphate aldolase 
CXl Fructose-bisphosphate aldolase A A A Fructose-bisphosphate aldolase A 1.0 
Galectin-I Galectin-I Galectin-I Galectin-I 
Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase 
Glutathione S-transferase 
omega-I 
Glutathione S-transferase P Glutathione S-transferase P Glutathione S-transferase P Glutathione S-transferase P 
Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate 
dehydrogenase dehydrogenase dehydrogenase dehydrogenase 
Guanine nucleotide-binding 
protein subunit beta-2-l 
GTP-binding nuclear protein GTP-binding nuclear protein 
GTP-binding nuclear protein Ran Ran Ran GTP-binding nuclear protein Ran 
Heat shock protein HSP 90- Heat shock protein HSP 90-
Heat shock protein HSP 90-alpha alpha alpha Heat shock protein HSP 90-alpha 
Heat shock protein HSP 90-beta Heat shock protein HSP 90-beta Heat shock protein HSP 90-beta Heat shock protein HSP 90-beta 
Heat shock protein beta-I Heat shock protein beta-I 
Heat shock-related 70 kDa protein Heat shock-related 70 kDa Heat shock-related 70 kDa 
2 protein 2 protein 2 Heat shock-related 70 kDa protein 2 
Heat shock 70 kDa protein 1 
Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 
Putative heat shock 70 kDa protein 7 
Heat shock 70 kDa protein lL 
Heat shock cognate 71 kDa Heat shock cognate 71 kDa Heat shock cognate 71 kDa 
protein protein protein Heat shock cognate 71 kDa protein 
Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP 90-
90-alpha A2 90-alpha A2 90-alpha A2 alpha A2 
Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP 90-
90-beta 2 90-beta 2 90-beta 2 beta 2 
Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP Putative heat shock protein HSP 90-
90-beta-3 90-beta-3 90-beta-3 beta-3 
Putative heat shock protein HSP Putative heat shock protein HSP 90-
90-beta 4 beta 4 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein Al ribonucleoprotein Al ribonucleoprotein Al 
Putative heterogeneous nuclear Putative heterogeneous nuclear Putative heterogeneous nuclear 
\0 ribonucleoprotein A ribonucleoprotein A ribonucleoprotein A 
0 Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein AI-like ribonucleoprotein AI-like ribonucleoprotein A I-like 
Heterogeneous nuclear 
ribonucleoprotein AlB 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins A21B I ribonucleoproteins A21B I ribonucleoproteins A21B I ribonucleoproteins A21B 1 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein C-like I ribonucleoprotein C-like I 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins C l/C2 ribonucleoproteins C l/C2 ribonucleoproteins C l/C2 ribonucleoproteins ClIC2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein DO ribonucleoprotein DO ribonucleoprotein DO 
Heterogeneous nuclear 
ribonucleoprotein D-like 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 




Importin subunit beta-I 
L-Iactate dehydrogenase A chain 







Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
12A 
Myosin regulatory light chain 
12B 
Histone H2A type I 
Histone H2A type I-BIE 
Histone H2A type I-C 
Histone H2A type 1-D 
Histone H2A type 1-H 
Histone H2A type I-J 
Histone H2A type 2-A 
Histone H2A type 2-C 
Histone H2A type 3 
Histone H2A.J 
Importin-5 
Importin subunit alpha-2 
Importin subunit beta-I 
Histone H2A type I 
Histone H2A type I-BIE 
Histone H2A type l-C 
Histone H2A type I-D 
Histone H2A type I-H 
Histone H2A type I-J 
Histone H2A type 2-A 
Histone H2A type 2-C 
Histone H2A type 3 
Histone H2A.J 
Importin subunit beta-I 
Latexin Latexin 
L-Iactate dehydrogenase A 
L-Iactate dehydrogenase A chain chain 
L-Iactate dehydrogenase B 








Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
12A 






Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
12A 
Myosin regulatory light chain 
12B 
Importin-5 
Importin subunit beta-l 
Integrin beta-l 
Latexin 
L-Iactate dehydrogenase A chain 
L-Iactate dehydrogenase B chain 






Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 12A 
Myosin regulatory light chain 12B 
Myosin regulatory light Myosin regulatory light Myosin regulatory light Myosin regulatory light polypeptide 
polypeptide 9 polypeptide 9 polypeptide 9 9 
Myristoylated alanine-rich C- Myristoylated alanine-rich C- Myristoylated alanine-rich C- Myristoylated alanine-rich C-kinase 
kinase substrate kinase substrate kinase substrate substrate 
Multifunctional protein ADE2 
NAD(P)H dehydrogenase [quinone] 
1 
Nicotinamide N- Nicotinamide N- Nicotinamide N-
methyl transferase methyltransferase methyl transferase Nicotinamide N-methyltransferase 
Neuroblast differentiation- Neuroblast differentiation- Neuroblast differentiation- Neuroblast differentiation-associated 
associated protein AHNAK associated protein AHNAK associated protein AHNAK protein AHNAK 
Nucleophosmin Nucleophosmin Nucleophosmin 
Nuclease-sensitive element-binding 
protein 1 
Putative nucleoside diphosphate 
kinase 
Nucleoside diphosphate kinase 
B 
\0 POTE ankyrin domain family POTE ankyrin domain family POTE ankyrin domain family POTE ankyrin domain family N 
memberE memberE memberE memberE 
POTE ankyrin domain family POTE ankyrin domain family POTE ankyrin domain family POTE ankyrin domain family 
memberF memberF memberF memberF 
Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans 
isomerase A isomerase A isomerase A Peptidyl-prolyl cis-trans isomerase A 
Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans 
isomerase B isomerase B isomerase B Peptidyl-prolyl cis-trans isomerase B 
Peroxiredoxin-l Peroxiredoxin-l Peroxiredoxin-l Peroxiredoxin-l 
Peroxiredoxin-6 Peroxiredoxin-6 Peroxiredoxin-6 
Peripherin Peripherin Peripherin 
Phosphoglycerate kinase 1 Phosphoglycerate kinase 1 Phosphoglycerate kinase 1 Phosphoglycerate kinase 1 
Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 
Phosphoglycerate mutase 2 Phosphoglycerate mutase 2 
Probable phosphoglycerate 
mutase 4 Probable phosphoglycerate mutase 4 
Proteasome subunit beta type-3 
Plastin-3 Plastin-3 Plastin-3 
Polyadenylate-binding protein I 
Proactivator polypeptide Pro activator polypeptide Pro activator polypeptide Proactivator polypeptide 
Profilin-l Profilin-l Profilin-l Profilin-l 
Prolactin-inducible protein 
Proteasome activator complex 
subunit 2 
Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase 
Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 
Protein disulfide-isomerase A4 
Protein disulfide-isomerase A6 Protein disulfide-isomerase A6 Protein disulfide-isomerase A6 
Pyruvate kinase isozymes Pyruvate kinase isozymes 
Pyruvate kinase isozymes MIIM2 MIIM2 MIIM2 Pyruvate kinase isozymes MIIM2 
Poly(rC)-binding protein I Poly(rC)-binding protein 1 Poly(rC)-binding protein I 
Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 
Poly(rC)-binding protein 3 
\0 Rab GOP dissociation inhibitor ~ 
alpha Rab GOP dissociation inhibitor alpha 
Rab GOP dissociation inhibitor 
beta Rab GOP dissociation inhibitor beta 
Radixin 
Ras-related protein Rab-5C 
Ras-related protein Rab-l 0 Ras-related protein Rab-l 0 Ras-related protein Rab-lO Ras-related protein Rab-l 0 
Ras-related protein Rab-IA Ras-related protein Rab-IA 
Ras-related protein Rab-lB Ras-related protein Rab-lB Ras-related protein Rab-lB 
Ras-related protein Rab-15 Ras-related protein Rab-15 Ras-related protein Rab-15 
Putative Ras-related protein 
Rab-lC Putative Ras-related protein Rab-IC 
Ras-related C3 botulinum toxin 
substrate 
Ras-related C3 botulinum toxin 
substrate 3 
Reticulon-4 Reticulon-4 Reticulon-4 Reticulon-4 
Rho GDP-dissociation inhibitor 
I 
Ribonuclease inhibitor 
RNA-binding protein EWS 
RNA-binding protein PUS RNA-binding protein FUS 
Sacsin 
Serpin HI Serpin HI 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
T-complex protein I subunit 
T-complex protein I subunit beta beta 
T -complex protein I subunit T-complex protein I subunit 
gamma gamma 
T-complex protein 1 subunit 
theta 
\0 
T -complex protein I subunit eta +:-
Thioredoxin Thioredoxin 
Thioredoxin domain-containing Thioredoxin domain-containing 






Triosephosphate isomerase Triosephosphate isomerase 
Tropomyosin alpha-4 chain 
Tubulin alpha-IA chain Tubulin alpha-I A chain 
Tubulin alpha-IB chain Tubulin alpha-IB chain 
Tubulin alpha-l C chain Tubulin alpha-IC chain 
Serpin HI 
T -complex protein I subunit 
beta 
T-complex protein I subunit 
gamma 







Tropomyosin alpha-4 chain 
Tubulin alpha-IA chain 
Tubulin alpha-lB chain 





T-complex protein I subunit beta 
T -complex protein I subunit gamma 
T-complex protein 1 subunit delta 
T-complex protein I subunit theta 
T -complex protein 1 subunit eta 







Tubulin alpha-IA chain 
Tubulin alpha-lB chain 
Tubulin alpha-IC chain 
Tubulin alpha chain-like 3 Tubulin alpha chain-like 3 Tubulin alpha chain-like 3 Tubulin alpha chain-like 3 
Tubulin alpha-3CID chain Tubulin alpha-3CID chain Tubulin alpha-3CID chain Tubulin alpha-3CID chain 
Tubulin alpha-3E chain Tubulin alpha-3E chain Tubulin alpha-3E chain Tubulin alpha-3E chain 
Tubulin alpha-4A chain Tubulin alpha-4A chain Tubulin alpha-4A chain Tubulin alpha-4A chain 
Tubulin alpha-8 chain Tubulin alpha-8 chain Tubulin alpha-8 chain Tubulin alpha-8 chain 
Tubulin beta chain Tubulin beta chain Tubulin beta chain Tubulin beta chain 
Tubulin beta-l chain Tubulin beta-l chain 
Tubulin beta-2C chain Tubulin beta-2C chain Tubulin beta-2C chain Tubulin beta-2C chain 
Tubulin beta-4 chain Tubulin beta-4 chain Tubulin beta-4 chain 
Tubulin beta-8 chain Tubulin beta-8 chain Tubulin beta-8 chain Tubulin beta-8 chain 
Tubulin beta-8 chain B Tubulin beta-8 chain B Tubulin beta-8 chain B Tubulin beta-8 chain B 
Putative tubulin beta-4q chain Putative tubulin beta-4q chain Putative tubulin beta-4q chain Putative tubulin beta-4q chain 
Tubulin beta-2A chain Tubulin beta-2A chain Tubulin beta-2A chain Tubulin beta-2A chain 
Tubulin beta-2B chain Tubulin beta-2B chain Tubulin beta-2B chain Tubulin beta-2B chain 
Tubulin beta-3 chain Tubulin beta-3 chain Tubulin beta-3 chain Tubulin beta-3 chain 
\0 Tubulin beta-6 chain Tubulin beta-6 chain Tubulin beta-6 chain Tubulin beta-6 chain 
Ul 
Putative tubulin-like protein Putative tubulin-like protein Putative tubulin-like protein Putative tubulin-like protein alpha-
alpha-4B alpha-4B alpha-4B 4B 
Tubulin alpha chain-like 3 
Ubiquitin Ubiquitin 
Ubiquitin carboxyl-terminal Ubiquitin carboxyl-terminal Ubiquitin carboxyl-terminal Ubiquitin carboxyl-terminal 
hydrolase isozyme L1 hydrolase isozyme L1 hydrolase isozyme L1 hydrolase isozyme L1 
Ubiquitin-conjugating enzyme E2 
variant 1 
Ubiquitin-conjugating enzyme E2 
variant 2 
Ubiquitin-conjugating enzyme E2 
N 
Vimentin Vimentin Vimentin Vimentin 
Zinc-alpha-2-glycoprotein 
Table 2: PKG-l pull-down 
Control PE Cu PE+Cu 
10 kDa heat shock protein, 10 kDa heat shock protein, 
mitochondrial mitochondrial 10 kDa heat shock protein, mitochondrial 
60 kDa heat shock protein, 60 kDa heat shock protein, 60 kDa heat shock protein, 
mitochondrial mitochondrial mitochondrial 60 kDa heat shock protein, mitochondrial 
Stress-70 protein, 
Stress-70 protein, mitochondrial mitochondrial Stress-70 protein, mitochondrial 
ATP synthase subunit alpha, ATP synthase subunit alpha, ATP synthase subunit alpha, 
mitochondrial mitochondrial mitochondrial ATP synthase subunit alpha, mitochondrial 
ATP synthase subunit beta, ATP synthase subunit beta, 
mitochondrial mitochondrial ATP synthase subunit beta, mitochondrial 
Malate dehydrogenase, Malate dehydrogenase, Malate dehydrogenase, 
mitochondrial mitochondrial mitochondrial Malate dehydrogenase, mitochondrial 
Thioredoxin-dependent 
Thioredoxin-dependent peroxide peroxide reductase, 
reductase, mitochon mitochon 
14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 
1.0 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 0\ 
14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 
14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 
14-3-3 protein eta 14-3-3 protein eta 14-3-3 protein eta 14-3-3 protein eta 
14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 
14-3-3 protein sigma 14-3-3 protein sigma 14-3-3 protein sigma 14-3-3 protein sigma 
40S ribosomal protein SA 40S ribosomal protein SA 40S ribosomal protein SA 40S ribosomal protein SA 
40S ribosomal protein S2 40S ribosomal protein S2 40S ribosomal protein S2 
40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 
40S ribosomal protein S4, X 40S ribosomal protein S4, X 40S ribosomal protein S4, X 
isoform isoform isoform 40S ribosomal protein S4, X isoform 
40S ribosomal protein S6 
40S ribosomal protein S8 40S ribosomal protein S8 40S ribosomal protein S8 
40S ribosomal protein S9 40S ribosomal protein S9 40S ribosomal protein S9 40S ribosomal protein S9 
40S ribosomal protein S 12 40S ribosomal protein S12 40S ribosomal protein S12 40S ribosomal protein S 12 
40S ribosomal protein S 15a 
40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S 18 
40S ribosomal protein S 19 40S ribosomal protein S 19 
40S ribosomal protein S20 40S ribosomal protein S20 40S ribosomal protein S20 
40S ribosomal protein S25 40S ribosomal protein S25 
60S ribosomal protein L6 60S ribosomal protein L6 
60S ribosomal protein L 7 60S ribosomal protein L 7 60S ribosomal protein L 7 60S ribosomal protein L 7 
60S ribosomal protein LI Oa 
60S ribosomal protein LI2 60S ribosomal protein LI2 60S ribosomal protein LI2 60S ribosomal protein L 12 
60S ribosomal protein LI3 60S ribosomal protein LI3 60S ribosomal protein LI3 
60S ribosomal protein LI4 60S ribosomal protein LI4 
60S ribosomal protein L 15 60S ribosomal protein LI5 
60S ribosomal protein LI8 60S ribosomal protein LI8 
60S ribosomal protein L22 60S ribosomal protein L22 60S ribosomal protein L22 60S ribosomal protein L22 
60S ribosomal protein L30 60S ribosomal protein L30 60S ribosomal protein L30 
60S ribosomal protein L36 
60S acidic ribosomal protein PO 60S acidic ribosomal protein PO 
60S acidic ribosomal protein 
60S acidic ribosomal protein P2 60S acidic ribosomal protein P2 P2 60S acidic ribosomal protein P2 
78 kDa glucose-regulated 78 kDa glucose-regulated 
78 kDa glucose-regulated protein protein protein 78 kDa glucose-regulated protein 
A-kinase anchor protein 12 A-kinase anchor protein 12 
1.0 ADP/ATP translocase 1 
-...,J 
ADPI ATP translocase 2 ADPI ATP translocase 2 
ADP/ATP translocase 3 ADP/ATP translocase 3 ADP/ATP translocase 3 
ADP-ribosylation factor I ADP-ribosylation factor I ADP-ribosylation factor 1 ADP-ribosylation factor 1 
ADP-ribosylation factor 3 ADP-ribosylation factor 3 ADP-ribosylation factor 3 ADP-ribosylation factor 3 
ADP-ribosylation factor 4 ADP-ribosylation factor 4 ADP-ribosylation factor 4 
ADP-ribosylation factor 5 ADP-ribosylation factor 5 
ATP-citrate synthase 
Probable ATP-dependent RNA Probable ATP-dependent 
helicase DDX 17 RNA helicase DDX17 
Probable ATP-dependent RNA Probable ATP-dependent Probable A TP-dependent RNA helicase 
helicase DDX5 RNA helicase DDX5 DDX5 
ATP-dependent RNA helicase A TP-dependent RNA helicase 
DDX39 DDX39 
ATP-dependent RNA helicase ATP-dependent RNA helicase ATP-dependent RNA 
DDX3X DDX3X helicase DDX3X 
ATP-dependent RNA helicase ATP-dependent RNA 
DDX3Y helicase DDX3Y 
Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle Actin, alpha cardiac muscle 1 
Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle 
Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle 
Actin, gamma-enteric smooth Actin, gamma-enteric smooth Actin, gamma-enteric 
muscle muscle smooth muscle Actin, gamma-enteric smooth muscle 
Actin, cytoplasmic I Actin, cytoplasmic I Actin, cytoplasmic I Actin, cytoplasmic I 
Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 
Adenylyl cyclase-associated Adenylyl cyclase-associated Adenylyl cyclase-associated 
protein I protein 1 protein I Adenylyl cyclase-associated protein I 
Adenosylhomocysteinase Adenosylhomocysteinase Adenosylhomocysteinase 
Alpha-actinin-I Alpha-actinin-l Alpha-actinin-l Alpha-actinin-l 
Alpha-actinin-2 Alpha-actinin-2 
Alpha-actinin-3 
Alpha-actinin-4 Alpha-actinin-4 Alpha-actinin-4 Alpha-actinin-4 
AnnexinAI Annexin Al Annexin Al AnnexinAI 
AnnexinA2 Annexin A2 AnnexinA2 AnnexinA2 
Annexin AS AnnexinA5 AnnexinAS AnnexinA5 
AnnexinA6 AnnexinA6 AnnexinA6 AnnexinA6 
\0 AnnexinA7 
00 
Calmodulin Calmodulin Calmodulin Calmodulin 
Calnexin 
Calponin-2 Calponin-2 Calponin-2 
Calreticulin Calreticulin Calreticulin Calreticulin 
CathepsinD 
Chloride intracellular channel Chloride intracellular channel 
protein I protein I Chloride intracellular channel protein I 
Chloride intracellular channel Chloride intracellular channel Chloride intracellular 
protein 4 protein 4 channel protein 4 
Clathrin heavy chain 1 Clathrin heavy chain 1 Clathrin heavy chain I Clathrin heavy chain 1 
Clathrin heavy chain 2 Clathrin heavy chain 2 Clathrin heavy chain 2 Clathrin heavy chain 2 
Coatomer subunit gamma 
Cofilin-l Cofilin-l Cofilin-l Cofilin-l 
Cofilin-2 Cofilin-2 Cofilin-2 
Complement component 1 
Complement component 1 Q Complement component 1 Q Q subcomponent-binding 
subcomponent-binding prot subcomponent-binding prot prot 








Elongation factor I-alpha I 
Elongation factor I-alpha 2 
Elongation factor I-gamma 
Elongation factor I-delta 




Eukaryotic initiation factor 4A-I 
Eukaryotic initiation factor 4A-II 
Eukaryotic translation initiation 
factor 5A-I 
Eukaryotic translation initiation 
factor 5A-2 
Ezrin 













Elongation factor I-alpha I 
Elongation factor I-alpha 2 
Elongation factor I-beta 
Elongation factor I-gamma 





Eukaryotic initiation factor 4A-I 
Eukaryotic initiation factor 4A-
II 
Eukaryotic translation initiation 
factor 5A-I 
















Elongation factor I-alpha I 
Elongation factor I-alpha 2 
Elongation factor I-beta 
Elongation factor I-gamma 





Eukaryotic initiation factor 
4A-I 
Eukaryotic initiation factor 
4A-II 
Eukaryotic translation 
initiation factor 5A-I 
Eukaryotic translation 







Elongation factor I-alpha 1 
Elongation factor I-alpha 2 
Elongation factor I-beta 
Elongation factor I-gamma 
Elongation factor I-delta 




Eukaryotic initiation factor 4A-I 
Eukaryotic initiation factor 4A-II 





Fructose-bisphosphate aldolase A 
Galectin-I 
Glucose-6-phosphate 
Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase isomerase Glucose-6-phosphate isomerase 
Glucosidase 2 subunit beta Glucosidase 2 subunit beta Glucosidase 2 subunit beta Glucosidase 2 subunit beta 
Glutathione S-transferase P Glutathione S-transferase P Glutathione S-transferase P Glutathione S-transferase P 
Glutathione S-transferase Glutathione S-transferase 
Glutathione S-transferase omega-l omega-l omega-l Glutathione S-transferase omega-l 
Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate GI yceraldehyde-3 -phosphate 
dehydrogenase dehydrogenase deh ydro genase Glyceraldehyde-3-phosphate dehydrogenase 
Guanine nucleotide-binding protein Guanine nucleotide-binding Guanine nucleotide-binding Guanine nucleotide-binding protein subunit 
subunit beta-2-1 protein subunit beta-2-l protein subunit beta-2-1 beta-2-l 
GTP-binding nuclear protein GTP-binding nuclear protein 
Ran Ran GTP-binding nuclear protein Ran 
Heat shock cognate 71 kDa Heat shock cognate 71 kDa 
Heat shock cognate 71 kDa protein protein protein Heat shock cognate 71 kDa protein 
Heat shock 70 kDa protein Heat shock 70 kDa protein 
Heat shock 70 kDa protein lA1lB lA11B IAlIB Heat shock 70 kDa protein IAlIB 
Heat shock-related 70 kDa 
protein 2 Heat shock-related 70 kDa protein 2 - Heat shock 70 kDa protein 4 0 
0 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 
Putative heat shock 70 kDa protein 7 
Hsp90 co-chaperone Cdc37 
Heat shock protein HSP 90- Heat shock protein HSP 90-
Heat shock protein HSP 90-alpha alpha alpha Heat shock protein HSP 90-alpha 
Heat shock protein HSP 90-
Heat shock protein HSP 90-beta Heat shock protein HSP 90-beta beta Heat shock protein HSP 90-beta 
Heat shock protein beta-I Heat shock protein beta-I Heat shock protein beta-l 
Heat shock-related 70 kDa protein Heat shock-related 70 kDa 
2 protein 2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoprotein 
ribonucleoprotein Ai ribonucleoprotein Al ribonucleoprotein Al Al 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein AlB ribonucleoprotein AlB ribonucleoprotein AlB 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoproteins 
ribonucleoproteins A21B I ribonucleoproteins A21B 1 ribonucleoproteins A21B I A2IBI 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoprotein 
ribonucleoprotein A3 ribonucleoprotein A3 A3 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoproteins 
ribonucleoproteins ClfC2 ribonucleoproteins Cl/C2 ribonucleoproteins C l/C2 Cl/C2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoprotein 
ribonucleoprotein DO ribonucleoprotein DO ribonucleoprotein DO DO 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein F ribonucleoprotein F ribonucleoprotein F Heterogeneous nuclear ribonucleoprotein F 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein G ribonucleoprotein G 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein H ribonucleoprotein H ribonucleoprotein H Heterogeneous nuclear ribonucleoprotein H 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear ribonucleoprotein 
ribonucleoprotein H2 ribonucleoprotein H2 ribonucleoprotein H2 H2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein K ribonucleoprotein K ribonucleoprotein K Heterogeneous nuclear ribonucleoprotein K 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein Q ribonucleoprotein Q ribonucleoprotein Q Heterogeneous nuclear ribonucleoprotein Q 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein R ribonucleoprotein R ribonucleoprotein R Heterogeneous nuclear ribonucleoprotein R 
--- Heterogeneous nuclear 0 
--- ribonucleoprotein U 
Histone H2A type I-BIE Histone H2A type 1-BIE Histone H2A type I-BIE 
Histone H2A type l-C Histone H2A type l-C Histone H2A type l-C 
Histone H2A type 1-D Histone H2A type I-D Histone H2A type 1-D 
Histone H2A type I-H Histone H2A type I-H Histone H2A type 1-H 
Histone H2A type I-J Histone H2A type I-J Histone H2A type I-J 
Histone H4 HistoneH4 HistoneH4 HistoneH4 
Hypoxia up-regulated protein 1 
Importin subunit beta-l Importin subunit beta-l Importin subunit beta-l Importin subunit beta-l 
Integrin beta-l Integrin beta-l Integrin beta-l 
Interleukin enhancer-binding factor 
2 
L-lactate dehydrogenase A L-lactate dehydrogenase A 
L-lactate dehydrogenase A chain chain chain L-lactate dehydrogenase A chain 
L-lactate dehydrogenase B 
L-lactate dehydrogenase B chain L-lactate dehydrogenase B chain chain L-Iactate dehydrogenase B chain 
Lamin-AiC Lamin-AiC Lamin-AiC Lamin-AiC 







Myosin light polypeptide 6 Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
Myosin regulatory light chain 12A 12A 
Myosin regulatory light chain 12B 





complex subunit alph 
Nestin 
Neuroblast differentiation-





Nucleoside diphosphate kinase A 
Nucleoside diphosphate kinase B 




Myosin regulatory light chain 
12B 
Myosin regulatory light 
polypeptide 9 
Nascent polypeptide-associated 
complex subunit alph 
Nestin 
Neuroblast differentiation-
associated protein AHNAK 
Nuclease-sensitive element-
binding protein I 
Nucleolin 
Nucleophosmin 
Nucleoside diphosphate kinase 
A 
Nucleoside diphosphate kinase 
B 
Nucleosome assembly protein 
I-like I 





containing protein 59 
Moesin 
Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light 
chain 12A 
Myosin regulatory light 
chain 12B 











POTE ankyrin domain 





Microtubule-associated protein 4 
Moesin 
Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 12A 
Myosin regulatory light chain 12B 
Myosin regulatory light polypeptide 9 









Nucleoside diphosphate kinase A 
Nucleoside diphosphate kinase B 
POTE ankyrin domain family member E 
Peroxiredoxin-l 
Peroxiredoxin-2 Peroxiredoxin-2 Peroxiredoxin-2 Peroxiredoxin-2 
Peroxiredoxin-6 Peroxiredoxin-6 Peroxiredoxin-6 Peroxiredoxin-6 
Peptidyl-prolyl cis-trans isomerase Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans 
A isomerase A isomerase A Peptidyl-prolyl cis-trans isomerase A 
Peptidyl-prolyl cis-trans isomerase Peptidyl-prolyl cis-trans Peptidyl-prolyl cis-trans 
B isomerase B isomerase B Peptidyl-prolyl cis-trans isomerase B 
Phosphoglycerate kinase I Phosphoglycerate kinase 1 Phosphoglycerate kinase I 
Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 Phosphoglycerate mutase 1 
Plasminogen activator inhibitor 
1 RNA-binding prot 
Plastin-3 Plastin-3 Plastin-3 
Plectin-l 
Poly(rC)-binding protein 1 Poly(rC)-binding protein I Poly(rC)-binding protein I Poly(rC)-binding protein I 
Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 
Poly(rC)-binding protein 3 Poly(rC)-binding protein 3 Poly(rC)-binding protein 3 
Polyadenylate-binding 
Polyadenylate-binding protein I Polyadenylate-binding protein 1 protein 1 Polyadenylate-binding protein I 
Polyadenylate-binding - Polyadenylate-binding protein 3 Polyadenylate-binding protein 3 protein 3 Polyadenylate-binding protein 3 0 w Polyadenylate-binding protein 4 
Polypyrimidine tract-binding Polypyrimidine tract-binding 
protein I protein 1 
Proactivator polypeptide Proactivator polypeptide Proactivator polypeptide Proactivator polypeptide 
Profilin-l Profilin-l Profilin-l Profilin-l 
Proliferation-associated protein 
2G4 
Prolyl 3-hydroxylase I 
Prostaglandin E synthase 3 
Protein SET 
Protein S lOO-AII Protein SlOO-All Protein SIOO-AII 
Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase 
Protein disulfide-isomerase 
Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 A3 Protein disulfide-isomerase A3 
Protein disulfide-isomerase A4 Protein disulfide-isomerase A4 Protein disulfide-isomerase A4 
Protein disulfide-isomerase 
Protein disulfide-isomerase A6 Protein disulfide-isomerase A6 A6 Protein disulfide-isomerase A6 




Rab GDP dissociation inhibitor 
alpha 
Rab GDP dissociation inhibitor 
beta 
Ras GTPase-activating-like protein 
IQGAPI 
Ras-related protein Rab-IA 
Ras-related protein Rab-lB 
Ras-related protein Rab-lO 
Ras-related protein Rab-15 
Rho GDP-dissociation inhibitor 
RNA-binding protein EWS 








phosphatase PP I-gamma 
Serpin HI 
Small nuclear ribonucleoprotein 
SmD3 
Spectrin alpha chain, brain 
Spliceosome RNA helicase BATl 
MIIM2 
Rab GDP dissociation inhibitor 
alpha 
Rab GDP dissociation inhibitor 
beta 
Ras-related protein Rab-IA 
Ras-related protein Rab-lB 
Putative Ras-related protein 
Rab-IC 
Ras-related protein Rab-l 0 
Ras-related protein Rab-15 
RNA-binding protein EWS 




phosphatase PP I-alpha 
Serine/threonine-protein 
phosphatase PP I-beta 
Serine/threonine-protein 
phosphatase PP I-gamma 
Serpin HI 
Spectrin alpha chain, brain 









Ras-related protein Rab-IA 
Ras-related protein Rab-lB 
Ras-related protein Rab-l 0 
Ras-related protein Rab-I5 
RNA-binding protein EWS 




Rab GDP dissociation inhibitor beta 
Ras-related protein Rab-IA 
Ras-related protein Rab-l B 
Putative Ras-related protein Rab-l C 
Ras-related protein Rab-l 0 
Ras-related protein Rab-15 




Ribosome-binding protein 1 
SH3 domain-binding glutamic acid-rich-
like protein 
Serpin HI 
Spectrin alpha chain, brain 
Splicing factor 3B subunit 2 Splicing factor 3B subunit 2 Splicing factor 3B subunit 2 
Splicing factor U2AF 65 kDa Splicing factor U2AF 65 kDa 
subunit subunit 
TAT A-binding protein-associated TATA-binding protein- TAT A-binding protein-
factor 2N associated factor 2N associated factor 2N 
T -complex protein I subunit 
alpha T -complex protein 1 subunit alpha 
T -complex protein I subunit 
T -complex protein 1 subunit beta beta T -complex protein I subunit beta 
T-complex protein 1 subunit T -complex protein I subunit T -complex protein I subunit 
gamma gamma gamma T -complex protein I subunit gamma 
T -complex protein I subunit T -complex protein I subunit 
T-complex protein 1 subunit delta delta delta T -complex protein I subunit delta 
T -complex protein I subunit T -complex protein 1 subunit T -complex protein 1 subunit 
epsilon epsilon epsilon T-complex protein 1 subunit epsilon 
T -complex protein 1 subunit T-complex protein 1 subunit 
T -complex protein 1 subunit theta theta theta T-complex protein 1 subunit theta 
T-complex protein 1 subunit zeta ..... T -complex protein 1 subunit eta T -complex protein I subunit eta 0 
VI Talin-l Talin-I Talin-l Talin-I 
Thioredoxin 
Thioredoxin domain-containing Thioredoxin domain-containing Thioredoxin domain-




Transgelin Transgelin Transgelin Transgelin 
Transgelin-2 Transgelin-2 Transgelin-2 Transgelin-2 
Transitional endoplasmic reticulum Transitional endoplasmic Transitional endoplasmic 
ATPase reticulum ATPase reticulum ATPase Transitional endoplasmic reticulum ATPase 
Transketolase Transketolase Transketolase Transketolase 
Translationally-controlled tumor Translationally-controlled 
protein tumor protein 
Triosephosphate isomerase Triosephosphate isomerase Triosephosphate isomerase Triosephosphate isomerase 
Tropomyosin alpha-I chain 
Tropomyosin alpha-3 chain Tropomyosin alpha-3 chain Tropomyosin alpha-3 chain 




Tropomyosin beta chain 
Tubulin alpha-lA chain 
Tubulin alpha-lB chain 
Tubulin alpha-l C chain 
Tubulin alpha-3CID chain 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin beta chain 
Tubulin beta-l chain 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 
Tubulin beta-4 chain 
UPF0568 protein C14orfl66 
Ubiquitin 
Ubiquitin carboxyl-terminal 
hydrolase isozyme Ll 
Ubiquitin-conjugating enzyme E2 
variant 1 






Tropomyosin beta chain 
Tubulin alpha-lA chain 
Tubulin alpha-lB chain 
Tubulin alpha-l C chain 
Tubulin alpha-3CID chain 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin alpha-8 chain 
Tubulin beta chain 
Tubulin beta-l chain 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 
Tubulin beta-4 chain 
Tubulin beta-6 chain 
UPF0568 protein C14orfl66 
Ubiquitin 
Ubiquitin carboxyl-terminal 
hydrolase isozyme Ll 
Ubiquitin-conj ugating enzyme 
E2 variant 1 
Ubiquitin-conjugating enzyme 
E2 variant 2 
uv excision repair protein 
RAD23 homolog B 
Vimentin 
Vinculin 
Tropomyosin beta chain 
Tubulin alpha-lA chain 
Tubulin alpha-lB chain 
Tubulin alpha-l C chain 
Tubulin alpha-3CID chain 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin beta chain 
Tubulin beta-l chain 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 
Tubulin beta-4 chain 
Tubulin beta-6 chain 
UPF0556 protein C190rflO 
UPF0568 protein C14orfl66 
Ubiquitin 
Ubiquitin-conjugating 
enzyme E2 variant 1 
Ubiquitin-conjugating 
enzyme E2 variant 2 
UV excision repair protein 
RAD23 homolog B 
Vimentin 
Tropomyosin beta chain 
Tubulin alpha-lA chain 
Tubulin alpha-lB chain 
Tubulin alpha-IC chain 
Tubulin alpha-3CID chain 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin alpha-8 chain 
Tubulin beta chain 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 
Tubulin beta-4 chain 
Tubulin beta-6 chain 
UPF0568 protein C14orfl66 
Ubiquitin 
Ubiquitin-conjugating enzyme E2 variant 1 
Vimentin 
Table 3: PK!!.J!ull-down 
Control PE Cu PE+Cu 
60 kDa heat shock protein, 60 kDa heat shock protein, 60 kDa heat shock protein, 
mitochondrial mitochondrial mitochondrial 
14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 
14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 
14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 
14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 
14-3-3 protein eta 14-3-3 protein eta 14-3-3 protein eta 
14-3-3 protein sigma 14-3-3 protein sigma 
14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 
40S ribosomal protein SA 
40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 
40S ribosomal protein S5 40S ribosomal protein S5 40S ribosomal protein S5 
40S ribosomal protein S9 40S ribosomal protein S9 
,..... 40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S 18 
0 60S ribosomal protein LII 60S ribosomal protein LII -....l 
60S ribosomal protein LI4 
60S ribosomal protein L22 
60S acidic ribosomal protein PO 
60S acidic ribosomal protein P2 
78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 78 kDa glucose-regulated protein 
Acyl-CoA-binding protein Acyl-CoA-binding protein 
Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 
Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle 
Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle 
Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 
Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 
Actin, gamma-enteric smooth Actin, gamma-enteric smooth Actin, gamma-enteric smooth Actin, gamma-enteric smooth 
muscle muscle muscle muscle 
Alpha-actinin-l 
Alpha-actininA 
AnnexinAI AnnexinAI Annexin Al Annexin Al 
AnnexinA2 AnnexinA2 AnnexinA2 Annexin A2 
Annexin A5 Annexin A5 AnnexinA5 Annexin A5 
Calmodulin Calmodulin Calmodulin 
Calumenin 
CathepsinB Cathepsin B CathepsinB 
Chloride intracellular channel 
protein 1 
Clathrin heavy chain 1 
Cofilin-l Cofilin-I Cofilin-I Cofilin-l 
Complement component I Q Complement component 1 Q Complement component 1 Q 
subcomponent-binding prot subcomponent-binding prot subcomponent-binding prot 
Cystatin-B 
Cytochrome c 
Elongation factor I-alpha 1 Elongation factor I-alpha 1 Elongation factor I-alpha 1 Elongation factor I-alpha 1 
Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 
Elongation factor 2 Elongation factor 2 Elongation factor 2 Elongation factor 2 
Endoplasmin Endoplasmin Endoplasmin 
Alpha-enolase Alpha-enolase Alpha-enolase Alpha-enolase 
Beta-enolase Beta-enolase Beta-enolase Beta-enolase 
Gamma-enolase Gamma-enolase Gamma-enolase .... Eukaryotic initiation factor 4A-I Eukaryotic initiation factor 4A-I 0 
00 Eukaryotic initiation factor 4A-II Eukaryotic initiation factor 4A-II 
Eukaryotic translation initiation 
factor 5A-I 
Eukaryotic translation initiation 
factor 5A-2 
Filamin-A 
Fructose-bisphosphate aldolase A 
Galectin-I Galectin-l 
Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase Glucose-6-phosphate isomerase 
Glutathione S-transferase P 
Gl yceraldehyde-3-phosphate Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate Glyceraldehyde-3-phosphate 
dehydrogenase dehydrogenase dehydrogenase dehydrogenase 
GTP-binding nuclear protein Ran GTP-binding nuclear protein Ran GTP-binding nuclear protein Ran GTP-binding nuclear protein Ran 
Heat shock 70 kDa protein IAlIB 
Heat shock 70 kDa protein 6 
Heat shock cognate 71 kDa Heat shock cognate 71 kDa 
protein protein Heat shock cognate 71 kDa protein Heat shock cognate 71 kDa protein 




Heat shock protein HSP 90-alpha 
Heat shock protein HSP 90-beta 
Hepatoma-derived growth factor 
Heat shock protein HSP 90-alpha 
Heat shock protein HSP 90-beta 
Heterogeneous nuclear ribonucleoprotein Al 
Heterogeneous nuclear ribonucleoprotein AlB 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins A21B I ribonucleoproteins A21B I 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins C l/C2 ribonucleoproteins C lIC2 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein DO ribonucleoprotein DO 
Heterogeneous nuclear ribonucleoprotein H 
Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein K ribonucleoprotein K 
Histone H4 
L-Iactate dehydrogenase A chain 
L-Iactate dehydrogenase B chain 
Moesin 
Myosin light chain 6B 
Myosin light polypeptide 6 
Myristoylated alanine-rich C-kinase 
substrate 
Nucleolin 
POTE ankyrin domain family 
memberE 
Peptidyl-prolyl cis-trans isomerase 
A 
Peptidyl-prolyl cis-trans isomerase 
B 
Lamin-A/C 
L-Iactate dehydrogenase A 
chain 
L-lactate dehydrogenase B 
chain 
Myosin light chain 6B 





Nucleolar RNA helicase 2 
Nucleolin 






Heat shock protein HSP 90-alpha 






ribonucleoproteins A21B I 
Heterogeneous nuclear 




L-Iactate dehydrogenase A chain 
L-lactate dehydrogenase B chain 
Myosin light chain 6B 
Myosin light polypeptide 6 
Myristoylated alanine-rich C-kinase 
substrate 
Nucleolin 
POTE ankyrin domain family 
memberE 
Peptidyl-prolyl cis-trans isomerase 
A 
Peptidyl-prolyl cis-trans isomerase 
B 
Heat shock protein HSP 90-alpha 
Heat shock protein HSP 90-beta 
Heterogeneous nuclear 




L-Iactate dehydrogenase A chain 











Plasminogen activator inhibitor I RNA-binding prot 




Protein disulfide-isomerase A3 
Protein disulfide-isomerase A6 
Pyruvate kinase isozymes MIIM2 
RNA-binding protein EWS 
RNA-binding protein FUS 
Serpin HI 
Splicing factor, arginine/serine-rich 
3 
TAT A-binding protein-associated 
factor 2N 
T -complex protein I subunit beta 
Transgelin-2 
Triosephosphate isomerase 
Tubulin alpha-IA chain 
Tubulin alpha-IB chain 
Tubulin alpha-IC chain 
Tubulin alpha-3CID 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin beta chain 
Protein disulfide-isomerase 
Protein disulfide-isomerase A3 
Protein disulfide-isomerase A6 
Pyruvate kinase isozymes 
MIIM2 
Reticulocalbin-l 
RNA-binding protein EWS 
RNA-binding protein FUS 
Serpin HI 
T ATA-binding protein-




Tubulin alpha-IA chain 
Tubulin alpha-lB chain 
Tubulin alpha-IC chain 
Tubulin alpha-3CID 
Tubulin alpha-3E chain 




Protein disulfide-isomerase A3 
Protein disulfide-isomerase A6 
Pyruvate kinase isozymes MlIM2 
RNA-binding protein FUS 





Protein disulfide-isomerase A3 
Protein disulfide-isomerase A6 
Pyruvate kinase isozymes MIIM2 
RNA-binding protein EWS 
Serpin HI Serpin HI 





Tubulin alpha-IA chain 
Tubulin alpha-lB chain 
Tubulin alpha-IC chain 
Tubulin alpha-3CID 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin beta chain 
Transgelin-2 
Transitional endoplasmic reticulum 
ATPase 
Tubulin alpha-l A chain 
Tubulin alpha-IB chain 
Tubulin alpha-IC chain 
Tubulin alpha-3CID 
Tubulin alpha-3E chain 
Tubulin alpha-4A chain 
Tubulin beta chain 
---
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 
Tubulin beta-4 chain 





hydrolase isozyme Ll 
Vimentin 
Tubulin beta-2A chain 
Tubulin beta-2B chain 




hydrolase isozyme Ll 
Vimentin 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 
Tubulin beta-3 chain 




hydrolase isozyme Ll 
Vimentin 
Tubulin beta-l chain 
Tubulin beta-2A chain 
Tubulin beta-2B chain 
Tubulin beta-2C chain 




Table 4: VEGFR-l pull-down 
Control PE Cu PE+Cu 
10 kDa heat shock protein, 10 kDa heat shock protein, 
mitochondrial mitochondrial 
60 kDa heat shock protein, 60 kDa heat shock protein, 60 kDa heat shock protein, 
mitochondrial mitochondrial mitochondrial 
ATP synthase subunit alpha, 
mitochondrial 
14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 14-3-3 protein beta/alpha 
14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 14-3-3 protein gamma 
14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 14-3-3 protein zeta/delta 
14-3-3 protein eta 14-3-3 protein eta 
14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 14-3-3 protein theta 
- 14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon 14-3-3 protein epsilon -N 14-3-3 protein sigma 
40S ribosomal protein SA 40S ribosomal protein SA 40S ribosomal protein SA 40S ribosomal protein SA 
40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 40S ribosomal protein S3 
40S ribosomal protein S6 
40S ribosomal protein S 12 
40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S 18 40S ribosomal protein S18 
60S acidic ribosomal 60S acidic ribosomal protein 
proteinP2 P2 60S acidic ribosomal protein P2 
60S ribosomal protein L 7 
60S ribosomal protein LII 
60S ribosomal protein LI4 
60S ribosomal protein LI8 
78 kDa glucose-regulated 78 kDa glucose-regulated 78 kDa glucose-regulated 
protein protein protein 78 kDa glucose-regulated protein 
Acyl-CoA-binding protein Acyl-CoA-binding protein Acyl-CoA-binding protein 
ADP-ribosylation factor 1 ADP-ribosylation factor 1 
ADP-ribosylation factor 3 ADP-ribosylation factor 3 
ADP-ribosylation factor 4 ADP-ribosylation factor 4 
ADP-ribosylation factor 5 ADP-ribosylation factor 5 
ATP-dependent RNA helicase 
DDX39 
Actin, alpha cardiac muscle 
1 Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 Actin, alpha cardiac muscle 1 
Actin, alpha skeletal 
muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle Actin, alpha skeletal muscle 
Actin, aortic smooth 
muscle Actin, aortic smooth muscle Actin, aortic smooth muscle Actin, aortic smooth muscle 
Actin, gamma-enteric Actin, gamma-enteric smooth Actin, gamma-enteric Actin, gamma-enteric smooth 
smooth muscle muscle smooth muscle muscle 
- Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 Actin, cytoplasmic 1 -w 
Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 Actin, cytoplasmic 2 
Adenylyl cyclase- Adenylyl cyclase-associated 
associated protein 1 protein I 
Alpha-actinin-l Alpha-actinin-l Alpha-actinin-l 
Alpha-actinin-4 Alpha-actinin-4 Alpha-actinin-4 
Annexin Al AnnexinAl AnnexinAI AnnexinAl 
AnnexinA2 AnnexinA2 Annexin A2 AnnexinA2 
AnnexinA5 AnnexinA5 AnnexinA5 AnnexinA5 
Astrocytic phosphoprotein 
PEA-15 
Brain acid soluble protein 1 
Calmodulin Calmodulin Calmodulin Calmodulin 
Calponin-2 Calponin-2 Calponin-2 
Calreticulin 
Calumenin Calumenin Calumenin 
Cathepsin B Cathepsin B Cathepsin B Cathepsin B 
Chloride intracellular channel 
protein 1 
Clathrin heavy chain 1 Clathrin heavy chain 1 Clathrin heavy chain 1 
Coactosin-like protein 
Cofilin-l Cofilin-l Cofilin-l Cofilin-l 
Cofilin-2 Cofilin-2 Cofilin-2 Cofilin-2 
Complement component 1 
Q subcomponent-binding Complement component 1 Q Complement component I Q Complement component 1 Q 
prot subcomponent-binding prot subcomponent-binding prot subcomponent-binding prot 
Cu-Zn Superoxide 
dismutase Cu-Zn Superoxide dismutase 
...... Cytochrome c Cytochrome c Cytochrome c Cytochrome c ...... 
.j:::.. 
Cystatin-B Cystatin-B Cystatin-B Cystatin-B 
DNA-binding protein A 
Desmo glein-I 
Alpha-enolase Alpha-enolase Alpha-enolase Alpha-enolase 
Beta-enolase Beta-enolase Beta-enolase Beta-enolase 
ELA V -like protein I ELA V -like protein I 
Elongation factor I-alpha I Elongation factor I-alpha I Elongation factor I-alpha I Elongation factor I-alpha I 
Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 Elongation factor I-alpha 2 
Elongation factor I-gamma 
Elongation factor 2 Elongation factor 2 Elongation factor 2 Elongation factor 2 
Endoplasmin Endoplasmin Endoplasmin 
Epididymal secretory protein EI 
Eukaryotic initiation factor Eukaryotic initiation factor 4A- Eukaryotic initiation factor 
4A-I I 4A-I Eukaryotic initiation factor 4A-I 
Eukaryotic initiation factor Eukaryotic initiation factor 4A- Eukaryotic initiation factor 
4A-II II 4A-II Eukaryotic initiation factor 4A-II 
Eukaryotic translation Eukaryotic translation Eukaryotic translation Eukaryotic translation initiation 
initiation factor 5A-I initiation factor 5A-I initiation factor 5A-I factor 5A-I 
Eukaryotic translation Eukaryotic translation Eukaryotic translation Eukaryotic translation initiation 
initiation factor 5A-2 initiation factor 5A-2 initiation factor 5A-2 factor 5A-2 
Ezrin Ezrin 
Far upstream element- Far upstream element- Far upstream element-binding 
binding protein I binding protein I protein I 
Filamin-A Filamin-A Filamin-A Filamin-A 
Filamin-B Filamin-B 
Filamin-C Filamin-C 
Fructose-bisphosphate Fructose-bisphosphate Fructose-bisphosphate aldolase 
aldolase A aldolase A A - GTP-binding nuclear GTP-binding nuclear protein -VI protein Ran Ran GTP-binding nuclear protein Ran 
Galectin-l Galectin-l Galectin-l 
Gamma-glutamyl Gamma-
hydrolase glutamylcyclotransferase 
Glucosidase 2 subunit beta Glucosidase 2 subunit beta 
Glutathione S-transferase P 
Glyceraldehyde-3- Glyceraldehyde-3-phosphate Gl yceraldeh yde-3-phosphate Glyceraldehyde-3-phosphate 
phosphate dehydrogenase dehydrogenase dehydrogenase dehydrogenase 
Guanine nucleotide-
binding protein subunit Guanine nucleotide-binding Guanine nucleotide-binding 
beta-2-l protein subunit beta-2 protein subunit beta-2 
Heat shock protein beta-l Heat shock protein beta-l Heat shock protein beta-l Heat shock protein beta-l 
Heat shock 70 kDa protein Heat shock 70 kDa protein Heat shock 70 kDa protein Heat shock 70 kDa protein 
IAilB IAilB IAlIB IAilB 
Heat shock 70 kDa protein 
6 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 Heat shock 70 kDa protein 6 
Heat shock cognate 71 kDa Heat shock cognate 71 kDa Heat shock cognate 71 kDa Heat shock cognate 71 kDa 
protein protein protein protein 
Heat shock protein HSP Heat shock protein HSP 90- Heat shock protein HSP 90-
90-alpha alpha alpha Heat shock protein HSP 90-alpha 
Heat shock protein HSP Heat shock protein HSP 90- Heat shock protein HSP 90-
90-beta beta beta Heat shock protein HSP 90-beta 
Hepatoma-derived growth Hepatoma-derived growth 
factor factor Hepatoma-derived growth factor 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein AlB ribonucleoprotein AlB ribonucleoprotein AlB ribonucleoprotein AlB 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein Al ribonucleoprotein Al ribonucleoprotein Al ribonucleoprotein Al 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins A21B I ribonucleoproteins A21B 1 ribonucleoproteins A21B 1 ribonucleoproteins A21B I 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoproteins C l/C2 ribonucleoproteins C l/C2 ribonucleoproteins ClfC2 ribonucleoproteins ClIC2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein DO ribonucleoprotein DO ribonucleoprotein DO ribonucleoprotein DO 
i-' Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear i-' 
0'1 ribonucleoprotein F ribonucleoprotein F ribonucleoprotein F ribonucleoprotein F 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein G ribonucleoprotein G ribonucleoprotein G ribonucleoprotein G 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein H ribonucleoprotein H ribonucleoprotein H ribonucleoprotein H 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein H2 ribonucleoprotein H2 ribonucleoprotein H2 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein H3 ribonucleoprotein H3 ribonucleoprotein H3 
Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear Heterogeneous nuclear 
ribonucleoprotein K ribonucleoprotein K ribonucleoprotein K ribonucleoprotein K 
High mobility group High mobility group protein High mobility group protein 
protein Bl BI BI High mobility group protein B I 
Histone H2A type I-BIE 
Histone H2A type I-C 
Histone H2A type I-D 
--l 
Histone H2A type l-H 
Histone H2A type l-J 
Histone H4 
Integrin beta-l 
L-lactate dehydrogenase A 
chain 




polypeptide 2, isoform 
alpha 
Lamina-associated 
polypeptide 2, isoforms 
beta/gam 
Lysosome-associated 




Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light 
polypeptide 9 
Myosin regulatory light 
chain 12A 





Importin subunit beta-l 
L-Iactate dehydrogenase A 
chain 








Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
l2A 




L-Iactate dehydrogenase A 
chain 




polypeptide 2, isoform alpha 
Importin subunit beta-l 
L-Iactate dehydrogenase A chain 
L-Iactate dehydrogenase B chain 
Lamin-A/C 
Lamina-associated polypeptide 2, 
isoform alpha 






4 Microtubule-associated protein 4 
Moesin 
Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light chain 
12A 





Myosin light polypeptide 6 
Myosin light chain 6B 
Myosin regulatory light polypeptide 9 
Myosin regulatory light chain 12A 
Myosin regulatory light chain 12B 
Myristoylated alanine-rich C-kinase 
substrate 
Nascent polypeptide-
associated complex subunit 
alph 
Nestin 







Neuroblast differentiation-- associated protein AHNAK -00 POTE ankyrin domain 









binding protein 1 
Plasminogen activator 
inhibitor 1 RNA-binding 
prot 




complex subunit alph 
Nuclease-sensitive element-
binding protein 1 
Nucleolin 
Nucleophosmin 
Nucleoside diphosphate kinase 
A 
Nucleoside diphosphate kinase 
B 
Neuroblast differentiation-
associated protein AHNAK 










binding protein 1 
Poly(rC)-binding protein 1 
N-acetylglucosamine-6-sulfatase 
Nascent polypeptide-associated Nascent polypeptide-associated complex 
complex subunit alph subunit alph 
Nucleolin Nucleolin 
Nucleophosmin Nucleophosmin 
Nucleoside diphosphate kinase 
A Nucleoside diphosphate kinase A 
Nucleoside diphosphate kinase 
B Nucleoside diphosphate kinase B 
Neuroblast differentiation- Neuroblast differentiation-associated 
associated protein AHNAK protein AHNAK 
POTE ankyrin domain family 
memberE POTE ankyrin domain family member E 
Peptidyl-prolyl cis-trans 
isomerase A Peptidyl-prolyl cis-trans isomerase A 
Peptidyl-prolyl cis-trans 





binding protein 1 
Phosphoglycerate mutase 1 
Plasminogen activator inhibitor 1 RNA-
binding prot 
Poly(rC)-binding protein 1 Poly(rC)-binding protein 1 
Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 Poly(rC)-binding protein 2 
Poly(rC)-binding protein 3 Poly(rC)-binding protein 3 Poly(rC)-binding protein 3 
Polyadenylate-binding Polyadenylate-binding protein Polyadenylate-binding protein 
protein I 1 1 Polyadenylate-binding protein 1 
Polyadenylate-binding Polyadenylate-binding protein Polyadenylate-binding protein 
protein 3 3 3 Polyadenylate-binding protein 3 
Proactivator polypeptide Proactivator polypeptide Proactivator polypeptide Pro activator polypeptide 
Profilin-l Profilin-l Profilin-l Profilin-l 
Protein CDV3 homolog Protein CDV3 homolog 
Protein SET Protein SET Protein SET 
Protein SIOO-All Protein S IOO-All 
Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase Protein disulfide-isomerase 
Protein disulfide-isomerase 
A3 Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 Protein disulfide-isomerase A3 - Protein disulfide-isomerase -\0 A6 Protein disulfide-isomerase A6 Protein disulfide-isomerase A6 Protein disulfide-isomerase A6 
Pyruvate kinase isozymes Pyruvate kinase isozymes Pyruvate kinase isozymes 
MIIM2 MIIM2 MIIM2 Pyruvate kinase isozymes MIIM2 
Radixin Radixin 
Ras-related protein Rab-lB 
Ras-related protein Rab-l 0 
Ras-related protein Rab-15 
Rab GDP dissociation inhibitor beta 
RNA-binding protein EWS RNA-binding protein EWS RNA-binding protein EWS RNA-binding protein EWS 
RNA-binding protein FUS RNA-binding protein FUS RNA-binding protein FUS RNA-binding protein FUS 
RNA-binding motif RNA-binding motif protein, X- RNA-binding motif protein, X-linked-




glutamic acid-rich-like SH3 domain-binding glutamic 
protein acid-rich-like protein 
SerpinHl Serpin HI 
Serum albumin 
Splicing factor 3B subunit Splicing factor, 





phosphoprotein 1 1 
T -complex protein 1 T-complex protein 1 subunit 
subunit gamma gamma 
TAT A-binding protein- TATA-binding protein-
...... associated factor 2N associated factor 2N N 
0 
Thioredoxin 
Thioredoxin reductase 1, Thioredoxin reductase 1, 
cytoplasmic cytoplasmic 
Thioredoxin domain-
containing protein 5 
Thioredoxin domain-




Triosephosphate isomerase Triosephosphate isomerase 
Transitional endoplasmic 
reticulum ATPase 
Tropomyosin alpha-1 chain 
Tropomyosin alpha-3 chain 
Serpin HI 
TATA-binding protein-
associated factor 2N 
Thioredoxin reductase 1, 
cytoplasmic 
Thioredoxin domain-






Splicing factor, arginine/serine-rich 3 
Spliceosome RNA helicase BAT! 
Stress-induced-phosphoprotein 1 
T-complex protein 1 subunit beta 
T ATA-binding protein-associated factor 
2N 
Thioredoxin reductase 1, cytoplasmic 






Transitional endoplasmic reticulum 
ATPase 
Tropomyosin alpha-3 chain 
Tropomyosin alpha-4 chain Tropomyosin alpha-4 chain Tropomyosin alpha-4 chain 
Tropomyosin beta chain Tropomyosin beta chain 
Tubulin alpha-lA chain 
Tubulin alpha-lB chain Tubulin alpha-lA chain Tubulin alpha-lA chain Tubulin alpha-IA chain 
Tubulin alpha-IC chain Tubulin alpha-IB chain Tubulin alpha-lB chain Tubulin alpha-IB chain 
Tubulin alpha-IC chain Tubulin alpha-IC chain Tubulin alpha-IC chain 
Tubulin alpha-3CID chain Tubulin alpha-3CID chain Tubulin alpha-3CID chain Tubulin alpha-3CID chain 
Tubulin alpha-3E chain Tubulin alpha-3E chain Tubulin alpha-3E chain Tubulin alpha-3E chain 
Tubulin alpha-4A chain Tubulin alpha-4A chain Tubulin alpha-4A chain Tubulin alpha-4A chain 
Tubulin alpha-8 chain Tubulin alpha-8 chain 
Tubulin beta chain Tubulin beta chain Tubulin beta chain Tubulin beta chain 
Tubulin beta-l chain Tubulin beta-l chain - Tubulin beta-2A chain Tubulin beta-2A chain Tubulin beta-2A chain Tubulin beta-2A chain N - Tubulin beta-2B chain Tubulin beta-2B chain Tubulin beta-2B chain Tubulin beta-2B chain 
Tubulin beta-2C chain Tubulin beta-2C chain Tubulin beta-2C chain Tubulin beta-2C chain 
Tubulin beta-3 chain Tubulin beta-3 chain Tubulin beta-3 chain Tubulin beta-3 chain 
Tubulin beta-4 chain Tubulin beta-4 chain Tubulin beta-4 chain Tubulin beta-4 chain 
Tubulin beta-6 chain Tubulin beta-6 chain 
Tubulin-specific chaperone 
A Tubulin-specific chaperone A Tubulin-specific chaperone A Tubulin-specific chaperone A 
Ubiquitin Ubiquitin Ubiquitin Ubiquitin 
Ubiquitin carboxyl-
terminal hydrolase isozyme Ubiquitin carboxyl-terminal Ubiquitin carboxyl-terminal Ubiquitin carboxyl-terminal hydrolase 
Ll hydrolase isozyme Ll hydrolase isozyme Ll isozyme Ll 
Ubiquitin-conjugating Ubiquitin-conjugating enzyme Ubiquitin-conjugating enzyme E2 
enzyme E2 variant 1 E2 variant 1 variant 1 
Ubiquitin-conjugating enzyme E2 
variant 2 
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1. Vimentin Western Blot 
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Control PE Cu PE+Cu 
Figure 29. Representative Western blot of Vimentin under different treatment groups 
and densitometric analysis of Western blot. Imrnunoblotting was performed with 
anti-Vimentin antibody. This blot is representative of two independent experiments, 
and densitometric analysis is the mean of both blots. 
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2. Interaction between Vimentin and PKG-1 








Figure 30. Co-immunoprecipitation of Vimentin and PKG-1. PKG-1 was co-
immunoprecipitated after a Vimentin pull down. Semi-quantitative analysis 
of Western blot detecting PKG-1, bars are means for each group. One-way 
ANOVA, followed by Bonferroni's Multiple Comparison Test. No 
significant difference among groups. n=3. 
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3. Interaction between Vimentin and VEGFR-1 












Control PE Cu PE+Cu 
Figure 31. Co-immunoprecipitation of Vimentin and VEGFR-1. 
Semi-quantitative analysis of Western blot detecting VEGFR-1, bars are means 
from each group. n=2. 
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IV. DISCUSSION 
It has been observed that Cu supplementation reverses cardiac myocyte 
hypertrophy of neonatal rat cardiac myocytes as well as embryonic cardiac 
myocytes derived from human embryos, and that this effect is VEGF-
dependent l77 • This study was undertaken to provide mechanistic insights into the 
action of Cu. We have demonstrated that Cu at physiologically relevant levels 
which were used in this study does not increase VEGF production in primary 
cultures, yet anti-VEGF antibody blocked the reversal effect. This VEGF-
dependent action of Cu suggests that while Cu did not result in an increase in 
VEGF production, it did result in downstream events that are VEGF-dependent, 
and such downstream events would include VEGFRs. We observed that Cu 
increased the ratio ofVEGFR-l :VEGFR-2, and that this increase was highly 
responsible for the reversal of cardiac myocyte hypertrophy (Figures 4 and 5). 
This cause-effect relationship between the increase in the ratio ofVEGFR-l to 
VEGFR-2 and the reversal of cardiac myocyte hypertrophy was obtained from the 
experiment using siRNA targeting VEGFR-2 to elevate the ratio ofVEGFR-
1 :VEGFR-2. By using siRNA targeting VEGFR-2, we were able to increase the 
ratio of VEGFR-l :VEGFR-2 and thereby differentiate the regression phenomenon 
from the action of Cu. However, it reproduced the same effect as Cu-induced 
reversal of cardiac myocyte hypertrophy (Figures 9, 10 and 11). Further evidence 
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from the experiment demonstrating that anti-VEGF antibody blocked the reversal of 
cardiac myocyte hypertrophy induced by VEGFR-2 gene silencing (Figures 12, 13 
and 14), which is indicative of the importance of the interaction between VEGFR-l 
and VEGF. siRNA targeting VEGFR-l blocked Cu-induced reversal of cardiac 
myocyte hypertrophy, further indicating the role of VEGFR-l in mediating Cu-
induced reversal of cardiac myocyte hypertrophy (Figures 18, 19 and 20). 
Numerous studies have established the differing functions of VEGFR -1 and 
VEGFR-2. VEGFR-2 is associated with cell growth stimulation by VEGF in 
endothelial cells. In cells with VEGFR-2 that are devoid ofVEGFR-l, activation of 
VEGFR-2 by VEGF culminates in a mitogenic response l78, 179. Additionally, 
VEGFR-2 is more predominant in many of the known cellular responses elicited by 
VEGF such as embryonic vasculogenesis and tumor angiogenesis 180. VEGFR-2 and 
its downstream pathways are more related to growth stimulation via MAPK signaling 
pathways. Aktl, which plays a critical role in the hypertrophic process has been 
linked to VEGFR-2, which was demonstrated in a study where a decoy VEGFR-2 
inhibited cardiac growth induced by Aktl activation I8I ,182. 
While previous studies have not given a clear, comprehensive understanding of 
the role of VEGFR-l in cellular function, several studies have shown a counter action 
ofVEGF-l relative to VEGFR-2, and it was suggested that VEGFR-l acted to 
negatively regulate VEGFR-2 183, 184, 185, 186. This study demonstrates that VEGFR-l 
is associated with PKG-l activation. The link between VEGFR-l to this well-known 
and well-studied pathway in the regression of heart hypertrophy provides an 
explanation of the VEGFR-l-dependent regression of cardiac myocyte hypertrophy. 
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It is likely that many pathways are triggered by VEGFR-1 activation. Yet, PKG-1 
signaling is the most studied and arguably the most important with respect to the 
regression of heart hypertrophy. We observed that siRNA targeting VEGFR-1 
reduced PKG-1 activity (Figure 21), suggesting that the activation of PKG-1 is at 
least in part VEGFR-1-dependent. Conversely, the PKG-1 antagonist, Rp-8-pCPT-
cGMPS blocked both Cu and VEGFR-2 knockdown-induced reversal of cardiac 
myocyte hypertrophy (Figures 22-27). Taken together, these results demonstrate that 
VEGFR-1 is likely involved in Cu-induced regression of cardiac myocyte 
hypertrophy, and that this pathway is likely associated with PKG-1 activation. 
PKG-1 is activated in hypertrophic myocardium induced by pressure overload187• 
In mouse models of cardiac pressure overload induced by transverse aortic 
constriction (T AC), heart hypertrophy was observed 3 weeks after TAC, and PKG-1 
activity was significantly elevated in the hypertrophic myocardium. Although PKG-1 
activation alone was not sufficient to stop the development of heart hypertrophy, 
treatment with the oral phosphidiesterase-5A inhibitor, sildenafil, blocks the intrinsic 
catabolism of cGMP, leading to further activation ofPKG-1 and resulted in the 
regression of heart hypertrophy. In our study, we observed that PE treatment 
enhanced PKG-1 activity, but Cu did not have any effect on PE-induced activation of 
PKG-l. But, Cu abrogated VEGFR-2, which is associated with Akt-1 signaling. In 
addition to this, inhibition was associated with the increase in the ratio of VEGF-
1:VEGFR-2, thus providing a molecular switch from growth via the VEGFR-2 
pathway, to regression of cardiac myocyte hypertrophy via the VEGFR-1 pathway. 
While Cu did not increase PKG-1 activity, the switch in signaling pathways from 
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VEGFR-2 to VEGFR-l would make the activity ofPKG-l become dominant, leading 
to activation of hypertrophic reversal signaling cascades. 
Initially, we hypothesized that the link between VEGFR-l and PKG-l was direct. 
However, after numerous VEGFR-l and PKG-l co-immunoprecipitations, we 
discovered that this was more than likely not the case. In order to elucidate the 
mechanism by which eu increased VEGFR-l signaling and thereby reversed cardiac 
myocyte hypertrophy, we turned to functional proteomics. Immune complex 
associated with VEGFR -lor PKG-l were sent off for analysis by liquid 
chromatography tandem mass spectrometry. Hundreds of proteins were identified. 
Upon further analysis of the data collected, we looked for proteins present in both the 
immune complexes of both VEGFR-l and PKG-l. A literature search revealed very 
little knowledge regarding the role of Vimentin in the heart. Of the hundreds of 
proteins identified, we chose to further investigate the role of a protein interacting 
with both VEGFR-l and PKG-l, Vimentin. 
Preliminary results showed that PE decreases Vimentin in human cardiac 
myocytes. To validate the interaction between Vimentin and VEGFR-l and Vimentin 
and PKG-l, co-immunoprecipitation was performed: pulling down Vimentin and 
analyzing the immunoprecipitate by Western blot to detect VEGFR-l, and then the 
reverse, pulling down VEGFR-l and subjecting the immunoprecipiate to Western 
blot to detect Vimentin. The same experiment was performed to validate the protein-
protein interaction between PKG-l and Vimentin. 
Vimentin is the most abundant intermediate filament protein and is widely 
expressed. It is thought to have a primary role in biological structural processes, such 
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as wound healing l88 and is secreted by activated macrophages. Because of its 
abundance, it was assumed to play an important role in the stabilization of the 
cytoplasm, but knockout animals who do not express Vimentin have remarkably 
nonnal phenotypes I89,190. However, Vimentin knockout mice exhibited phenotypic 
abnonnalities under specific conditions, such as injuryl91. Therefore, Vimentin may 
playa specialized role that contributes to distinct dynamic cellular processes 192. 
Previously thought to be an exclusively intracellular protein, recent studies have 
shown that Vimentin is also secreted by human macrophages into the extracellular 
space in a process that is regulated by pro- and anti-inflammatory cytokines l93. 
Vimentin is phosphorylated at serine and threonine residues, and is phosphorylated by 
numerous protein kinases and is a substrate for protein kinase C (PKC). Additionally, 
the secretion of Vimentin is blocked by G06983, a specific PKC inhibitor. These 
findings are consistent with previous research that phosphorylation of Vimentin 
impacts its intracellular localization194,195. Interestingly, PKC is also an essential 
mediator of heart hypertrophyI96,197,198,199. Thus providing a possible link and further 
clue to the mechanism by which Cu can reverse cardiac hypertrophy. While the exact 
implications have yet to be understood, it is also interesting to note that Vimentin is 
also a known copper binding protein. It may also playa role in tissue repair I57• We 
hypothesize that Vimentin acts as a molecular switch, somehow switching pathways 
from growth to regression upon the addition of Cu. 
Recently, a lot of attention has been given to the role of VEGF and it's receptors 
in cancer. In 2004, the FDA approved bevacizumab (A vastin TM), the first approved 
biological therapy for the prevention of angiogenesis in tumors. It is one of many 
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inhibitors developed on the idea of inhibiting angiogenesis in tumors and thereby 
delaying or completely halting the progression of cancer. Additionally, they have the 
benefit of fewer side effects than chemotherapy. However, results of these inhibitors 
may be dependent upon the type of cancer being treated. The investigators in a recent 
study that involved 2385 glioblastoma patients treated with small molecule kinase 
inhibitors suggested that the efficacy did not warrant their use in clinical practice2OO• 
Other studies have shown that the prognostic value of VEGF and FIt -1 expression in 
tumors has yet to be determined, and in patients with stage IIIIII non-small cell lung 
cancer, tumor expression did not appear to have a significant impact on overall 
survival, locoregional control or metastases-free survivat2°1• While there is great 
potential for drugs targeting VEGF and its receptors, there is clearly also a need to 
proceed with caution and take into careful consideration if the potential 
cardiovascular side effects outweigh the risk. 
There were several limits to this study. We did not examine how eu regulates the 
expression or differentialdistribution of VEGFRs. This is an important question and 
the answer to this question will help further understand the role of eu in regression of 
heart hypertrophy. From our observation that eu suppressed PE-elevated VEGFR-2 
levels, it would suggest that eu would not cause overexpression of VEGFR -1. Then 
the question needs to be addressed is how eu reduces VEGFR-2, suppressing its 
expression or enhancing its degradation? Our future studies will address this question. 
Another limitation of this study is that the mechanism by which VEGFR -1 regulates 
PKG-1 activation has not been defined. While it is clear that Vimentin plays a role, 
the mechanistic insight is important for further understanding the signalling pathway 
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leading to regression of cardiomyocyte hypertrophy, which will be an important focus 
in our future studies. 
In conclusion, the present study demonstrates that Cu-induced regression of 
cardiomyocyte hypertrophy is related to a switch of signaling pathways from 
VEGFR-2 to VEGFR-l. Although both pathways are VEGF-dependent, the data 
suggest that VEGFR-l is associated with signaling pathways linked to PKG-l, which 
has been demonstrated both in vivo and in vitro to be associated with cardiomyocyte 
growth inhibition and regression of cardiomyocyte hypertrophy. It remains to be 
elucidative how Cu regulates the differential distribution between VEGFR-l and 
VEGFR-2 in hypertrophic cardiomyocytes and how VEGFR-l interacts with PKG-l 
leading to the activation of hypertrophic reversal signalling pathways, however, we 
have observed that Vimentin is associated with both VEGFR-l and PKG-l 
suggesting it may act as a link between the two, or perhaps acts as a molecular switch 
between hypertrophic and reversal of regression signaling. Further studies using 
siRNA targeting Vimentin will be instrumental in testing the hypothesis that it is a 
critical component in the reversal effect. 
132 
REFERENCES 
1. Heart disease and stroke statistics: 2008 update. Dallax, TX: American Heart 
Association; 2008. 
2. Keehan S. et al. National Health Spending Projections Through 2020: Economic 
Recovery and Reform Drive Faster Spending Growth, Health Affairs, 
2011;30(8):1-12. 
3. Chen, J. and Fishman, M. Zebrafish tinman homolog demarcates the heart field 
and initiates myocardial differentiation. Development, 1996;122: 3809-3816. 
4. Grossman, W. Cardiac hypertrophy: Useful adaptation or pathological process? 
American Journal of Medicine, 1980;69(4):576-584. 
5. Dorn, G. and Force T. Protein kinase cascade in the regulation of cardiac 
hypertrophy. Journal of Clinical Investigation, 2005;115(3):527-537. 
6. Frey N. and Olson EN. Cardiac hypertrophy: the good, the bad and the ugly. 
Annual Review of Physiology, 2003; 65:45-79. 
7. Stewart S. et al. More 'malignant' than cancer? Five-year survival following a 
first admission for heart failure. European Journal of Heart Failure, 2001; 3(3): 
315-322. 
8. Valentine J and Gralla E. Delivering Copper Inside Yeast and Human Cells. 
Science, 1997;278:817-818. 
9. Evans GW. Copper homeostasis in the mammalian system. Pathological 
Reviews, 1973;53:535-570. 
10. Lowe, N. et al. Is there a potential therapeutie value of copper and zinc for 
osteoporosis? Proceedings of the Nutrition Society, 2002; 61:181-485. 
11. Olivares, M and Uauy R. Copper as an essential nutrient. American Journal of 
Clinical Nutrition, 1996;63: 791S-796S. 
12. Folkman J and Shing Y. Angiogenesis, The Journal of Biological Chemistry, 
1992;267: 10931-10934. 
13. Stemmer KL et al. Copper deficiency effects on cardiovascular system and lipid 
133 
of the Society for Experimental Biology and Medicine, 1989;192:166-171. 
15. Xie H and Kang YJ. Role of copper in angiogenesis and its medicinal 
implications. Current Medicinal Chemistry. 2009;16:1304-1314. 
16. Berger, Rudolph et al. B-Type Natriuretic Peptide Predicts Sudden Death in 
Patients with Chronic Heart Failure, Circulation, 2002;105:2392-2397. 
17. Mann, D.L. Mechanisms and Models in Heart Failure. Circulation, 1999;100: 
999-1008. 
18. Scarabelli, T.M., Knight, R, Stephanou, A, Townsend, P.A, Chen-Scarabelli, c., 
Lawrence, K., Gottlieb, R, Latchman, D., and Narula, J. Clinical implications of 
apoptosis in ischemic myocardium. Current Problems in Cardiology, 2006; 
31:181.,264. 
19. Apstein CA, morgan JP: Cellular mechanisms underlying left ventricular diastolic 
function. Pp. 3-24. In Gaasch WH, Le Winter MM (eds): Left ventricular diastolic 
dysfunction and Heart Failure. Lea & Febiger, Philadelphia, 1994. 
20. Morgan IP: Mechanisms of disease. Abnormal intracellular modulation of 
calcium as a major cause of cardiac contractile dysfunction .. New England Journal 
of Medicine, 1991;325:625-632. 
21. Katz AM: Interplay between inotropic and lusitropic effects of cyclic adenosine 
monophosphate on the myocardial cell. Circulation 1990;82:7-11. 
22. Rich, M.W., Nease, RF. Cost-Effective Analysis in Clinical Practice The Cost of 
Heart Failure. Archives ofInternal Medicine. 1999; 159:1690-1700. 
23. American Heart Association. Heart Disease and Stroke Facts, 2006 Update. 
Dallas, Texas: AHA, 2006. 
24. Dipla, Konstantina et al. Myocyte Recovery After Mechanical Circulatory 
Support in Humans With End-Stage Heart Failure. Circulation. 1998;97:2316-
2322. 
25. Lopez AD. Assessing the burden of mortality from cardiovascular diseases. 
World Health Statatistics Quarterly, 1993;46(2):91-6. 
26. Pearson TA Cardiovascular disease in developing countries: myths, realities, and 
opportunities. Cardiovascular Drugs and Therapy, 1999;13(2):95-104. 
27. Wielgosz AT. The decline in cardiovascular health in developing countries. 
World Health Statistics Quarterly, 1993;46(2):90. 
134 
28. Feenstra, Johannes et al. Drug-Induced Heart Failure, Journal of the American 
College of Cardiology, 1999;33(5):1152-62. 
29. Turnlund JR. Copper. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, 
eds. Modem Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott 
Williams & Wilkins; 2006:289-299. 
30. Zatuchni, G. 1. Advances in Contraception. Advances in Contraception, 
1989;5(4): 193-196. 
31. The historical part of this paper is based on H.H.A. Dollwet and J.R.I. Sorenson, 
Historic uses of copper compounds in medicine, Trace Elements in Medicine, 
1985;2(2):80-87. 
32. Linder, M.e. (1991). Biochemistry of Copper (New York: Plenum Press). 
33. Pen- a, M.M.O., Lee, J., and Thiele, D.I. A delicate balance: Homeostatic 
control of copper uptake and distribution. Journal of Nutrition, 1999: 129(7): 
1251-1260. 
34. Puig, S., and Thiele, D.I. Molecular mechanisms of copper uptake and 
distribution. Current Opinion in Chemical Biology, 2002:6(2):171-180. 
35. Wester PO. Trace elements in human myocardial infarction determined by 
neutron activation analysis. Acta Medica Scandanavia, 1965: 178(6):765-788. 
36. Schroeder, H.A. et al. Essential trace metals in man: copper. Journal of Chronic 
Diseases,1996: 19(9): 1007-1034. 
37. Taylor, G 0 & Wiilliams AO. Lipid and trace metal content in coronary 
arteries of Nigerian Africans. Experimental Molecular Pathology 
1974:21(3):371-380. 
38. Anderson TW et al. Letter:ischemic heart disease, water hardness and 
myocardial magnesium. Canadian Medical Association Journal, 1975: 
113(3):199-203. 
39. Chipperfield B & Chipperfield JR. Differences in metal content of the heart 
muscle in death from ischemic heart disease. American Heart Journal, 1995: 
95(6):732-737. 
40. Casey CE, Guthrie BE & Robinson MF. Copper, manganese, zinc and 
cadmium in tissues from New Zealanders. Biology of Trace Elemental 
Research, 1982:4105-4115. 
41. Reiser S, et al. Indices of copper status in humans consuming a typical 
135 
American diet containing either fructose or starch. American Journal of Clinical 
Nutrition, 1985:42(2):242-251. 
42. Zama N, Towns RLR. Cardiac copper, magnesium, and zinc in recent and 
old myocardial infarction. Biology Trace Element Research 1986:19:201-208. 
43. Martin BJ, Lyon TD & Fell GS (1991). Comparison of inorganic elements from 
autopsy tissue of young and elderly subjects. J Trace Elem Electrolytes Health 
Dis 1991:5(3):203-211. 
44. Falcone JC, Saari JT, Kang YJ & Schuschke DA. Vasoreactivity in an adult 
rat model of marginal copper deficiency. Nutritional Research, 
2005:25(2):25177-25186. 
45. Nose Y, Kim B, Thiele E. Ctrl drives intestinal absorption and is essential for 
growth, iron metabolism, and neonatal cardiac function. Cell Metabolism, 
2006:4(3):235-244. 
46. Cherukuri S. et al. Unexpected role of ceruloplasmin in intestinal iron absorption. 
Cell Metabolism, 2005:2(5):309-319. 
47. Schuschke, D. et al. Microvascular control mechanisms in copper deficiency. The 
Journal of Trace Elements in Experimental Medicine. 1996:9:63-72. 
48. Jiang Y et al. Dietary copper supplementation reverses hypertrophic 
cardiomyopathy induced by chronic pressure overload in mice. Journal of 
Experimental Medicine. 2007:204 (3):657-666. 
49. N. Rusinko and J.R. Prohaska. Adenine nucleotide and lactate levels in organs 
from copper-deficient mice and brindled mice. Journal of Nutrition. 
1985:115(7):936-943. 
50. J.C.J. Chao, D.M. Medeiros, R.A. Altschuld and C.M. Hohl. Cardiac nucleotide 
levels and mitochondrial respiration in copper-deficient rats. Comparative 
Biochemistry and Physiology. 1993:104(1):163-168. 
51. A.M. Bode, L.A. Miller, J. Faber and J.T. Saari, Mitochondrial respiration in 
heart, liver and kidney of copper-deficient rats, Journal of Nutritional 
Biochemistry. 1992:3(12): 668-672. 
52. J .M. Matz, J. T Saari and A.M. Bode. Functional aspects of oxidative 
phosphorylation and electron transport in cardiac mitochondria of copper-
deficient rats. Journal of Nutritional Biochemistry. 1995:6(12):644-652. 
53. Rae TD et al. Undetectable Intracellular Free Copper: The Requirement of a 
Copper Chaperone for Superoxide Dismutase. Science. 1999:284(5415):805-808. 
136 
54. Hart EB, Steenbock J, Waddell J, Elvehjem CA. Iron in nutrition. VII. Copper as 
a supplement to iron for hemoglobin building in the rat. Journal of Biological 
Chemistry. 2002;277(34 )e22. 
55. Chou T, Adolph WHo Copper metabolism in man. Biochemistry Journal. 
1935;29(2):476-9. 
56. Tompsett SL. The copper and "inorganic" iron contents of human tissues. 
Biochemical Journal. 1935;29(2):480-6. 
57. Tompsett SL. The excretion of copper in urine and faeces and its relation to the 
copper content of the diet. Biochemical Journal. 1934;28(6):2088-91. 
58. Leverton RM, Binkley ES. The copper metabolism and requirement of young 
women. Journal of Nutrition. 1944;27(1):43-52. 
59. Food and Nutrition Board, Institute of Medicine. Copper. Dietary reference 
intakes for vitamin A, vitamin K, boron, chromium, copper, iodine, iron, 
manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, D.C.: 
National Academy Press; 2001:224-257 
60. Kim BE, Nevitt T & Thiele DJ . Mechanisms for copper acquisition, 
distribution and regulation. Nature Chemical Biology. 2008:4(3): 176-185. 
61. Hellman NE & Gitlin JD. Ceruloplasmin metabolism and function. Annual 
Reviews of Nutrition. 2002:22439-22448. 
62. Turnland J. Human whole-body copper metabolism. American Journal of 
Clinical Nutrition. 1998:67:960-4S. 
63. Turnland JR, Keen CL, Smith RG. Copper status and urinary and salivary copper 
in young men at three levels of dietary copper. American Journal of Clinical 
Nutrition. 1990;51:658-64. 
64. Milne DB. Copper intake and assessment of copper status. American Journal of 
Clinical Nutrition. 1998:67(5):1041S-1045S. 
65. Konig JS & Elmadfa I. Plasma copper concentration as marker of copper 
intake from food. Annals of Nutrition and Metababolism. 2000:44(3):129-
134. 
66. Araya M, Olivares M, Pizarro F, Gonzalez M, Speisky H & Uauy R. Copper 
exposure and potential biomarkers of copper metabolism. Biometals. 
2003: 16( 1): 199-204. 
137 
67. Kanikowska D, Grzymislawski M & Wiktorowicz K. Seasonal rhythms of 
"acute phase proteins" in humans. Chronobiology International. 2005:22(3): 
591-596. 
68. Montagna 0, Grosso R, Santoro A & Mautone A. Plasma levels of the serum 
antioxidants (uric acid, ceruloplasmin, transferrin) in term and preterm neonates 
in the first week of life. Minerva Pediatrica. 1994:46(6): 255-260. 
69. Hambidge M. Biomarkers of trace mineral intake and status. Journal of Nutrition. 
2003: 133:Suppl. 3:948S-955S. 
70. Bertinato J, Iskandar M & L' Abbe MR. Copper deficiency induces the 
upregulation of the copper chaperone for CU/Zn superoxide dismutase in weanling 
male rats. Journal of Nutrition. 2003: 133(1):28-31. 
71. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding 
growth factor specific for vascular endothelial cells. Biochemical and 
Biophysical ResearchCommunications. 1989: 161(2):851-858. 
72. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science. 
1989:246: 1306-1309. 
73. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino n, 
Siegel NR, Leimgruber RM, Feder J. Tumor vascular permeability factor 
stimulates endothelial cell growth and angiogenesis. Journal of Clinical 
Investigation. 1989:84(5): 1470-1478. 
74. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. 
Vascular permeability factor, an endothelial cell mitogen related to platelet 
derived growth factor. Science. 1989:246(4935):1309-1312. 
75. PloUet J, Schilling J, Gospodarowicz D. Isolation and characterization of a 
newly identified endothelial cell mitogen produced by AtT20 cells. European 
Mecular Biology Organization Journal. 1989:8(12):3801-3806. 
76. Conn G, Bayne M, Soderman L, Kwok PW, Sullivan KA, Palisi TM, Hope DA, 
Thomas KA. Amino acid and cDNA sequence of a vascular endothelial 
cell mitogen homologous to platelet-derived growth factor. Proceedings of the 
National Acadamy of Sciences USA 1990:87:2628-2632. 
77. Pepper MS, Wasi S, Ferrara N, Orci L, Montesano R. In vitro angiogenic and 
proteolytic properties of bovine lymphatic endothelial cells. Experimental Cell 
Research. 1994:210(2):298-305. 
78. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor 
138 
cells secrete a vascular permeability factor that promotes accumulation of 
ascites fluid. Science. 1983:219(4587):983-985. 
79. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, 
Haymore BL, Leimgruber R, Feder J. Human vascular permeability 
factor. Isolation from U937 cells. Journal of Biological Chemistry. 
1989:264(33):20017-20024. 
80. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose 
transport in aortic endothelial cells by vascular permeability factor and tumor 
necrosis factor-alpha, but not by insulin. Journal of Biological Chemistry. 
1990:265(30): 18051-18054. 
81. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. 
During angiogenesis, vascular endothelial growth factor and basic fibroblast 
growth factor regulate natural killer cell adhesion to tumor endothelium. 
Nature Medicine. 1996:2(9):992-997. 
82. Kim I, et al. VEGF Stimulates Expression of ICAM-l, VCAM-l and E-Selectin 
through Nuclear Factor-K B Activation in Endothelial Cells. Journal of 
Biological Chemistry. 2006:276:7614-7620. 
83. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan Y-C, 
Olander JV, Connolly DT, Stem D. Vascular permeability factor: a tumor-derived 
polypeptide that induces endothelial cell and monocyte procoagulant activity, and 
promotes monocyte migration. Journal of Experimental Medicine. 
1990:172(6):1535-1545. 
84. Ku DD, Zaleski JK, Liu S, Brock T. Vascular endothelial growth factor 
induces EDRF-dependent relaxation of coronary arteries. American Journal of 
Physiology. 1993:265:H586-592. 
85. Ku DD, Zaleski JK, Liu S, Brock T. Vascular endothelial growth factor 
induces EDRF-dependent relaxation of coronary arteries. American Journal of 
Physiology. 1993: 19265:H586-592. 
86. Cuevas P, Garcia-Calvo M, Carceller F, Reimers D, Zazo M, Cuevas B, Munoz-
Willery I, Martinez-Coso V, Lamas S, Gimenez-Gallego G. Correction of 
hypertension by normalization of endothelial levels of fibroblast growth factor 
and nitric oxide synthase in spontaneously hypertensive rats. Proceedings of the 
National Academy of Sciences USA. 1996:93:11996-12001. 
87. Robinson, C.J. and S.E. Stringer. The Splice Variants of Vascular Endothelial 
Growth Factor and Their Receptors. Journal of Cell Science. 2001:114:853. 
88. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological 
139 
properties of the vascular endothelial growth factor family of proteins. Endocrine 
Reviews. 1992:13(1):18-32. 
89. Ostendorf T, et al. VEGF165 mediates glomerular endothelial repair. Journal of 
. Clinical Investigation. 1999;104(7):913-923. 
90. Byrne, A.M. et al. Angiogenic and cell survival functions of vascular endothelial 
growth factor (VEGF). Journal of Cellular and Molecular Medicine. 
2005:9(4):777-794. 
91. Angelo, L.S. and R. Kurzrock. Vascular endothelial growth factor and its 
relationship to inflammatory mediators. Clinical Cancer Research. 
2007: 13(10):2825-2830. 
92. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of 
vascular endothelial growth factor bioavailability by genetic and proteolytic 
mechanisms. Journal of Biological Chemistry. 1992:267:26031-26037. 
93. Cohen, T., Gitay-Goren, H., Sharon, R. et al. VEGFI21, a vascular 
endothelial growth factor (VEGF) isoform lacking heparin binding ability, 
requires cell surface heparan sulfates for efficient binding to the VEGF 
receptors of human melanoma cells. Journal of Biological Chemistry. 
1995:270: 11322-11326. 
94. Park JE, Keller G-A, Ferrara N. The vascular endothelial growth factor 
(VEGF) isoforms: differential deposition into the subepithelial extracellular 
matrix and bioactivity of ECM-bound VEGF. Molecular Biology of the Cell. 
1993:4(12):1317-1326. 
95. Keyt B, Berleau L, Nguyen H, Heinshon H, Chen H, Vandlen R, Ferrara N. The 
carboxyl-terminal domain (111-165) of VEGF is critical for mitogenic potency. 
Journal of Biological Chemistry. 1996:271(13):7788-7795. 
96. Petrova, T. V., Makinen, T., and Alitalo, K. Signaling via vascular endothelial 
growth factor receptors. Experimental Cell Research. 1999:253( 1): 117 -130. 
97. Karkkainen, MJ., Makinen, T. & Alitalo, K. Lymphatic endothelium: a new 
frontier of metastasis research. Nature Cell Biology. 2002:4(1): E2-E5. 
98. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, 
M.L., and Schuh, A. C. Failure of blood island formation and vasculogenesis 
in Flk-l-deficient mice. Nature. 1995:376,62-66. 
99. Fong, G. H., Rossant, J., Gertsenstein, M., and Breitman, M. L. Role of the Flt-
lreceptor tyrosine kinase in regulating the assembly of vascular endothelium. 
Nature 1995:376(6535):66-70. 
140 
100. Ferrara, N., Gerber H. and LeCouter J. The biology of VEGF and its 
receptors. Nature Medicine 2003:9:669-676. 
101. Shibuya, M. et al. Nucleotide sequence and expression of a novel human 
receptor-type tyrosine kinase (fit) closely related to the fms family. Oncogene. 
1990:5(4): 519-527. 
102. Terman, B.I. et al. Identification of a new endothelial cell growth factor 
receptor tyrosine kinase. Oncogene. 1991:6(9):1677-1683. 
103. deVries C, Escobedo JA, Veno H, Houck KA, Ferrara N, Williams LT. 
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. 
Science. 1992:255(5047):989-991. 
104. Terman BI, Vermazen MD, Carrion ME, Dimitrov D, Armellino DC, 
Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase 
as a receptor for vascular endothelial growth factor. Biochemical and 
Biophysical Research Communications. 1992:187(3):1578-1586. 
105. Ziche, M., Jones, J., and Gullino, P.M. Role of prostaglandin El and 
copper in angiogenesis. Journal of the National Cancer Institute. 1982:69(2):475-
482. 
106. Harris, E.D. A requirement for copper in angiogenesis. Nutritional. 
Reviews. 2004:62(2):60-64. 
107. Sen, c.K. et al. Copper-induced vascular endothelial growth factor 
expression and wound healing. American Journal of Heart and Circulatory 
Physiology. 2002:282(5): HI821-HI827. 
108. Wenger, R.H. Cellular adaptation to hypoxia: 02-sensing protein 
hydroxylases, hypoxia-inducible transcription factors and 02-regulated gene 
expression. Federation of American Societies of Experimental Biology Journal. 
2002: 16(10):1151-1162. 
109. Semenza, G.L. Hypoxia-inducible factor 1: master regulator of 02 
homeostasis. Current Opinion in Genetic Development. 1998:8(5):588-594. 
110. Safran, M. & Kaeline, W.J. HIF hydroxylation and the mammalian 
oxygen-sensing pathway. Journal of Clinical Investigation. 2003:111(6), 779-
783. 
111. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau 
ubiquitylation complex by 02-regulated prolyl hydroxylation. Science. 
2001:292(5516): 468-472. 
141 
112. Ivan, M. et al. HIPalpha targeted for VHL-mediated destruction by proline 
hydroxylation: implications for 02 sensing. Science. 2001:292(5516): 464-468. 
113. Masson, N. and Ratcliffe, PJ., HIP prolyl and asparaginyl hydroxylases in 
the biological response to intracellular 02 levels. Journal of Cell Science. 
2003:116(Pt 15): 3041-3049. 
114. Maxwell, P.H. & Ratcliffe, PJ. Oxygen sensors and angiogenesis. 
Seminars in Cell and Developmental Biology. 2002:13(1):29-37. 
115. Kallio, PJ. et al. Signal transduction in hypoxic cells: inducible nuclear 
translocation and recruitment of the CBP/p300 coactivator by the hypoxia-
inducible factor-1 alpha. European Molecular Biology Organization Journal. 
1998: 17(22):6537-6586. 
116. Jiang, et. al Dietary copper supplementation reverses hypertrophic 
cardiomyopathy induced by chronic pressure overload in mice. 
Journal Experimental Medicine. 2007:204(3):657-666. 
117. Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 
5A prevents and reverses cardiac hypertrophy. Nature Medicine. 2005:11(2): 
214-222. 
118. Elsherif, L. Jiang, Y., Saari, J.T., and Kang, Y.J., Dietary copper 
restriction-induced changes in myocardial gene expression and the effect of 
copper repletion. Experimental Biology and Medicine. 2004:229(7): 616-622. 
119. Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and 
angiogenesis contributes to the transition to heart failure. Journal of Clinical 
Investigation. 2005:115(8): 2108-2118. 
120. Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes 
the transition from compensatory cardiac hypertrophy to failure in response to 
pressure overload. Hypertension. 2006:47(5): 887-893. 
121. Friehs, I. et al. Vascular endothelial growth factor delays onset of failure 
in pressure-overloaded hypertrophy through matrix metalloproteinase activation 
and angiogenesis. Basic Research in Cardiology. 2006: 101(3):204-213. 
122. Lee, L.Y., et al. Focal angiogen therapy using intramyocardial delivery of 
an adenovirus vector conding for vascular endothelical growth factor 121. Annals 
of Thoracic Surgery. 2000:69(1):14-23. 
123. Friehs, I. et al. Promoting angiogenesis protects severely hypertrophied 
hearts from ischemic injury. Annals of Thoracic Surgery. 2004:77(6): 2004-2010. 
142 
124. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and 
arteriovenous contribution by angiopoietins and vascular endothelial growth 
factor (VEGF). Proceedings of the National Academy of Sciences USA. 2002: 
99(12):8219-24. 
125. Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that 
promotes accumulation of ascites fluid. Science 1983:219(4587): 983-985. 
126. Dvorak, H.F. et al. Vascular permeability factor/vascular endothelial 
growth factor, microvascular hypermeability, and angiogenesis. American Journal 
of Pathology. 1995:146(5): 1029-1039. 
127. Tham E, Wang J, Piehl F, Weber G. Upregulation of VEGF-A without 
angiogenesis in a mouse model of dilated cardiomyopathy caused by 
mitochondrial dysfunction. Journal of Histochemistry and Cytochemistry. 2002: 
50(7): 935-44. 
128. Tsai, EJ and Kass DA. Cyclic GMP signaling in cardiovascular 
pathophysiology and therapeutics. Pharmacology and Therapeutics. 2009:122(3): 
216-238. 
129. Hofmann, F. The biology of cyclic GMP-dependent protein kinases. 
Journal of Biological Chemistry. 2005:280(1):1-4. 
130. Komalavilas, P. et al. Activation of mitogen-activated protein kinase 
pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile 
vascular smooth muscle cells. Journal of Biological Chemistry. 
1999:274(48):34301-34309. 
131. Lincoln, TM and Cornwell TL. Intracellular cyclic GMP receptor proteins. 
Federation of American Societies of Experimental Biology Journal. 
1993:7(2):328-338. 
132. Feil R. et al. Cyclic GMP-dependent protein kinases and the 
cardiovascular system: insights from genetically modified mice. Circulation 
Research. 2003:93(10):907-916. 
133. Lukowski, R. Cardiac hypertrophy is not amplified by deletion of cGMP-
dependent protein kinase I in cardiomyocytes. Proceedins of the National 
Academy of SciencesU.S.A. 2010:107(12): 5646-5651. 
134. Ammendola, A. et al. Molecular determinants of the interaction between 
the inositoll,4,5-trisphosphate receptor-associated cGMP kinase substrate 
(IRAG) and cGMP kinase Theta. Journal of Biological Chemistry. 
2001:276(26): 24153-24159. 
143 
135. Surks, H.K. et al. Regulation of myosin phosphatase by a specific 
interaction with cGMP- dependent protein kinase lalpha. 
Science. 1999:286(5444 ): 1583-1587. 
136. Burgoyne, J.R. et al. Cysteine redox sensor in PKGla enables oxidant-
induced activation. Science. 2007:317(5843):1393-1397. 
137. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a 
delay of lethal cell injury in ischemic myocardium. Circulation. 1986:74: 1124-
1136. 
138. Kishimoto let al. A genetic model provides evidence that the receptor for 
atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte 
hypertrophy. Proceedings of the National Academy of Sciences USA. 2001 :98: 
2703-2706. 
139. Zahabi A. et al. Expression of constitutively active guanylate cyclase in 
cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic 
constriction on mouse hearts. Journal of Biological Chemistry. 2003:278(48): 
27694-47699. 
140. Wollert KC et al. Gene transfer of cGMP-dependent protein kinase I 
enhances the antihypertrophic effects of nitric oxide in cardiomoyocytes. 
Hypertension 2002:39(1): 87-92. 
141. Knowles JW et al. Pressure-independent enhancement of cardiac 
hypertrophy in natriuretic peptide receptor A-deficient mice. Journal of Clinical 
Investigation. 2001: 107 (8): 975-984. 
142. Koneru S et al. Sildenafil-mediated neovascularization and protection 
against myocardial ischaemia reperfusion injury in rats: role of 
VEGF/angiopoietin-1. Journal of Cellular and Molecular Medicine. 2008: 12(6B) 
:2651-64. 
143. Senthilkumar, A et al. Sildenafil promotes ischemia-induced angiogenesis 
through a PKG-dependent pathway. Arteriosclerosis Thrombosis Vascular 
Biology. 2007: 27(9):1947-195. 
144. Lukowski R et al. Cardiac hypertrophy is not amplified by deletion of 
cGMP-dependent protein kinase I in cardiomyocytes. Proceedings of the National 
Academy of Sceinces USA. 2010: 107(12):5646-5651. 
145. Forfia, PR et al. Acute phosphodiesterase 5 inhibition mimics 
hemodynamic effects of B-type natriuretic peptide and potentiates B-type 
144 
natriuretic peptide effects in failing but not normal canine heart. Journal of the 
American College of Cardiology. 2007:49(10):1079-1088. 
146. Corbin JD et al. High lung PDE5: a strong basis for treating pulmonary 
hypertension with PDE5 inhibitors. Biochemical and Biophysical Research 
Communications. 2005:334(3): 930-938. 
147. Nagendran, J. et al. Phosphodiesterase type 5 is highly expressed in the 
hypertrophied human right ventricle, and acute inhibition of 
phosphodiesterase type 5 improves contractility. Circulation 2007:116(3): 238-
248. 
148. Kukreja RC et al. Pharmacological preconditioning with sildenafil: basic 
mechanisms and clinical implications. Vascular Pharmacology. 2005:42(5-6): 
219-232. 
149. Das A., Xi, L. & Kukreja, R.c. Phosphodiesterase-5 inhibitor sildenafil 
preconditions adult cardiac myocytes against necrosis and apoptosis. Essential 
role of nitric oxide signaling. Journal of Biological Chemistry. 2005:280(13): 
12944-12955. 
150. Das A. et al. Protein kinase C plays an essential role in sildenafil-induced 
cardioprotection in rabbits. American Journal of Physiology. 2004:286(4): 
H1455-H1460. 
151. Ockaili R et al. Sildenafil (Viagra) induces powerful cardioprotective 
effect via opening of mitochondrial K(ATP) channels in rabbits. American 
Journal of Physiology. 283(3):H1263-H1269. 
152. Salloum F et al. Sildenafil induces delayed preconditioning through 
inducible nitric oxide synthase-dependent pathway in mouse heart. Circulation 
Research. 2003:92(6):595-597. 
153. Das A et al. Phosphodiesterase-5 inhibitor sildenafil preconditions adult 
cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide 
signaling. Journal of Biological Chemistry. 2005:280(13):12944-12955. 
154. Salloum, FN et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy 
and improves left ventricular function in mice. American Journal of Physiology. 
2008:294(3): H1398-H1406. 
155. Fisher PW et al. Phosphodiesterase-5 inhibition with sildenafil attenuates 
cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of 
doxorubicin cardiotoxicity. Circulation. 2005:111(13):1601-1610. 
145 
156. Salloum, FN. Et al. Vardenafil: a novel type 5 phosphodiesterase inhibitor 
reduces myocardial infarct size following ischemiaireperfusion injury via opening 
of mitochondrial K(APT) channels in rabbits. Journal of Molecular andCellular 
Cardiology. 2006:40(3): 405-411. 
157. Sesti C et al. The phosphodiesterase-5 inhibitor tadalafil reduces 
myocardial infarct size. International Journal of Impotence Research. 
2007: 19(1):55-61. 
158. Hardt, SE & Sadoshima J. Glycogen synthase kinase-3p: a novel regulator 
of cardiac hypertrophy and development. Circulation Research. 
2002:90(10): 1055-1063. 
159. Kaga S. et al. Glycogen synthase kinase-3betalbeta-catenin promotes 
angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 
and survivin expression in rat ischemic preconditioned myocardium. Journal of 
Molecular and Cellular Cardiology. 2006:40(1):138-147. 
160. Das, A. et al. Protein kinase G-dependent cardioprotective mechanism of 
phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. 
Journal of Biological Chemistry. 2008:283(43):29572-29585. 
161. Nishi J et al. Vascular endothelial growth factor receptor-l regulates 
postnatal angiogenesis through inhibition of the excessive activation of Akt. 
Circulation Research. 2008: 103(3):261-268. 
162. Fujio Y et al. Akt promotes survival of cardiomyocytes in vitro and 
protects against ischemia-reperfusion injury in mouse heart. Circulation. 
2000: 101 (6):660-667. 
163. Matsui T. et al. Akt activation preserves cardiac function and prevents 
injury after transient cardiac ischemia in vivo. Circulation 2001:104(3): 330-335. 
164. Ku N-O, Zhou X, Toivola DM, Omary MB. The cytoskeleton of digestive 
epithelia in health and disease. American Journal of Physiology. 1999;277(6 Pt 
1):Gll08-G1l37. 
165. Fuchs E, Cleveland DW. A structural scaffolding of intermediate 
filaments in health and disease. Science. 1998:279(5350):514-519. 
166. Cleveland D and Fuchs E. A Structural Scaffolding of Intermediate 
Filaments in Health and Disease. Science. 1998:279(5350):514-519. 
167. E. Fuchs and K. Weber. Intermediate filaments: structure, dynamics, 
function, and disease. Annual Review of Biochemistry. 1994:63:345-82. 
146 
168. Colucci-Guyon E et al. Mice Lacking Vimentin Develop and Reproduce 
without an Obvious Phenotype. Cell. 1994:79(4): 679-694. 
169. Ando Jet al. Changes in cell morphology and cytoskeletal organization 
are induced by human mitotic checkpoint gene, Bub1. Biochemical and 
Biophysical Research Communications 2008:365(4):691-69. 
170. Eckes, B. et al. Impaired wound healing in embryonic and adult mice 
lacking vimentin. Journal of Cell Science. 2000: 113(Ptl3): 2455-2462. 
171. Eckes, B. et al. Impaired mechanical stability, migration and contractile 
capacity in vimentin-deficient fibroblasts. Journal of Cell Science. 1998: 
111(Ptl3): 1897 -1907. 
172. Schiffers PMH et al. Altered Flow-Induced Arterial Remodeling in 
Vimentin-Deficient Mice. Arteriosclerosis Thrombosis and Vascular Biology. 
2000:20(3):611-616. 
173. Siddiqui, et al. Inhibition of phenylephrine-induced cardiac hypertrophy 
by docosahexaenoic acid. Journal of Biological Chemistry. 2004:92(6), 1141-
1159. 
174. Chen et al. Hydrogen peroxide dose dependent induction of cell death or 
hypertrophy in cardiac myocytes. Archives of Biochemistry and Biophysics. 
2000:373(1): 242-248. 
175. Madonna R and Caterina R. VEGF receptor switching in heart 
development and disease. Cardiovascular Research. 2009:84(1):4-6. 
176. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. 
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses 
cardiac hypertrophy. Nature Medicine. 2005: 11(2):214-222. 
177. Zhou Y, Jiang Y Kang YJ. Copper reverses cardiomyocyte hypertrophy 
through vascular endothelial growth factor-mediated reduction in the cell size. 
Journal of Molecuar and Cellular Cardiology. 2008: 45(1):106-117. 
178. Seetharam L et al. A unique signal transduction from FLT tyrosine kinase, 
a receptor for vascular endothelial growth factor VEGF. Oncogene 
1995: 10(1): 135-147. 
179. Waltenberger Jet al. Different signal transduction properties of KDR and 
Fltl, two receptors for vascular endothelial growth factor. Journal of Biological 
Chemistry. 1994;269(43):26988-26995. 
147 
180. Reynolds AR et al. Elevated Flk1 (vascular endothelial growth factor 
receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient 
mice. Cancer Research. 2004:64(23):8643-8650. 
181. Shiojima I et al. Disruption of coordinated cardiac hypertrophy and 
angiogenesis contributes to the transition to heart failure. Journal of Clinical 
Investigation. 2005: 115(8):2108- 2118. 
182. Izumiya Y et al. Vascular endothelial growth factor blockade promotes the 
transition from compensatory cardiac hypertrophy to failure in response to 
pressure overload. Hypertenstion. 2006:47(5):887-893. 
183. Clark DE et al. A vascular endothelial growth factor antagonist is 
produced by the human placenta and released into the maternal circulation. 
Biology of Reproduction. 1998:59(6):1540-1548. 
184. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor 
(VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates 
VPFNEGF receptor-2 mediated endothelial cell proliferation, but not migration, 
through phosphotidylinositol 3-kinase-dependent pathways. Journal of Biological 
Chemistry. 2001:276(29):26969-26979. 
185. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the 
vascular endothelial growth factor receptor-1 (VEGFR1) modulates mitogenic 
activity of VEGFR2 in endothelial cells. Journal of Biological Chemistry. 
2000;275(22): 16986-16992. 
186. Autiero M et al. Role of PIGF in the intra- and intermolecular cross talk 
between VEGF receptors FItl and FLK1. Nature Medicine. 2003:9(7):936-943. 
187. Takimoto Et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A 
prevents and reverses cardiac hypertrophy. Nature Medicine. 2005:11(2):214-222. 
188. Eckes, B. et al. Impaired mechanical stability, migration and contractile 
capacity in vimentin-deficient fibroblasts. Journal of Cell Science. 
1998:111(Pt13): 1897-1907. 
189. Traub, P. Intermediate Filaments: A Review (Springer-Verlag, New York, 
1985). 
190. Christian JL, Edelstein NG & Moon RT. Overexpression of wild-type and 
dominant negative mutant vimentin subunits in developing Xenopus embryos. 
New Biologist. 1990:2(8):700-711. 
148 
191. Eckes B et al. Impaired mechanical stability, migration and contractile 
capacity in vimentin-deficient fibroblasts. Journal Cell Science. 1998:111(Pt13), 
1897-1907. 
192. Eckes B et al. Impaired wound healing in embryonic and adult mice 
lacking vimentin. Journal Cell Science. 2000:113(Pt13): 2455-2462. 
193. Mor-Vaknin, N et al. Vimentin is secreted by activated macrophages. 
Nature Cell Biology. 2002:5(1):59 - 63. 
194. Turowski P et al. Vimentin dephosphorylation by protein phosphatase 2A 
is modulated by the targeting subunit B55. Molecular Biology of the Cell. 
1999: 10(6): 1997 -2015. 
195. Yasui Y et al. Protein kinases required for segregation of vimentin 
filaments in mitotic process. Oncogene. 2001:20(23):2868-2876. 
196. Takeisi Y et al. Transgenic overexpression of Constitutively Active 
Protein Kinase C e Causes Concentric Cardiac Hypertrophy. Circulation 
Research. 2000:86(12): 1218-1223. 
197. Palaniyandi S et al. Protein kinase C in heart failure: a therapeutic target? 
Cardiovascular Research. 2009:82(2):229-239. 
198. Hanh H et al. Protein Kinase C Negatively Regulates Systolic and 
Diastolic Function in Pathological Hypertrophy. Circulation Research. 
2003:93(11):1111-1119. 
199. Braz JC et al. PKC alpha regulates the hypertrophic growth of 
cardiomyocytes through extracellular signal-regulated kinase 112 (ERK1I2). 
Journal of Cell Biology. 2002:156(5):905-19. 
200. De Witt Hammer. Small molecule kinase inhibitors in glioblastoma: a 
systematic review of clinical studies. Neurological Oncology. 2010:12(3):304-16. 
201. Rades, D, Setter C, Dunst J, Dahl 0, Schild SE, Noack F. Prognostic 
impact ofVEGF and VEGF Receptor 1 (FLT1) expression in patients irradiated 






















List of Abbreviations 
Atrial Natriuretic Peptide 
Anal ysis of Variance 
5' -Bromo-2' -DeoxyUridine 
Calcium Chloride 
Cytochrome C Oxidase 




Double Distilled Water 
Fluorescence-Activated Cell Sorting 
Fetal Bovine Serum 
Fetal Liver Kinase 1 
fins-Like Tyrosine Kinase 1 
Forward Scatter Light 
































Phosphate Buffered Saline 
Phosphodiesterase 
Phenylephrine 
Protein Kinase C 
Protein Kinase G 
Phenylmethanesulfonyl Fluoride 
8-(4-Chlorophenylthio)-guanosine 3' ,5' -cyclic 
monophosphorothioate, Rp Isomer triethylammonium salt 
Tryosine Kinase Receptor 
Standard Deviation 
Superoxide Dismutase 
Side Scatter Light 
Small Interfering RNA 
Tumor Nectrosis Factor-a 




Katherine S. Bourcy 
505 S. Hancock Street 




Ph.D. Pharmacology & Toxicology, University of Louisville, August 2011 
M.S. Pharmacology & Toxicology, University of Louisville, August 2008 
B.S. Biology, University of Louisville, 2002 
Graduate Research 
Research Assistant 
Y. James Kang 
Research Assistant in Cardiovascular Toxicology 
Research Assistant 
Department of Pharmacology & Toxicology 
Undergraduate & Post-baccalaureate Research 
2007- July 2011 
University of Louisville 
2006-2007 
University of Louisville 
Laboratory Technician 2003-2004 
Frank Adamsky, Ph.D. Agentase, LLC Pittsburgh, PA 
Tested and analyzed enzymatic-polymer for pesticide remediation. 
Research Assistant 2001-2002 
David Schultz, Ph.D. University of Louisville 
Studied the production of unusual monoenoic fatty acids in transgenic plants. 
Publications, Theses & Posters 
Bourcy K, Feng W, Kang YJ. The Involvement of Vimentin in Copper 
Regression of Hypertrophy in Human Cardiac Myocytes. In Process. 
Zhan L, Hussain LR, Yao Y, Feng W, Bourcy K, Eaton J, Johnson WT, Moraes 
CT, Kang YJ. Recovery of cytochrome c oxidase activity is required for dietary 
copper supplementation-induced regression of cardiac hypertrophy in mice. In 
process. 
Bomcy K, Zhou Y, Feng W, Kang YJ. Association of Vascular Endothelial 
Growth Factor Receptor 1 with cOMP-dependent Protein Kinase-l is involved in 
Copper-induced Regression of Cardiac Myocyte Hypeltrophy in Cultures. Poster 
Presentation, March 2010, Society of Toxicology, Salt Lake City, Utah. 
153 
Zhou Y, Bourcy K, Kang YJ. Copper-induced regression of cardiomyocyte 
hypertrophy is associated with enhanced vascular endothelial growth factor 
receptor-1 signaling pathway. Cardiovasc Res. 2009 Oct 1;84(1):54-63. 
Graduate Honors and Awards 
NIH Pre-doctoral Trainee (T32-ES011564), 2009- 2011 
University of Louisville School of Medicine Fellowship, 2006 
Undergraduate Honors and Awards 
PLEN Alumni (Fall 2004) 
Received over $10,000 in merit-based scholarships 
Activities 
Foreign languages (Spanish, French & Brazilian Portuguese) 
Outdoor activities (Running, Biking, Hiking) 
No Kill Louisville volunteer (Grant Writing Committee, Events & Publicity 
committee) 
Bully Brigade of No Kill Louisville, Founder & Chair 
154 
